
<html lang="en"     class="pb-page"  data-request-id="0cfb6efb-b25c-4540-812d-1f9dfa7cedca"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm300596s;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2012.55.issue-12;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Biological Evaluation of 1-Benzylidene-3,4-dihydronaphthalen-2-one as a New Class of Microtubule-Targeting Agents" /></meta><meta name="dc.Creator" content="Jia  Liu" /></meta><meta name="dc.Creator" content="Can-Hui  Zheng" /></meta><meta name="dc.Creator" content="Xiao-Hui  Ren" /></meta><meta name="dc.Creator" content="Feng  Zhou" /></meta><meta name="dc.Creator" content="Wei  Li" /></meta><meta name="dc.Creator" content="Ju  Zhu" /></meta><meta name="dc.Creator" content="Jia-Guo  Lv" /></meta><meta name="dc.Creator" content="You-Jun  Zhou" /></meta><meta name="dc.Description" content="A series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were designed and synthesized, and their biological activities in vitro and in vivo were evaluated. The results showed a number of ..." /></meta><meta name="Description" content="A series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were designed and synthesized, and their biological activities in vitro and in vivo were evaluated. The results showed a number of ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 15, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300596s" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300596s" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300596s" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300596s" /></link>
        
    
    

<title>Synthesis and Biological Evaluation of 1-Benzylidene-3,4-dihydronaphthalen-2-one as a New Class of Microtubule-Targeting Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300596s" /></meta><meta property="og:title" content="Synthesis and Biological Evaluation of 1-Benzylidene-3,4-dihydronaphthalen-2-one as a New Class of Microtubule-Targeting Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0004.jpeg" /></meta><meta property="og:description" content="A series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were designed and synthesized, and their biological activities in vitro and in vivo were evaluated. The results showed a number of the title compounds exhibiting potent nanomolar activity in several human cancer cell lines. Of these, compound 22b showed the strongest inhibitory activity against human CEM, MDA-MBA-435, and K562 cells (IC50 = 1 nM), displayed in vitro inhibition of tubulin polymerization (IC50 = 3.93 μM), and significantly induced cell cycle arrest in G2/M phase. In addition, compound 22b could inhibit the tumor growth in colon nude mouse xenograft tumor model significantly and seemed safer than CA-4 when achieving a similar tumor suppression. This study provided a new molecular scaffold for the further development of antitumor agents that target tubulin." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300596s"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300596s">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300596s&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300596s&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300596s&amp;href=/doi/10.1021/jm300596s" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5720-5733</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm2011657" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm300063b" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Biological Evaluation of 1-Benzylidene-3,4-dihydronaphthalen-2-one as a New Class of Microtubule-Targeting Agents</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Liu">Jia Liu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Can-Hui++Zheng">Can-Hui Zheng</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-Hui++Ren">Xiao-Hui Ren</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Zhou">Feng Zhou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Li">Wei Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ju++Zhu">Ju Zhu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jia-Guo++Lv">Jia-Guo Lv</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=You-Jun++Zhou">You-Jun Zhou</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People’s Republic of China</span></div><div class="corresp-info"><strong>*</strong>For C.-H.Z.: phone, +86 021 81871240; e-mail, <a href="/cdn-cgi/l/email-protection#2a494b44425f437550424f444d6a534b42454504494547044944"><span class="__cf_email__" data-cfemail="a5c6c4cbcdd0ccfadfcdc0cbc2e5dcc4cdcaca8bc6cac88bc6cb">[email protected]</span></a>. For J.-G.L.: phone, +86 021 81871234; e-mail, <a href="/cdn-cgi/l/email-protection#84e8eee3b6b4b4b2b4b1b4bcc4fde5ecebebaae7ebe9aae7ea"><span class="__cf_email__" data-cfemail="88e4e2efbab8b8beb8bdb8b0c8f1e9e0e7e7a6ebe7e5a6ebe6">[email protected]</span></a>. For Y.-J.Z.: phone, +86 021 81871231; e-mail, <a href="/cdn-cgi/l/email-protection#374d5f58424e58425d425905070701774e565f58581954585a195459"><span class="__cf_email__" data-cfemail="b8c2d0d7cdc1d7cdd2cdd68a88888ef8c1d9d0d7d796dbd7d596dbd6">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300596s&amp;href=/doi/10.1021%2Fjm300596s" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5720–5733</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 7, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 December 2011</li><li><span class="item_label"><b>Published</b> online</span>15 June 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 June 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300596s" title="DOI URL">https://doi.org/10.1021/jm300596s</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5720%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJia%2BLiu%252C%2BCan-Hui%2BZheng%252C%2BXiao-Hui%2BRen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D12%26contentID%3Djm300596s%26title%3DSynthesis%2Band%2BBiological%2BEvaluation%2Bof%2B1-Benzylidene-3%252C4-dihydronaphthalen-2-one%2Bas%2Ba%2BNew%2BClass%2Bof%2BMicrotubule-Targeting%2BAgents%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5733%26publicationDate%3DJune%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300596s"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1931</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300596s" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Biological Evaluation of 1-Benzylidene-3,4-dihydronaphthalen-2-one as a New Class of Microtubule-Targeting Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Can-Hui&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Xiao-Hui&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Ju&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Jia-Guo&quot;,&quot;last_name&quot;:&quot;Lv&quot;},{&quot;first_name&quot;:&quot;You-Jun&quot;,&quot;last_name&quot;:&quot;Zhou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;5720-5733&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300596s&quot;},&quot;abstract&quot;:&quot;A series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were designed and synthesized, and their biological activities in vitro and in vivo were evaluated. The results showed a number of the title compounds exhibiting potent nanomolar activity in several human cancer cell lines. Of these, compound 22b showed the strongest inhibitory activity against human CEM, MDA-MBA-435, and K562 cells (IC50 = 1 nM), displayed in vitro inhibition of tubulin polymerization (IC50 = 3.93 μM), and significantly induced cell cycle arrest in G2/M phase. In addition, compound 22b could inhibit the tumor growth in colon nude mouse xenograft tumor model significantly and seemed safer than CA-4 when achieving a similar tumor suppression. This study provided a new molecular scaffold for the further development of antitumor agents that target tubulin.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300596s&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300596s" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300596s&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300596s" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300596s&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300596s" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300596s&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300596s&amp;href=/doi/10.1021/jm300596s" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300596s" /></input><a href="/doi/pdf/10.1021/jm300596s" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300596s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300596s%26sid%3Dliteratum%253Aachs%26pmid%3D22676247%26genre%3Darticle%26aulast%3DLiu%26date%3D2012%26atitle%3DSynthesis%2Band%2BBiological%2BEvaluation%2Bof%2B1-Benzylidene-3%252C4-dihydronaphthalen-2-one%2Bas%2Ba%2BNew%2BClass%2Bof%2BMicrotubule-Targeting%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D12%26spage%3D5720%26epage%3D5733%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291120" title="Hydrophobicity">Hydrophobicity</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jmcmar.2012.55.issue-12/production/jmcmar.2012.55.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were designed and synthesized, and their biological activities in vitro and in vivo were evaluated. The results showed a number of the title compounds exhibiting potent nanomolar activity in several human cancer cell lines. Of these, compound <b>22b</b> showed the strongest inhibitory activity against human CEM, MDA-MBA-435, and K562 cells (IC<sub>50</sub> = 1 nM), displayed in vitro inhibition of tubulin polymerization (IC<sub>50</sub> = 3.93 μM), and significantly induced cell cycle arrest in G2/M phase. In addition, compound <b>22b</b> could inhibit the tumor growth in colon nude mouse xenograft tumor model significantly and seemed safer than CA-4 when achieving a similar tumor suppression. This study provided a new molecular scaffold for the further development of antitumor agents that target tubulin.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span>†</span> Author Contributions</h4><p class="last">These authors contributed equally to this work.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30737" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30737" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Microtubule arrangement and rearrangement play important roles in many aspects of cellular structure and function. Investigations into the polymerization dynamics that regulate microtubule efficacy and in turn cellular replication may prove useful in the development of anticancer therapeutics.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> This is one of the reasons why microtubules are an attractive molecular target for anticancer agents. Compounds target microtubules bind at three distinct binding sites:<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> the taxane site for microtubule-stabilizing agents,<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> the vinca site,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and the colchicine site<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> for microtubule-destabilizing agents. The taxanes and vinca alkaloids have been successfully used in clinical oncology;<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> however, none of the colchicine site inhibitors (CSIs) have been approved in clinic as antitumor agents.</div><div class="NLM_p">The first CSI colchicine, which inhibits cancer cell proliferation powerfully, has limited its applications in clinic as antitumor agent because of its narrow therapeutic index.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Recent studies show that another CSI combretastatin A-4 (CA-4, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) with strong cytotoxicities has activity as vascular disrupting agents (VDAs) targeting already established vasculature of solid tumors, causing rapid and catastrophic vascular shutdown to induce widespread necrosis in solid tumors.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> Then a large number of structurally diverse CA-4 analogues have been developed<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15-18)</a> as VDAs in the past decade, and some of them have entered clinical trials.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26">(19-26)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of CA-4 and its analogues that entered clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The early phase clinical trials in many solid tumors have demonstrated that these CA-4 analogues have promising therapeutic benefits.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> However, many of them were also hampered by dose-limiting toxicities<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> or cumulative toxicities.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Some of these toxicities came from the effect on other tissues of these drugs (lack of specificity of tumor-related vasculature)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> or from the systemic effects of cytokines and other factors produced in compensatory response of tumors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Currently, CA4P in combination with antiangiogenic drugs, metronomic chemotherapy, or radiotherapy has been investigated to improve the therapeutic index in preclinical and clinical studies.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34">(31-34)</a> Furthermore, developing novel CA-4 analogues of improved specificity is another important approach to reduce their toxicity.<a onclick="showRef(event, 'ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38">(35-38)</a></div><div class="NLM_p">It is well-known that CSIs have three important pharmacophore components, a linking bridge and two hydrophobic rings (rings A and B, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), and the appropriate dihedral angle and cis-configuration of the two rings are important. As the two hydrophobic rings of the CA-4 analogues are essential to their activities,<a onclick="showRef(event, 'ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42">(39-42)</a> a large number of modifications of CA-4 focused on the linking bridge.<a onclick="showRef(event, 'ref43 ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45 ref46 ref47 ref48">(43-48)</a> There also some modifications focused on combining the linking bridge with the B ring, which provided a potential advantage in promoting the acitivities,<a onclick="showRef(event, 'ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52 ref53">(49-53)</a> enhancing the tumor selectivity, and minimizing the toxicity.<a onclick="showRef(event, 'ref36 ref37 ref38 ref54'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref54">(36-38, 54)</a> Therefore, we designed a new CA-4 analogue with the 1-benzylidene-3,4-dihydronaphthalen-2-one skeleton, in which the relatively flexible six-membered ring connects the linking bridge and B ring. It provided proper restriction to the dihedral angle of the two aromatic rings, and the carbonyl group near the linking bridge can improve its solubility and may be favorable for activity because of its polar interactions with the β-Ala250–Leu255 loop at the tubulin colchicine site.<a onclick="showRef(event, 'ref55 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57">(55-57)</a></div><div class="NLM_p last">In this study, a series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were synthesized, and their cytotoxicity levels were evaluated. The effects on tubulin polymerization and the tumor cell cycle distribution of selected compounds were investigated to determine their exact mechanism, and their modes of binding to tubulin were studied by molecular docking. The most promising compound was further tested for antitumor activity and toxicity in vivo.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83025" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83025" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The general route for the synthesis of the target 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives is depicted in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The appropriate dimethoxynaphthalenes were prepared by methylation with dimethyl sulfate. The intermediates <b>2a</b>–<b>c</b> were chemoselectively reduced at the β-position of the naphthalene ring using sodium in refluxing ethanol to yield derivatives <b>3a</b>–<b>c</b>. The Knoevenael reaction with the appropriate benzylidene catalyzed by piperidine and acetic acid at room temperature furnished 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The structures of 60 targeting compounds are listed in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) (CH<sub>3</sub>)<sub>2</sub>SO<sub>2</sub>, NaOH; (ii) Na, EtOH; (iii) substituted benzylidene, AcOH/piperidine, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><div class="NLM_p">The steric hindrance of the carbonyl group on naphthalen-2-one was found to favor the <i>E</i> isomer. Though the final compounds could exist as either <i>E</i> or <i>Z</i> isomers because of the presence of the exocyclic double bond, the synthesis gave rise to a single (predominant) isomer. To distinguish the configuration (<i>E</i> or <i>Z</i>) of these compounds, we focused on the chemical shifts of the H-2′ or H-6′ protons on the benzylidene A ring. In the literature,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> deshielding by the carbonyl group on the naphthalen-2-one would make chemical shifts of the H-2′ or H-6′ protons downfield from 7.45–7.84 ppm (<i>E</i> isomer) to 7.85–8.53 ppm (<i>Z</i> isomer). All the chemical shifts of the aromatic protons were below 7.84 ppm, consistent with the literature and indicating that the products were <i>E</i> isomers. To unequivocally confirm the configuration of these 1-benzylidene-3,4-dihydronaphthalen-2-one analogues, compound <b>22b</b> was subjected to single-crystal X-ray analysis, as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A, which also verified the <i>E</i> configuration.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of compound <b>22b</b>: (A) ORTEP drawing of compound <b>22b</b>; (B) superposition of <b>22b</b> (green) with the docking modes of CA4 (gray) bound to the colchicine of tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">X-ray crystal analysis of one compound indicated a low-energy conformation. In order to determine whether the 1-benzylidene-3,4-dihydronaphthalen-2-one skeleton could provide a proper restriction to the dihedral angle of the two aromatic rings, the X-ray crystal structure of compound <b>22b</b> was superimposed onto the binding conformation to tubulin of CA-4. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B, the conformation of compound <b>22b</b> fits that of CA-4 very well. The 1-benzylidene-3,4-dihydronaphthalen-2-one, via its flexible nonplanar structure incorporating an olefin linking bridge, restricted the appropriate dihedral angle of the two rings in a proper range.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Biological Activity</h3><div class="NLM_p">The in vitro antitumor activity of all the synthesized 1-benzylidene-3,4-dihydronaphthalen-2-one analogues was tested in three human tumor cell lines by MTT assay: the CEM human leukemia, HCT-116 human colon cancer, and MDA-MB-435 human breast carcinoma cell lines. These cell lines were selected from the solid tumors<a onclick="showRef(event, 'ref19 ref32'); return false;" href="javascript:void(0);" class="ref ref19 ref32">(19, 32)</a> and non-solid tumors<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> used in preclinical and clinical research of CA-4 analogues. CA-4 was used as a positive control. The results showed that all of the target compounds exhibited anticancer activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Compound <b>22b</b> displayed the strongest antiproliferative activity against CEM (IC<sub>50</sub> = 1 nM), MDA-MBA-435 (IC<sub>50</sub> = 1 nM), and HCT-116 cells (IC<sub>50</sub> = 0.1 μM). The compounds’ cytotoxicities against CEM and MDA-MBA-435 cells were compared to those of CA-4. In a follow-up assay, compound <b>22b</b> also showed potent cytotoxicity against other cell lines of these three tumors: the K562 human leukemia (IC<sub>50</sub> = 1 nM), HT-29 human colon cancer (IC<sub>50</sub> = 0.01 μM), and ZR-75-30 human breast carcinoma cell lines (IC<sub>50</sub> = 0.01 μM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Antiproliferative Effects of the Target Compounds<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0003.gif" alt="" id="GRAPHIC-d7e495-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">CEM</th><th class="colsep0 rowsep0" align="center">HCT-116</th><th class="colsep0 rowsep0" align="center">MDA-MB-435</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">CEM</th><th class="colsep0 rowsep0" align="center">HCT-116</th><th class="colsep0 rowsep0" align="center">MDA-MB-435</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">CEM</th><th class="colsep0 rowsep0" align="center">HCT-116</th><th class="colsep0 rowsep0" align="center">MDA-MB-435</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">8.69 ± 0.81</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">6.31 ± 0.84</td><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.92 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.94 ± 0.18</td><td class="colsep0 rowsep0" align="left"><b>4c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">1.53 ± 0.12</td><td class="colsep0 rowsep0" align="left">3.21 ± 0.30</td><td class="colsep0 rowsep0" align="left">1.45 ± 0.087</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2.64 ± 0.32</td><td class="colsep0 rowsep0" align="left">3.58 ± 0.30</td><td class="colsep0 rowsep0" align="left">1.37 ± 0.13</td><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.11 ± 0.021</td><td class="colsep0 rowsep0" align="left">0.86 ± 0.11</td><td class="colsep0 rowsep0" align="left">0.21 ± 0.04</td><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.89 ± 0.051</td><td class="colsep0 rowsep0" align="left">1.91 ± 0.10</td><td class="colsep0 rowsep0" align="left">0.73 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2.31 ± 0.44</td><td class="colsep0 rowsep0" align="left">2.56 ± 0.32</td><td class="colsep0 rowsep0" align="left">1.33 ± 0.24</td><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3.77 ± 0.30</td><td class="colsep0 rowsep0" align="left">3.68 ± 0.37</td><td class="colsep0 rowsep0" align="left">2.62 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left">4-C(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="left">4-C(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3.10 ± 0.16</td><td class="colsep0 rowsep0" align="left">6.70 ± 0.85</td><td class="colsep0 rowsep0" align="left">1.77 ± 0.25</td><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left">4-C(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">4-OH</td><td class="colsep0 rowsep0" align="left">4.32 ± 0.34</td><td class="colsep0 rowsep0" align="left">2.69 ± 0.28</td><td class="colsep0 rowsep0" align="left">1.54 ± 0.26</td><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">4-OH</td><td class="colsep0 rowsep0" align="left">0.96 ± 0.10</td><td class="colsep0 rowsep0" align="left">1.13 ± 0.11</td><td class="colsep0 rowsep0" align="left">0.45 ± 0.058</td><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="left">4-OH</td><td class="colsep0 rowsep0" align="left">1.05 ± 0.20</td><td class="colsep0 rowsep0" align="left">3.24 ± 0.58</td><td class="colsep0 rowsep0" align="left">0.86 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">4-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">8.68 ± 0.68</td><td class="colsep0 rowsep0" align="left">7.68 ± 0.80</td><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="left">4-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.68 ± 0.13</td><td class="colsep0 rowsep0" align="left">2.23 ± 0.086</td><td class="colsep0 rowsep0" align="left">0.54 ± 0.067</td><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="left">4-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">8.95 ± 0.79</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">5.38 ± 0.64</td><td class="colsep0 rowsep0" align="left">5.89 ± 0.16</td><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">1.21 ± 0.17</td><td class="colsep0 rowsep0" align="left">2.32 ± 0.30</td><td class="colsep0 rowsep0" align="left">0.75 ± 0.15</td><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">6.16 ± 0.78</td><td class="colsep0 rowsep0" align="left">6.45 ± 0.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">4-Br</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">6.80 ± 0.48</td><td class="colsep0 rowsep0" align="left">7.59 ± 1.02</td><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">4-Br</td><td class="colsep0 rowsep0" align="left">1.52 ± 0.11</td><td class="colsep0 rowsep0" align="left">2.94 ± 0.54</td><td class="colsep0 rowsep0" align="left">1.12 ± 0.067</td><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="left">4-Br</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">8.53 ± 0.48</td><td class="colsep0 rowsep0" align="left">7.52 ± 1.00</td><td class="colsep0 rowsep0" align="left">6.86 ± 0.43</td><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">0.95 ± 0.16</td><td class="colsep0 rowsep0" align="left">1.25 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.13</td><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">4.69 ± 0.69</td><td class="colsep0 rowsep0" align="left">5.83 ± 0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13a</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">8.91 ± 0.57</td><td class="colsep0 rowsep0" align="left">5.77 ± 1.06</td><td class="colsep0 rowsep0" align="left">3.35 ± 0.51</td><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.11</td><td class="colsep0 rowsep0" align="left">1.70 ± 0.30</td><td class="colsep0 rowsep0" align="left">0.46 ± 0.049</td><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">5.26 ± 0.51</td><td class="colsep0 rowsep0" align="left">2.35 ± 0.36</td><td class="colsep0 rowsep0" align="left">1.68 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14a</b></td><td class="colsep0 rowsep0" align="left">2,4-Cl<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">7.14 ± 0.75</td><td class="colsep0 rowsep0" align="left">9.32 ± 0.38</td><td class="colsep0 rowsep0" align="left"><b>14b</b></td><td class="colsep0 rowsep0" align="left">2,4-Cl<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.20 ± 0.08</td><td class="colsep0 rowsep0" align="left">2.15 ± 0.24</td><td class="colsep0 rowsep0" align="left">0.33 ± 0.064</td><td class="colsep0 rowsep0" align="left"><b>14c</b></td><td class="colsep0 rowsep0" align="left">2,4-Cl<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="left">3,4-Cl<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"><b>15b</b></td><td class="colsep0 rowsep0" align="left">3,4-Cl<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.86 ± 0.32</td><td class="colsep0 rowsep0" align="left">2.52 ± 0.34</td><td class="colsep0 rowsep0" align="left">1.23 ± 0.11</td><td class="colsep0 rowsep0" align="left"><b>15c</b></td><td class="colsep0 rowsep0" align="left">3,4-Cl<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16a</b></td><td class="colsep0 rowsep0" align="left">2,6-Cl<sub>2</sub></td><td class="colsep0 rowsep0" align="left">8.64 ± 0.87</td><td class="colsep0 rowsep0" align="left">6.71 ± 0.98</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"><b>16b</b></td><td class="colsep0 rowsep0" align="left">3-OH</td><td class="colsep0 rowsep0" align="left">1.46 ± 0.26</td><td class="colsep0 rowsep0" align="left">1.76 ± 0.28</td><td class="colsep0 rowsep0" align="left">0.76 ± 0.12</td><td class="colsep0 rowsep0" align="left"><b>16c</b></td><td class="colsep0 rowsep0" align="left">3-OH</td><td class="colsep0 rowsep0" align="left">2.57 ± 0.13</td><td class="colsep0 rowsep0" align="left">4.91 ± 0.84</td><td class="colsep0 rowsep0" align="left">2.07 ± 0.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="left">4-N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">9.78 ± 0.15</td><td class="colsep0 rowsep0" align="left">7.76 ± 0.93</td><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="left">4-N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">8.03 ± 1.28</td><td class="colsep0 rowsep0" align="left">8.73 ± 0.47</td><td class="colsep0 rowsep0" align="left">5.68 ± 0.55</td><td class="colsep0 rowsep0" align="left"><b>17c</b></td><td class="colsep0 rowsep0" align="left">4-N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18a</b></td><td class="colsep0 rowsep0" align="left">3-OH-4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">6.31 ± 1.13</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">5.62 ± 0.98</td><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="left">3-OH-4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.12 ± 0.020</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.049</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.062</td><td class="colsep0 rowsep0" align="left"><b>18c</b></td><td class="colsep0 rowsep0" align="left">3-OH-4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">1.42 ± 0.16</td><td class="colsep0 rowsep0" align="left">1.37 ± 0.18</td><td class="colsep0 rowsep0" align="left">1.05 ± 0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub>-4-OH</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">8.63 ± 0.39</td><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub>-4-OH</td><td class="colsep0 rowsep0" align="left">5.81 ± 0.47</td><td class="colsep0 rowsep0" align="left">7.50 ± 0.82</td><td class="colsep0 rowsep0" align="left">4.51 ± 0.54</td><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub>-4-OH</td><td class="colsep0 rowsep0" align="left">6.93 ± 1.07</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">4.35 ± 0.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="left">3,4-O(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.35 ± 0.26</td><td class="colsep0 rowsep0" align="left">2.12 ± 0.36</td><td class="colsep0 rowsep0" align="left">1.54 ± 0.22</td><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="left">3,4-O(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.072 ± 0.013</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.020</td><td class="colsep0 rowsep0" align="left">0.20 ± 0.023</td><td class="colsep0 rowsep0" align="left"><b>20c</b></td><td class="colsep0 rowsep0" align="left">3,4-O(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.27 ± 0.036</td><td class="colsep0 rowsep0" align="left">1.32 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="left">3,5-O(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">5.67 ± 0.71</td><td class="colsep0 rowsep0" align="left">3.95 ± 0.44</td><td class="colsep0 rowsep0" align="left"><b>21b</b></td><td class="colsep0 rowsep0" align="left">3,5-O(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.078 ± 0.013</td><td class="colsep0 rowsep0" align="left">0.15 ± 0.027</td><td class="colsep0 rowsep0" align="left">0.39 ± 0.078</td><td class="colsep0 rowsep0" align="left"><b>21c</b></td><td class="colsep0 rowsep0" align="left">3,5-O(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.26 ± 0.044</td><td class="colsep0 rowsep0" align="left">0.50 ± 0.071</td><td class="colsep0 rowsep0" align="left">0.85 ± 0.080</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" align="left">3,4,5-O(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2.19 ± 0.42</td><td class="colsep0 rowsep0" align="left">1.24 ± 0.18</td><td class="colsep0 rowsep0" align="left">0.61 ± 0.10</td><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">3,4,5-O(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left">0.10 ± 0.014</td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left"><b>22c</b></td><td class="colsep0 rowsep0" align="left">3,4,5-O(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left">0.51 ± 0.092</td><td class="colsep0 rowsep0" align="left">0.34 ± 0.062</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="left">2,3,4-O(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="left">2,3,4-O(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.85 ± 0.13</td><td class="colsep0 rowsep0" align="left">1.68 ± 0.24</td><td class="colsep0 rowsep0" align="left">0.95 ± 0.14</td><td class="colsep0 rowsep0" align="left"><b>23c</b></td><td class="colsep0 rowsep0" align="left">2,3,4-O(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">4.21 ± 0.48</td><td class="colsep0 rowsep0" align="left">2.68 ± 0.23</td><td class="colsep0 rowsep0" align="left">1.35 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent determinations.</p></div></div></div><div class="NLM_p">The hydrophobic B ring was fundamental for antiproliferative activity.<a onclick="showRef(event, 'ref40 ref61'); return false;" href="javascript:void(0);" class="ref ref40 ref61">(40, 61)</a> The position of the methoxy substituent on the 3,4-dihydronaphthalen-2-one moiety (B ring) had a critical influence on their cytotoxicities. The SAR information indicated that the methoxy group located at the C-6 position exhibited the best activity; shifting it to the C-5 or C-7 position resulted in moderate activity. Most of the 6-methoxy substituted compounds were 2- to 60- fold more potent than 5- or 7-methoxy counterparts against all the test cancer cells. Notably, the most active compound, <b>22b</b>, caused a distinct increase in cytotoxicity by 2–3 orders of magnitude (<b>22b</b> vs <b>22a</b>, <b>22c</b>). The 6-methoxy group on the tetralone ring in 1-benzylidene-3,4-dihydronaphthalen-2-ones may mimic the para-methoxy on the B ring of CA-4, exerting maximum activity.</div><div class="NLM_p">In the series of 6-methoxy-3,4-dihydronaphthalen-2-one analogues, compound <b>22b</b>, which has a 3,4,5- trimethoxy group on its A ring, showed the most pronounced antiproliferative activity. To determine the role of SAR substitutions on the 1-benzylidene ring (A ring of CA-4), we introduced various groups to the A ring. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, compounds with a methoxy group were generally more cytotoxic than the other moieties. Neither replacement with a smaller group (<b>5b</b> vs <b>6b</b>) nor replacement with a larger (<b>5b</b> vs <b>7b</b>, <b>17b</b>) caused any decrease in potency. Replacement with more polar groups (<b>5b</b> vs <b>8b</b>, <b>9b</b>, <b>10b</b>) resulted in a slight loss of cytotoxic activity.</div><div class="NLM_p">The number and location of methoxy substituted on A ring played a profound role on antiproliferative activity. A comparison between the antiproliferative activities of compounds <b>22b</b>, <b>20b</b>, <b>21b</b>, and <b>5b</b> illustrated the cytotoxic SAR of the number of methoxy groups substituted on the A ring (3 > 2 > 1). However, introducing a methoxy group at the C-2 position on the A ring showed a deleterious effect on activity. It was supported by compound <b>23b</b> (2,3,4- trimethoxy), which was around 5- to 10-fold less active than the dimethoxy substituent (<b>20b</b> and <b>21b</b>) and about 2- to 8-fold less potent than the methoxy substituent (<b>5b</b>). Replacing any methoxy on compound <b>20b</b> with a hydroxyl moiety (resulting in compounds <b>18b</b> and <b>19b</b>) was found to cause a 3- to 80-fold decrease in antiproliferative activity against all cell lines, further indicating that the presence of polar substituents on the A ring is unfavorable to potency.</div><div class="NLM_p">To determine whether these compounds exert their activities by direct interaction with microtubules, selected compounds (<b>5b</b>, <b>20b</b>, <b>21b</b>, <b>22a</b>, <b>22b</b>, <b>22c</b>, and <b>23b</b>) were examined for their effects on the in vitro polymerization of tubulin (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). CA-4 was also examined for comparative purposes. The results showed that compound <b>22b</b>, which had shown the strongest cytotoxicity, has the strongest antitubulin activity (IC<sub>50</sub> of 3.93 μM compared to 1.77 μM for CA-4). This trend for the inhibition of tubulin polymerization of the compounds was in good qualitative agreement with their cytotoxic SAR. Compound <b>22b</b> (6-methoxy on the B ring), which has the same 3,4,5-trimethoxy group on the A ring, was found to be more potent than <b>22a</b> (5-methoxy) and <b>22c</b> (7-methoxy) against cancer cell lines. It was also more active against tubulin polymerization. This is consistent with the conclusion that methoxy substituted at the C-6 position of 3,4-dihydronaphthalen-2-one is more effective than at C-5 or C-7. A gradual decrease in antitubulin activity was observed as we moved from compounds <b>22b</b>, <b>20b</b>, <b>21b</b> to <b>5b</b>. This was also consistent with their antiproliferative tendencies, which appear to be based on the number of methoxy groups on the A ring. In addition, the antitubulin abilities (<b>23b</b> vs <b>5b</b>) also illustrated that a methoxy group at the C-2 position on the A ring had a negative effect. This was consistent with the observation of cytotoxicities. On the basis of this correlation between the antitubulin and anticancer activities, we concluded that the antiproliferative effects of these compounds were mediated by direct interaction with tubulin.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Antitubulin Effects of the Target Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">inhibition of tubulin assembly, IC<sub>50</sub> ± SD (μM) </th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" align="left">18.68 ± 2.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">3.93 ± 0.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22c</b></td><td class="colsep0 rowsep0" align="left">9.63 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="left">6.42 ± 0.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21b</b></td><td class="colsep0 rowsep0" align="left">6.88 ± 1.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">25.82 ± 2.96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="left">25.78 ± 2.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4</td><td class="colsep0 rowsep0" align="left">1.77 ± 0.42</td></tr></tbody></table></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Analysis of Cell Cycle Effects</h3><div class="NLM_p">Because the inhibition of tubulin polymerization is often implicated in G2/M-phase cell cycle arrest in various cancer cell lines, the effects of different concentrations of compound <b>22b</b> on cell cycle progression were examined with HCT-116 cells. After 24 h of exposure, compound <b>22b</b> was found to cause an obvious increase in the number cells in the G2/M phase with a concomitant decrease of cells in the G1 and S phases. This effect appeared to be dose dependent. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, lower concentrations of <b>22b</b> (0.2 μM) induced a slight alteration (17% of cells were in the G2/M phase, compared to 13% of untreated cells) in the distribution of HCT-116 cells throughout the cell cycle, whereas higher concentrations (2 μM) induced a massive accumulation (74%).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell cycle distribution of human cancer HCT-116 cells treated for 24 h with different amounts of <b>22b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Molecular Modeling Studies</h3><div class="NLM_p">To make sense of the cytotoxic and antitubulin data observed, molecular docking simulations of the relative compounds to tubulin were carried out. The X-ray crystal structure of the DAMA–colchicine–tubulin complex (PDB code <a href="https://" class="ext-link">1SA0</a>) was used as the tubulin protein template. The result shows that most of the compounds bound to the colchicine binding site of tubulin in the same orientation with CA-4. Compound <b>22b</b> bound to tubulin nicely, and the binding mode is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A. The trimethoxyphenyl moiety can foster van der Waals interactions with the hydrophobic P1 pocket bounded by Leu248, Ala316, Val318, Lys352, and Ile378 of β-tubulin, while the tetralone ring can foster van der Waals interactions with the hydrophobic P2 pocket consisting of Thr179, Val181 of α-tubulin and Asn258, Met259, Lys352 of β-tubulin. Two methoxy O atoms on the A ring form a hydrogen bond with the thiol group of Cys241 of β-tubulin. The carbonyl group on tetralone remains in proximity to the polar region L (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) with large flexibility (Leu248-Lys254 of β-tubulin), which has the possibility to form hydrogen bonds directly or through the structured water molecules.<a onclick="showRef(event, 'ref57 ref62'); return false;" href="javascript:void(0);" class="ref ref57 ref62">(57, 62)</a></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Predicted binding modes with DAMA-colchicine at the β-tubulin binding site: (A) CA-4 (green) and <b>22b</b> (red); (B) <b>22b</b> (red) and <b>23b</b> (blue). P1 and P2 are two hydrophobic pockets in the interface between α- and β-tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The methoxy on the B ring is placed in the hydrophobic P2 pocket and enhances the van der Waals interactions with it. However, the methoxy at the C-6 position was buried deeper in the pocket than C-5 or C-7 position when binding, leading to compounds bearing this group to have relatively higher binding abilities, which is consistent with their biological activity levels observed. In addition, the methoxy at C-3, C-4, and C-5 positions of the A ring forms van der Waals interactions well with the hydrophobic P1 pocket. This may be the reason why adding methoxy groups to these positions can enhance their cytotoxic activity, and the presence of polar substituents is unfavorable to activity. The methoxy is the group with optimal volume for interaction with this pocket, which can explain why replacement with neither a smaller group nor a larger group is unfavorable to activity. However, introducing a methoxy group at the C-2 position on the A ring showed a dramatic loss in activity, which can be rationalized by the docking result of compound <b>23b</b> compared to compound <b>22b</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). The A ring cannot occupy the P1 pocket well because of steric hindrance with tubulin of the C-2 position methoxy.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vivo Antitumor Activity</h3><div class="NLM_p">Compound <b>22b</b> and CA-4 were preliminarily evaluated for toxicity against male ICR mice, using ip administration once on day 1. Mice were randomly divided into the control group and intervention groups (150, 300, 600 mg/kg for compound <b>22b</b>; 50 and 100 mg/kg for CA-4) with 20 mice in each group and half male and half female. The dose 100 mg/kg for CA-4 caused one mouse (1/20) to die on day 2 and another two mice to die on day 5, and the other doses for CA-4 and compound <b>22b</b> did not cause any mouse to die. The body weight change of the mice over the course of the experiment is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>. Compared to the control vehicle-treated mice, compound <b>22b</b>, even at a dose of 600 mg/kg, did not cause significant body weight loss, which is indicative of negligible systemic toxicity over 10 days. However, significant body weight loss was observed at 50 mg/kg CA-4, suggesting some systemic toxicity.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Acute toxicity testing for compound <b>22b</b> and CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Guided by the preliminary toxicity experiment, the doses (100, 150, 300 mg/kg for compound <b>22b</b>; 30 and 50 mg/kg for CA-4) were chosen to evaluate their in vivo antitumor activity. Human colon carcinoma xenografts were established by subcutaneous implantation of HT-29 cells (5 × 10<sup>6</sup>) on the right flanks of BALB/C nude mice. Once the HT-29 xenografts reached a size of around 100 mm<sup>3</sup>, mice were randomly assigned into control group (12 mice) and intervention groups (6 mice per group). Antitumor activities of compound <b>22b</b> and CA-4 (ip once a day) were studied with cisplatin (ip the first 2 days) as a positive control. The results (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) showed that compound <b>22b</b> at 100, 150, and 300 mg/kg dose-dependently decreased tumor volumes on day 21 (<i>T</i>/<i>C</i> = 52%, 45%, and 34%, respectively), while the <i>T</i>/<i>C</i> of CA-4 at 50 mg/kg was 47%. Compared to the control vehicle-treated mice, compound <b>22b</b> at diverse doses did not cause obvious body weight loss, and the vital organs (kidney, liver, and spleen) examined after euthanization at the end of the experiment appear the same in terms of color, weight, and size, indicating negligible toxicity to the mice. However, obvious body weight loss was observed at every dose of CA-4, and lost weight of the vital organs was observed at 50 mg/kg CA-4. The biochemical parameters (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) examined at the end of the experiment showed that, after compound treatment, white blood cells and lymphocytes may decrease and alanine transaminase and alkaline phosphatase may increase compared to the vehicle control, which indicated some toxicity to liver and bone marrow. However, at a dose (compound <b>22b</b>, 150 mg/kg; CA-4, 50 mg/kg) achieving a similar <i>T</i>/<i>C</i> ratio, the change of the biochemical parameters of compound <b>22b</b> was less obvious than that of CA-4. Even at a greater dose achieving a larger <i>T</i>/<i>C</i> ratio (300 mg/kg, <i>T</i>/<i>C</i> = 34%), compound <b>22b</b> still displayed this advantage.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibition of human xenograft growth in vivo by compound <b>22b</b> and CA-4. HT-29 tumor-bearing nude mice were administered vehicle alone or 100, 150, 300 mg/kg compound <b>22b</b> or 30, 50 mg/kg CA-4 intraperitoneally once a day. The figure shows the tumor volume of <b>22b</b> (A) and CA-4 (B) recorded at the indicated days after treatments. Data are expressed as mean ± SEM of tumor volume at each time point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Blood Analysis after in Vivo Antitumor Activity against Human Colon Carcinoma Model<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd (mg/kg)</th><th class="colsep0 rowsep0" align="center">mice (<i>n</i>)</th><th class="colsep0 rowsep0" align="center">toxic death</th><th class="colsep0 rowsep0" align="center">tumor volume, mean ± SD (mm<sup>3</sup>)</th><th class="colsep0 rowsep0" align="center"><i>T</i>/<i>C</i> (%)</th><th class="colsep0 rowsep0" align="center">body wt change, mean (g)</th><th class="colsep0 rowsep0" align="center">WBC (×10<sup>3</sup> mm<sup>–3</sup>)</th><th class="colsep0 rowsep0" align="center">LY (×10<sup>3</sup> mm<sup>–3</sup>)</th><th class="colsep0 rowsep0" align="center">PLT (×10<sup>3</sup> mm<sup>–3</sup>)</th><th class="colsep0 rowsep0" align="center">ALT (IU/L)</th><th class="colsep0 rowsep0" align="center">ALP (IU/L)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">control</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">0/12</td><td class="colsep0 rowsep0" align="left">1702 ± 114</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">25.38 ± 0.22</td><td class="colsep0 rowsep0" align="left">15.88 ± 0.41</td><td class="colsep0 rowsep0" align="left">1509 ± 34</td><td class="colsep0 rowsep0" align="left">28 ± 0.4</td><td class="colsep0 rowsep0" align="left">107.6 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b> (100)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0/6</td><td class="colsep0 rowsep0" align="left">888 ± 126**</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">24.42 ± 0.27**</td><td class="colsep0 rowsep0" align="left">11.08 ± 0.27**</td><td class="colsep0 rowsep0" align="left">1440 ± 4</td><td class="colsep0 rowsep0" align="left">24 ± 0.6*</td><td class="colsep0 rowsep0" align="left">112 ± 1.3*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b> (150)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0/6</td><td class="colsep0 rowsep0" align="left">772 ± 149**</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">20.18 ± 0.10**</td><td class="colsep0 rowsep0" align="left">10.03 ± 0.85*</td><td class="colsep0 rowsep0" align="left">1375 ± 21</td><td class="colsep0 rowsep0" align="left">28 ± 0.6</td><td class="colsep0 rowsep0" align="left">116.3 ± 0.8*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b> (300)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0/6</td><td class="colsep0 rowsep0" align="left">595 ± 73**</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">19.96 ± 0.49**</td><td class="colsep0 rowsep0" align="left">8.87 ± 0.61**</td><td class="colsep0 rowsep0" align="left">1240 ± 34*</td><td class="colsep0 rowsep0" align="left">26 ± 0.6</td><td class="colsep0 rowsep0" align="left">107.6 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4 (30)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0/6</td><td class="colsep0 rowsep0" align="left">905 ± 98**</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">19.34 ± 0.38**</td><td class="colsep0 rowsep0" align="left">10.62 ± 2.01</td><td class="colsep0 rowsep0" align="left">1923 ± 38*</td><td class="colsep0 rowsep0" align="left">25 ± 0.6*</td><td class="colsep0 rowsep0" align="left">105.3 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4 (50)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0/6</td><td class="colsep0 rowsep0" align="left">799 ± 98**</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">12.09 ± 0.20**</td><td class="colsep0 rowsep0" align="left">4.14 ± 0.04**</td><td class="colsep0 rowsep0" align="left">2206 ± 38**</td><td class="colsep0 rowsep0" align="left">66.3 ± 0.4**</td><td class="colsep0 rowsep0" align="left">149.3 ± 1.1**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cisplatin (7)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0/6</td><td class="colsep0 rowsep0" align="left">493 ± 41**</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">7.34 ± 0.24**</td><td class="colsep0 rowsep0" align="left">4.11 ± 0.14**</td><td class="colsep0 rowsep0" align="left">902 ± 14**</td><td class="colsep0 rowsep0" align="left">29.6 ± 1.1</td><td class="colsep0 rowsep0" align="left">127.6 ± 2.8*</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">WBC = white blood cell. LY = lymphocyte. PLT = platelet. ALT = alanine transaminase. ALP = alkaline phosphatase. Data are expressed as the mean ± SEM. (∗) <i>P</i> < 0.05, (∗∗) <i>P</i> < 0.01 vs control.</p></div></div></div><div class="NLM_p last">All these results showed that this CA-4 analogue compound <b>22b</b> could inhibit tumor growth significantly and seemed safer than CA-4 when achieving a similar tumor suppression, which is probably attributed to its negligible effect on normal tissues and good specificity of tumor-related vasculature. The exact mechanism still needs further research.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26616" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26616" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were designed and synthesized, and their biological activities were evaluated in vitro and in vivo. The results showed all the title compounds to exhibit inhibitory activity against the three human cancer cell lines. Preliminary structure–activity relationship studies indicated that substitution at the C-6 position of the B ring of the title molecule was beneficial to cytotoxic activity. Among all analogues synthesized in this study, (<i>E</i>)-1-(3,4,5-trimethoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>22b</b>) was the most potent inhibitor of human tumor cell growth (IC<sub>50</sub> of 1 nM against several human tumor cell lines) and tubulin polymerization (IC<sub>50</sub> of 3.93 μM). A flow cytometric study showed that a significant percentage of HCT-116 cells treated with the most potent compound, <b>22b</b>, became arrested in the G2/M phases of the cell cycle. These results showed that the antiproliferative effects of these compounds were mediated by direct interaction with tubulin. Then molecular docking simulations of these compounds to tubulin were carried out. The results show that they are nicely bound to the colchicine binding site of tubulin with a very similar binding mode of CA-4 and can rationalize the experimental SAR well. The antitumor activity in vivo of compound <b>22b</b> was tested, and the results showed that compound <b>22b</b> could inhibit the tumor growth in colon nude mouse xenograft tumor model (HT-29 cells) significantly and seemed safer than CA-4 when achieving a similar tumor suppression. This study provides a new molecular scaffold for the further development of antitumor agents that target tubulin.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry. General Methods</h3><div class="NLM_p last">Melting points were measured on an electrically heated RK-Z melting point apparatus and are uncorrected. Infrared (IR) spectra were recorded on a PE Spectrum One FI-IR spectrometer as KBr pellets. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AC-300P spectrometer (Bruker Company, Germany), using TMS as an internal standard and CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> as solvents. Chemical shifts are given in ppm (δ), and the spectral data are consistent with the assigned structures. The mass spectra were recorded on a Micromass Qtof-Micro LC–MS instrument. Crystal structure was determined on a Bruker SMART CCD (Bruker Company, Germany). Silica gel thin-layer chromatography was performed on precoated plates GF-254. Silica gel column chromatography was performed with silica gel 60 G. All compounds were routinely checked by TLC by using silica gel plates GF-254. All solvents and reagents were analytically pure and, when necessary, were purified and dried by standard protocols. All starting materials were commercially available unless otherwise indicated. Yields of purified products were not optimized. The purity of each compound (>95%) was determined on an Agilent 1100 series LC system (column, ZORBAX Eclipse XDB C8, 4.6 mm × 150 mm, 5 μm; mobile phase, methanol (80%)/H<sub>2</sub>O; flow rate, 1.0 mL/min; UV wavelength, absorbance at 254 nm; temperature, ambient; injection volume, 20 μL).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Method for the Synthesis of Methoxy-2-tetralones <b>3a</b>–<b>c</b></h3><div class="NLM_p">The method to synthesize 5-methoxy-2-tetralone (<b>3a</b>) is described. To a 1 L round-bottom flask fitted with mechanical stirrer, 1,6-dimethoxynaphthalene (20.0 g, 0.11 mol) was added to the refluxing anhydrous ethanol (200 mL). Sodium (19 g, 0.83 mol), cut into small pieces, was added as rapidly as possible to the solution. Refluxing was continued until all sodium disappeared. The reaction mixture was cooled to 10 °C, and then 2 N hydrochloric acid (about 330 mL) was added dropwise until the pH was changed to 3. The reaction mixture was extracted with acetic ether (50 mL × 3). The ethyl acetate layers were combined and washed with saturated brine solution (50 mL × 3), dried over anhydrous sodium sulfate, and filtrated, and the solvent was evaporated. The residual oil was purified by distillation under reduced pressure to yield 11.8 g (63%) of <b>3a</b> as yellow oil, which solidified under room temperature: bp 160–165 °C (10 mmHg). Recrystallization from petroleum ether (bp 60–90 °C) gave <b>3a</b> as a white needle: mp 38–40 °C</div><div class="NLM_p last">Similarly, <b>3b</b> and <b>3c</b> were synthesized from the appropriate dimethoxynaphthalenes. Compound <b>3b</b>: mp 36–38 °C (lit. mp 36 °C). Compound <b>3c</b>: mp 28–30 °C (lit. mp 27–28 °C)</div></div><div id="sec4_1_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Method for the Synthesis of (<i>E</i>)-1-Benzylidenemethoxy-2-tetralone Analogues (<b>4</b>–<b>23</b>). (<i>E</i>)-1-(3,4,5-Trimethoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>22b</b>)</h3><div class="NLM_p">A solution of compound <b>3b</b> (1.76 g, 10 mmol) and 3,4,5-trimethoxybenzaldehyde (1.96 g, 10 mmol) in dichloromethane (30 mL) was stirred under room temperature for 24 h. The reaction mixture was washed with water, saturated brine solution. The combined organic layers were dried over anhydrous sodium sulfate, filtered, evaporated in vacuo, and purified by column chromatography on silica gel (eluent, petroleum ether/acetic ether, 50:1 to 10:1 v/v) or recrystallization to afford the pure compound <b>22b</b> as a yellow crytstal. Yield 47%. Mp: 102–104 °C. HPLC: 99.7%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.49 (s, 1H), 7.44 (d, <i>J</i> = 8.6 Hz, 1H), 6.80 (d, <i>J</i> = 2.2 Hz, 1H), 6.72 (s, 2H), 6.64 (dd, <i>J</i> = 8.6, 2.2 Hz, 1H), 3.85 (s, 6H), 3.71 (s, 6H), 3.01 (t, <i>J</i> = 6.4 Hz, 2H), 2.62 (t, <i>J</i> = 6.4 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.78, 159.42, 152.91, 140.23, 138.68, 133.21, 132.59, 130.60, 130.46, 124.86, 112.73, 111.81, 106.86, 60.89, 55.93, 55.25, 36.98, 28.05; HRMS (ES+) <i>m</i>/<i>z</i> found 354.1466; C<sub>21</sub>H<sub>22</sub>O<sub>5</sub>(M<sup>+</sup>) requires 354.1467.</div><div class="NLM_p last">The synthetic methods for the following compounds were similar to the synthesis of compound <b>22b</b>.</div></div><div id="sec4_1_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (<i>E</i>)-1-Benzylidene-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>4a</b>)</h3><div class="NLM_p last">Yield 58%, yellow crystal. Mp: 110–112 °C. HPLC: 96.2%. IR (KBr) ν (cm<sup>–1</sup>): 3355, 3072, 3020, 2995, 2958, 2904, 2831, 1688, 1606, 1569, 1488, 1439, 1403, 1359, 1303, 1278, 1241, 1190, 1167, 1096, 1038, 991, 934, 899, 874, 850, 808, 756, 710, 690, 586, 553, 504, 462, 425. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.71 (s, 1H), 7.41–7.44 (m, 2H), 7.24–7.29 (m, 3H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 6.83 (s, 1H), 6.77 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 3.45 (s, 3H), 2.99 (t, <i>J</i> = 6.3 Hz, 2H), 2.62 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.50, 157.54, 135.37, 135.27, 133.84, 130.73, 129.56, 128.90, 128.87, 128.40, 115.33, 113.16, 55.00, 37.32, 26.90; HRMS (ES+) <i>m</i>/<i>z</i> found 264.1152; C<sub>18</sub>H<sub>16</sub>O<sub>2</sub> (M<sup>+</sup>) requires 264.1150.</div></div><div id="sec4_1_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<i>E</i>)-1-Benzylidene-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>4b</b>)</h3><div class="NLM_p last">Yield 52%, yellow crystal. Mp: 105–107 °C. HPLC: 95.8%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.60 (s, 1H), 7.40–7.47 (m, 2H), 7.24–7.29 (m, 4H), 6.80 (d, <i>J</i> = 2.4 Hz, 1H), 6.57 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 3.83 (s, 3H), 3.02 (t, <i>J</i> = 6.6 Hz, 2H), 2.63 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.78, 159.40, 140.07, 135.55, 133.31, 133.24, 130.38, 129.40, 128.60, 128.34, 124.94, 112.78, 112.03, 55.20, 37.01, 28.04; HRMS (ES+) <i>m</i>/<i>z</i> found 264.1166; C<sub>18</sub>H<sub>16</sub>O<sub>2</sub> (M<sup>+</sup>) requires 264.1150.</div></div><div id="sec4_1_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<i>E</i>)-1-Benzylidene-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>4c</b>)</h3><div class="NLM_p last">Yield 58%, yellow crystal. Mp: 118–120 °C. HPLC: 97.4%. IR (KBr) ν (cm<sup>–1</sup>): 3077, 3043, 3021, 2996, 2966, 2933, 2873, 2837, 2795, 1686, 1599, 1574, 1473, 1442, 1408, 1365, 1342, 1301, 1272, 1253, 1181, 1159, 1138, 1067, 1020, 962, 929, 910, 841, 783, 756, 732, 697, 662, 564, 537, 471, 441. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.71 (s, 1H), 7.30–7.36 (m, 2H), 7.23–7.27 (m, 3H), 6.98 (d, <i>J</i> = 7.8 Hz, 1H), 6.92 (d, <i>J</i> = 7.8 Hz, 1H), 6.79 (d, <i>J</i> = 7.8 Hz, 1H), 3.88 (s, 3H), 3.10 (t, <i>J</i> = 6.3 Hz, 2H), 2.58 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.09, 156.19, 135.44, 135.29, 134.00, 133.91, 129.65, 128.85, 128.28, 127.02, 126.54, 121.45, 109.69, 55.56, 36.55, 19.33; HRMS (ES+) <i>m</i>/<i>z</i> found 264.1151; C<sub>18</sub>H<sub>16</sub>O<sub>2</sub> (M<sup>+</sup>) requires 264.1150.</div></div><div id="sec4_1_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>E</i>)-1-(4-Methoxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>5a</b>)</h3><div class="NLM_p last">Yield 55%, yellow crystal. Mp: 106–108 °C. HPLC: 96.6%. IR (KBr) ν (cm<sup>–1</sup>): 3075, 2994, 2953, 2906, 2842, 1682, 1606, 1588, 1510, 1490, 1462, 1442, 1409, 1364, 1295, 1251, 1208, 1171, 1136, 1110, 1028, 946, 904, 871, 826, 720, 590, 527, 502. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 7.46 (d, <i>J</i> = 7.2 Hz, 2H), 7.18 (d, <i>J</i> = 8.1 Hz, 1H), 6.99 (s, 1H), 6.81 (d, <i>J</i> = 7.8 Hz, 2H), 6.76 (s, 1H), 3.82 (s, 3H), 3.55 (s, 3H), 2.96 (s, 2H), 2.60 (s, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.69, 160.38, 157.52, 135.30, 133.76, 131.93, 131.63, 130.70, 128.81, 127.19, 114.83, 113.78, 112.93, 55.25, 55.14, 37.36, 26.92; HRMS (ES+) <i>m</i>/<i>z</i> found 294.1255; C<sub>19</sub>H<sub>18</sub>O<sub>3</sub> (M<sup>+</sup>) requires 294.1256.</div></div><div id="sec4_1_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>E</i>)-1-(4-Methoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>5b</b>)</h3><div class="NLM_p last">Yield 52%, yellow crystal. Mp: 118–120 °C. HPLC: 97.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.62 (s, 1H), 7.47 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.38 (d, <i>J</i> = 8.1 Hz, 2H), 6.87 (d, <i>J</i> = 8.1 Hz, 2H), 6.80 (d, <i>J</i> = 2.7 Hz, 1H), 6.60 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.00 (t, <i>J</i> = 6.6 Hz, 2H), 2.61 (t, <i>J</i> = 6.6 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 294.1257; C<sub>19</sub>H<sub>18</sub>O<sub>3</sub> (M<sup>+</sup>) requires 294.1256.</div></div><div id="sec4_1_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>E</i>)-1-(4-Methoxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>5c</b>)</h3><div class="NLM_p last">Yield 60%, yellow crystal. Mp: 128–130 °C. HPLC: 95.8%. IR (KBr) ν (cm<sup>–1</sup>): 3091, 3072, 3002, 2955, 2932, 2906, 2882, 2835, 1687, 1604, 1568, 1507, 1466, 1438, 1367, 1340, 1305, 1255, 1168, 1140, 1110, 1067, 1031, 964, 911, 825, 798, 779, 732, 517, 428. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 6.98–7.07 (m, 2H), 6.77 (d, <i>J</i> = 8.7 Hz, 2H), 6.76 (s, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.07 (t, <i>J</i> = 6.3 Hz, 2H), 2.56 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.17, 160.33, 156.20, 135.40, 134.44, 132.05, 131.61, 127.41, 126.96, 126.48, 121.17, 113.72, 109.46, 55.55, 55.23, 36.64, 19.34; HRMS (ES+) <i>m</i>/<i>z</i> found 294.1254; C<sub>19</sub>H<sub>18</sub>O<sub>3</sub> (M<sup>+</sup>) requires 294.1256.</div></div><div id="sec4_1_3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>E</i>)-1-(4-Methylbenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>6a</b>)</h3><div class="NLM_p last">Yield 40%, yellow crystal. Mp: 104–106 °C. HPLC: 96.2%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.68 (s, 1H), 7.36 (d, <i>J</i> = 8.1 Hz, 2H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.1 Hz, 2H), 6.92 (s, 1H), 6.77 (dd, <i>J</i> = 8.4, 2.7 Hz, 1H), 6.83 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.2 Hz, 1H), 3.52 (s, 3H), 2.98 (t, <i>J</i> = 6.6 Hz, 2H), 2.61 (t, <i>J</i> = 6.6 Hz, 2H), 2.34 (s, 3H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.63, 157.49, 139.26, 135.56, 133.57, 133.03, 132.08, 130.68, 129.70, 129.06, 128.76, 114.96, 113.17, 55.06, 37.31, 26.89, 21.38; HRMS (ES+) <i>m</i>/<i>z</i> found 278.1330; C<sub>19</sub>H<sub>18</sub>O<sub>2</sub>(M<sup>+</sup>) requires 278.1307.</div></div><div id="sec4_1_3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>E</i>)-1-(4-Methylbenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>6b</b>)</h3><div class="NLM_p last">Yield 46%, yellow crystal. Mp: 120–122 °C. HPLC: 96.8%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.58 (s, 1H), 7.35 (dd, <i>J</i> = 8.1, 2.7 Hz, 3H), 7.07 (d, <i>J</i> = 8.1 Hz, 2H), 6.80 (d, <i>J</i> = 2.7 Hz, 1H), 6.60 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 3.83 (s, 3H), 3.00 (t, <i>J</i> = 6.3 Hz, 2H), 2.62 (t, <i>J</i> = 6.3 Hz, 2H), 2.34 (s, 3H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.88, 159.34, 140.05, 138.94, 133.57, 132.53, 130.29, 129.52, 129.11, 125.23, 112.76, 112.03, 55.23, 37.10, 28.10, 21.41; HRMS (ES+) <i>m</i>/<i>z</i> found 278.1307; C<sub>19</sub>H<sub>18</sub>O<sub>2</sub>(M<sup>+</sup>) requires 278.1307.</div></div><div id="sec4_1_3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>E</i>)-1-(4-Methylbenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>6c</b>)</h3><div class="NLM_p last">Yield 48%, yellow crystal. Mp: 160–162 °C. HPLC: 97.9%. IR (KBr) ν (cm<sup>–1</sup>): 3092, 3022, 2959, 2889, 2855, 2835, 1690, 1608, 1594, 1573, 1503, 1474, 1438, 1400, 1365, 1340, 1303, 1264, 1249, 1183, 1163, 1141, 1109, 1068, 1020, 986, 965, 910, 887, 844, 813, 789, 780, 731, 693, 669, 573, 499, 472, 430. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.32 (d, <i>J</i> = 7.8 Hz, 2H), 7.06 (d, <i>J</i> = 8.1 Hz, 2H), 6.99 (d, <i>J</i> = 4.5 Hz, 2H), 6.78 (t, <i>J</i> = 4.5 Hz, 1H), 3.89 (s, 3H), 3.08 (t, <i>J</i> = 6.6 Hz, 2H), 2.57 (t, <i>J</i> = 6.6 Hz, 2H), 2.34 (s, 3H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.19, 156.16, 139.22, 135.65, 134.25, 133.12, 132.22, 129.78, 129.02, 126.95, 126.50, 121.35, 109.54, 55.55, 36.60, 21.43, 19.33; HRMS (ES+) <i>m</i>/<i>z</i> found 278.1306; C<sub>19</sub>H<sub>18</sub>O<sub>2</sub>(M<sup>+</sup>) requires 278.1307.</div></div><div id="sec4_1_3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>E</i>)-1-(4-<i>tert</i>-Butylbenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>7a</b>)</h3><div class="NLM_p last">Yield 53%, yellow crystal. Mp: 140–142 °C. HPLC: 99.3%. IR (KBr) ν (cm<sup>–1</sup>): 3027, 2955, 2952, 2906, 2863, 2836, 1693, 1612, 1594, 1571, 1489, 1402, 1362, 1302, 1273, 1244, 1192, 1166, 1093, 1040, 993, 904, 828, 800, 709, 591, 549, 492, 420. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.70 (s, 1H), 7.43 (d, <i>J</i> = 8.1 Hz, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 7.31 (d, <i>J</i> = 8.4 Hz, 2H), 7.16 (d, <i>J</i> = 8.4 Hz, 1H), 6.89 (d, <i>J</i> = 2.7 Hz, 1H), 6.77 (dd, <i>J</i> = 8.4, 2.7 Hz, 1H), 3.47 (s, 3H), 2.98 (t, <i>J</i> = 6.6 Hz, 1H), 2.62 (t, <i>J</i> = 6.6 Hz, 1H), 1.31 (s, 9H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.68, 157.45, 152.43, 135.52, 133.57, 133.29, 132.25, 130.70, 129.49, 128.79, 125.30, 115.39, 112.92, 54.94, 37.37, 34.76, 31.11, 26.92; HRMS (ES+) <i>m</i>/<i>z</i> found 320.1778; C<sub>22</sub>H<sub>24</sub>O<sub>2</sub> (M<sup>+</sup>) requires 320.1776.</div></div><div id="sec4_1_3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>E</i>)-1-(4-<i>tert</i>-Butylbenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>7b</b>)</h3><div class="NLM_p last">Yield 56%, yellow crystal. Mp: 146–148 °C. HPLC: 97.1%. IR (KBr) ν (cm<sup>–1</sup>): 3445, 3360, 3027, 2972, 2952, 2864, 1688, 1600, 1494, 1460, 1406, 1362, 1308, 1259, 1229, 1191, 1163, 1141, 1108, 1089, 1029, 912, 873, 843, 824, 714, 664, 621, 561, 470. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.58 (s, 1H), 7.40 (s, 3H), 7.28 (d, <i>J</i> = 6.6 Hz, 2H), 6.81 (s, 1H), 6.62 (d, <i>J</i> = 8.4 Hz, 1H), 3.84 (s, 3H), 3.00 (s, 2H), 2.61 (s, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.02, 159.33, 152.21, 140.01, 133.44, 132.57, 132.37, 130.30, 129.41, 125.28, 112.71, 112.06, 55.23, 37.06, 34.74, 31.14, 28.07; HRMS (ES+) <i>m</i>/<i>z</i> found 320.1776; C<sub>22</sub>H<sub>24</sub>O<sub>2</sub> (M<sup>+</sup>) requires 320.1776.</div></div><div id="sec4_1_3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>E</i>)-1-(4-<i>tert</i>-Butylbenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>7c</b>)</h3><div class="NLM_p last">Yield 46%, yellow powder. Mp: 150–152 °C. HPLC: 96.3%. IR (KBr) ν (cm<sup>–1</sup>): 3079, 3002, 2960, 2869, 2838, 1688, 1595, 1572, 1505, 1471, 1440, 1403, 1364, 1342, 1250, 1176, 1158, 1139, 1105, 1072, 1019, 962, 912, 827, 777, 727, 674, 576, 440. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.66 (s, 1H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.27 (d, <i>J</i> = 8.4 Hz, 2H), 7.02 (d, <i>J</i> = 7.8 Hz, 2H), 6.80 (d, <i>J</i> = 7.5 Hz, 1H), 3.89 (s, 3H), 3.08 (t, <i>J</i> = 6.6 Hz, 2H), 2.57 (t, <i>J</i> = 6.6 Hz, 2H), 1.31 (s, 9H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.33, 156.16, 152.48, 135.49, 134.31, 133.19, 132.12, 129.68, 126.94, 126.52, 125.20, 121.40, 109.60, 55.56, 36.58, 34.76, 31.15, 19.34; HRMS (ES+) <i>m</i>/<i>z</i> found 320.1779; C<sub>22</sub>H<sub>24</sub>O<sub>2</sub> (M<sup>+</sup>) requires 320.1776.</div></div><div id="sec4_1_3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>E</i>)-1-(4-Hydroxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>8a</b>)</h3><div class="NLM_p last">Yield 40%, yellow crystal. Mp: 150–152 °C. HPLC: 95.4%. IR (KBr) ν (cm<sup>–1</sup>): 3377, 3021, 2995, 2940, 2908, 2834, 1679, 1612, 1586, 1512, 1488, 1432, 1403, 1367, 1303, 1275, 1249, 1191, 1167, 1100, 1039, 994, 961, 906, 831, 803, 706, 627, 587, 549, 525, 477, 446; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.62 (s, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 2H), 6.98–7.12 (m, 2H), 6.82 (d, <i>J</i> = 7.2 Hz, 2H), 6.70–6.76 (m, 1H), 5.50 (s, 1H), 3.82 (s, 3H), 2.99 (t, <i>J</i> = 6.3 Hz, 2H), 2.59 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 280.1098; C<sub>18</sub>H<sub>16</sub>O<sub>3</sub> (M<sup>+</sup>) requires 280.1099.</div></div><div id="sec4_1_3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>E</i>)-1-(4-Hydroxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>8b</b>)</h3><div class="NLM_p last">Yield 42%, yellow crystal. Mp: 146–148 °C. HPLC: 95.7%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.60 (s, 1H), 7.41 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 6.77 (dd, <i>J</i> = 8.1, 2.7 Hz, 2H), 6.70 (d, <i>J</i> = 2.7 Hz, 1H), 6.58 (dd, <i>J</i> = 8.7, 2.4 Hz, 2H), 5.62 (s, 1H) 3.88 (s, 3H), 3.83 (s, 3H), 3.00 (t, <i>J</i> = 6.6 Hz, 2H), 2.61 (t, <i>J</i> = 6.6 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 280.1086; C<sub>18</sub>H<sub>16</sub>O<sub>3</sub> (M<sup>+</sup>) requires 280.1099.</div></div><div id="sec4_1_3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>E</i>)-1-(4-Hydroxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>8c</b>)</h3><div class="NLM_p last">Yield 42%, yellow crystal. Mp: 153–155 °C. HPLC: 99.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 2H), 7.98–7.07 (m, 2H), 6.78 (d, <i>J</i> = 7.2 Hz, 1H), 6.73 (d, <i>J</i> = 8.4 Hz, 2H), 5.58 (s, 1H), 3.88 (s, 3H), 3.06 (t, <i>J</i> = 6.3 Hz, 2H), 2.56 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 203.02, 156.91, 156.21, 135.85, 134.31, 131.90, 127.26, 126.89, 126.55, 121.18, 115.36, 109.52, 55.59, 36.70, 19.31; HRMS (ES+) <i>m</i>/<i>z</i> found 280.1119; C<sub>18</sub>H<sub>16</sub>O<sub>3</sub> (M<sup>+</sup>) requires 280.1099.</div></div><div id="sec4_1_3_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>E</i>)-1-(4-Nitrobenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>9a</b>)</h3><div class="NLM_p last">Yield 52%, yellow crystal. Mp: 131–133 °C. HPLC: 95.2%. IR (KBr) ν (cm<sup>–1</sup>): 3097, 3021, 2998, 2969, 2943, 2907, 2835, 1698, 1608, 1520, 1485, 1462, 1343, 1305, 1282, 1247, 1209, 1165, 1107, 1038, 889, 866, 848, 812, 751, 709, 689, 586, 558, 498, 441; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.15 (d, <i>J</i> = 9 Hz, 2H), 7.65 (s, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.27 (s, 1H), 7.24 (d, <i>J</i> = 9 Hz, 1H), 6.83 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 3.51 (s, 3H), 3.03 (t, <i>J</i> = 6.3 Hz, 2H), 2.66 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 309.0998; C<sub>18</sub>H<sub>15</sub>NO<sub>4</sub> (M<sup>+</sup>) requires 309.1001.</div></div><div id="sec4_1_3_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>E</i>)-1-(4-Nitrobenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>9b</b>)</h3><div class="NLM_p last">Yield 50%, yellow crystal. Mp: 150–152 °C. HPLC: 95.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.95 (d, <i>J</i> = 8.7 Hz, 2H), 7.63 (s, 1H), 7.50 (d, <i>J</i> = 8.7 Hz, 2H), 7.24 (s, 1H), 7.18 (d, <i>J</i> = 2.4 Hz, 1H), 6.70 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 3.51 (s, 3H), 3.03 (t, <i>J</i> = 6.3 Hz, 2H), 2.66 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 309.1002; C<sub>18</sub>H<sub>15</sub>NO<sub>4</sub> (M<sup>+</sup>) requires 309.1001.</div></div><div id="sec4_1_3_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>E</i>)-1-(4-Nitrobenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>9c</b>)</h3><div class="NLM_p last">Yield 50%, yellow crystal. Mp: 156–158 °C. HPLC: 96.4%. IR (KBr) ν (cm<sup>–1</sup>): 3112, 3082, 3029, 2989, 2966, 2931, 2906, 2859, 2833, 1697, 1594, 1516, 1471, 1434, 1405, 1342, 1296, 1247, 1176, 1133, 1108, 1066, 962, 914, 841, 787, 749, 688, 566, 478, 417. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.10 (d, <i>J</i> = 11.1 Hz, 2H), 7.62 (s, 1H), 7.48 (d, <i>J</i> = 11.1 Hz, 2H), 6.98 (t, <i>J</i> = 8.1 Hz, 1H), 6.82 (d, <i>J</i> = 7.5 Hz, 1H), 6.72 (d, <i>J</i> = 7.5 Hz, 1H), 3.88 (s, 3H), 3.11 (t, <i>J</i> = 6.6 Hz, 2H), 2.65 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.47, 156.42, 147.34, 142.49, 136.73, 132.81, 131.99, 130.21, 127.44, 127.00, 123.58, 121.31, 110.48, 55.58, 36.17, 19.27; HRMS (ES+) <i>m</i>/<i>z</i> found 309.1004; C<sub>18</sub>H<sub>15</sub>NO<sub>4</sub> (M<sup>+</sup>) requires 309.1001.</div></div><div id="sec4_1_3_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>E</i>)-1-(4-Trifluoromethylbenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>10a</b>)</h3><div class="NLM_p last">Yield 46%, yellow crystal. Mp: 130–131 °C. HPLC: 96.8%. IR (KBr) ν (cm<sup>–1</sup>): 3063, 2994, 2965, 2944, 2907, 2847, 1699, 1614, 1599, 1568, 1489, 1412, 1356, 1322, 1247, 1165, 1129, 1104, 1063, 1042, 1015, 885, 833, 803, 703, 645, 602, 564. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.66 (s, 1H), 7.48–7.55 (m, 4H), 7.19 (d, <i>J</i> = 8.4 Hz, 1H), 6.78 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 6.67 (d, <i>J</i> = 2.1 Hz, 1H), 3.43 (s, 3H), 3.00 (t, <i>J</i> = 6.3 Hz, 2H), 2.63 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.16, 157.63, 139.21, 135.55, 133.07, 132.55, 130.92, 129.68, 129.12, 125.33, 125.29, 115.57, 113.27, 54.89, 37.05, 26.77; HRMS (ES+) <i>m</i>/<i>z</i> found 332.1021; C<sub>19</sub>H<sub>15</sub>F<sub>3</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.1024.</div></div><div id="sec4_1_3_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>E</i>)-1-(4-Trifluoromethylbenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>10b</b>)</h3><div class="NLM_p last">Yield 48%, yellow crystal. Mp: 123–125 °C. HPLC: 97.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.54 (s, 1H), 7.51 (s, 4H), 7.15 (d, <i>J</i> = 8.7 Hz, 1H), 6.81 (d, <i>J</i> = 2.7 Hz, 1H), 6.58 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 3.83 (s, 3H), 3.03 (t, <i>J</i> = 6.3 Hz, 2H), 2.65 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.02, 159.87, 140.41, 139.52, 134.96, 131.09, 130.49, 129.55, 125.37, 124.25, 113.17, 112.25, 55.29, 36.86, 28.00; HRMS (ES+) <i>m</i>/<i>z</i> found 332.1018; C<sub>19</sub>H<sub>15</sub>F<sub>3</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.1024.</div></div><div id="sec4_1_3_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>E</i>)-1-(4-Trifluoromethylbenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>10c</b>)</h3><div class="NLM_p last">Yield 53%, yellow crystal. Mp: 123–125 °C. HPLC: 96.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 2H), 7.48 (d, <i>J</i> = 8.1 Hz, 2H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 6.95 (s, 1H), 6.67 (d, <i>J</i> = 2.7 Hz, 1H), 3.62 (s, 3H), 3.05 (t, <i>J</i> = 6.3 Hz, 2H), 2.62 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 332.1028; C<sub>19</sub>H<sub>15</sub>F<sub>3</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.1024.</div></div><div id="sec4_1_3_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>E</i>)-1-(4-Bromobenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>11a</b>)</h3><div class="NLM_p last">Yield 43%, yellow powder. Mp: 126–128 °C. HPLC: 96.4%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.55 (s, 1H), 7.42 (d, <i>J</i> = 8.7 Hz, 2H), 7.36 (s, 1H), 7.30 (s, 1H), 7.07 (d, <i>J</i> = 8.7 Hz, 2H), 7.00 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 3.51 (s, 3H), 3.05 (t, <i>J</i> = 6.3 Hz, 2H), 2.59 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.42, 157.64, 134.31, 134.10, 133.76, 132.95, 131.63, 131.15, 130.84, 129.03, 123.01, 115.24, 113.24, 55.13, 37.16, 26.84; HRMS (ES+) <i>m</i>/<i>z</i> found 342.0257; C<sub>18</sub>H<sub>15</sub>BrO<sub>2</sub> (M<sup>+</sup>) requires 342.0255.</div></div><div id="sec4_1_3_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>E</i>)-1-(4-Bromobenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>11b</b>)</h3><div class="NLM_p last">Yield 47%, yellow crystal. Mp: 126–128 °C. HPLC: 97.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.47 (s, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.27 (d, <i>J</i> = 8.4 Hz, 2H), 7.22 (d, <i>J</i> = 8.7 Hz, 1H), 6.79 (d, <i>J</i> = 2.4 Hz, 1H), 6.57 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 3.83 (s, 3H), 2.99 (t, <i>J</i> = 6.3 Hz, 2H), 2.61 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.53, 159.62, 140.24, 134.52, 133.73, 131.69, 131.60, 130.95, 130.27, 124.52, 122.59, 113.03, 112.15, 55.24, 36.91, 28.00; HRMS (ES+) <i>m</i>/<i>z</i> found 342.0251; C<sub>18</sub>H<sub>15</sub>BrO<sub>2</sub> (M<sup>+</sup>) requires 342.0255.</div></div><div id="sec4_1_3_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>E</i>)-1-(4-Bromobenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>11c</b>)</h3><div class="NLM_p last">Yield 56%, yellow crystal. Mp: 130–132 °C. HPLC: 96.5%. IR (KBr) ν (cm<sup>–1</sup>): 3089, 2955, 2836, 1688, 1599, 1573, 1474, 1460, 1436, 1394, 1362, 1340, 1298, 1266, 1252, 1164, 1100, 1067, 1012, 1010, 986, 967, 906, 889, 846, 817, 797, 783, 733, 711, 697, 669, 647, 568, 545, 499, 476, 441. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.57 (s, 1H), 7.38 (d, <i>J</i> = 8.7 Hz, 2H), 7.25 (d, <i>J</i> = 8.4 Hz, 2H), 6.98 (d, <i>J</i> = 8.1 Hz, 1H), 6.87 (d, <i>J</i> = 7.8 Hz, 1H), 6.79 (d, <i>J</i> = 8.1 Hz, 1H), 3.88 (s, 3H), 3.08 (t, <i>J</i> = 6.6 Hz, 2H), 2.56 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.81, 156.27, 134.38, 134.21, 133.86, 133.58, 131.54, 131.17, 127.12, 126.74, 122.92, 121.23, 109.88, 55.56, 36.43, 19.29; HRMS (ES+) <i>m</i>/<i>z</i> found 342.0258; C<sub>18</sub>H<sub>15</sub>BrO<sub>2</sub> (M<sup>+</sup>) requires 342.0255.</div></div><div id="sec4_1_3_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>E</i>)-1-(4-Chlorobenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>12a</b>)</h3><div class="NLM_p last">Yield 46%, yellow powder. Mp: 140–142 °C. HPLC: 97.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.62 (s, 1H), 7.39 (d, <i>J</i> = 8.7 Hz, 2H), 7.28 (d, <i>J</i> = 8.4 Hz, 1H), 6.89 (d, <i>J</i> = 8.7 Hz, 2H), 6.84 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.79 (d, <i>J</i> = 8.4 Hz, 1H), 3.52 (s, 3H), 3.00 (t, <i>J</i> = 6.3 Hz, 2H), 2.58 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 299.0835; C<sub>18</sub>H<sub>15</sub>ClO<sub>2</sub> (M + H<sup>+</sup>) requires 299.0839.</div></div><div id="sec4_1_3_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>E</i>)-1-(4-Chlorobenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>12b</b>)</h3><div class="NLM_p last">Yield 42%, yellow powder. Mp: 142–144 °C. HPLC: 97.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.43 (s, 1H), 7.31 (d, <i>J</i> = 8.7 Hz, 2H), 7.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.21 (d, <i>J</i> = 8.7 Hz, 1H), 6.78 (d, <i>J</i> = 2.7 Hz, 1H), 6.57 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 3.83 (s, 3H), 2.99 (t, <i>J</i> = 6.6 Hz, 2H), 2.62 (t, <i>J</i> = 6.6 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 298.0758; C<sub>18</sub>H<sub>15</sub>ClO<sub>2</sub> (M<sup>+</sup>) requires 298.0761.</div></div><div id="sec4_1_3_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>E</i>)-1-(4-Chlorobenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>12c</b>)</h3><div class="NLM_p last">Yield 46%, yellow powder. Mp: 148–150 °C. HPLC: 95.9%. IR (KBr) ν (cm<sup>–1</sup>): 3089, 3046, 3009, 2989, 2958, 2936, 2901, 2857, 2835, 1691, 1600, 1574, 1480, 1438, 1397, 1363, 1339, 1301, 1269, 1250, 1164, 1093, 1068, 1009, 965, 909, 823, 800, 781, 733, 668, 566, 501. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.59 (s, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 2H), 7.21 (d, <i>J</i> = 8.4 Hz, 2H), 6.99 (t, <i>J</i> = 8.1 Hz, 1H), 6.88 (d, <i>J</i> = 8.1 Hz, 1H), 6.79 (d, <i>J</i> = 8.1 Hz, 1H), 3.88 (s, 3H), 3.08 (t, <i>J</i> = 6.3 Hz, 2H), 2.57 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.87, 156.26, 134.60, 133.82, 133.74, 133.60, 130.93, 128.57, 127.13, 126.70, 121.22, 109.87, 55.55, 36.43, 19.29; HRMS (ES+) <i>m</i>/<i>z</i> found 299.0832; C<sub>18</sub>H<sub>15</sub>ClO<sub>2</sub> (M + H<sup>+</sup>) requires 299.0839.</div></div><div id="sec4_1_3_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>E</i>)-1-(2-Chlorobenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>13a</b>)</h3><div class="NLM_p last">Yield 46%, yellow powder. Mp: 98–100 °C. HPLC: 96.2%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.83 (s, 1H), 7.43 (d, <i>J</i> = 8.1 Hz, 1H), 7.20–7.26 (m, 2H), 7.09–7.18 (m, 2H), 6.76 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 6.56 (d, <i>J</i> = 2.7 Hz, 1H), 3.40 (s, 3H), 3.00 (t, <i>J</i> = 6.3 Hz, 2H), 2.66 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 200.72, 157.58, 135.18, 134.77, 134.49, 132.98, 132.30, 130.68, 130.08, 129.87, 129.65, 128.89, 126.43, 115.44, 113.10, 54.91, 37.46, 26.91; HRMS (ES+) <i>m</i>/<i>z</i> found 298.0783; C<sub>18</sub>H<sub>15</sub>ClO<sub>2</sub> (M<sup>+</sup>) requires 298.0761.</div></div><div id="sec4_1_3_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>E</i>)-1-(2-Chlorobenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>13b</b>)</h3><div class="NLM_p last">Yield 50%, yellow crystal. Mp: 122–124 °C. HPLC: 97.2%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 7.38 (d, <i>J</i> = 8.1 Hz, 1H), 7.20–7.24 (m, 2H), 7.15–7.26 (m, 2H), 6.56 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.56 (d, <i>J</i> = 2.4 Hz, 1H), 3.63 (s, 3H), 2.99 (t, <i>J</i> = 6.3 Hz, 2H), 2.68 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.72, 160.01, 140.24, 135.41, 134.52, 133.86, 132.01, 130.48, 129.93, 128.86, 128.35, 126.88, 124.36, 113.09, 112.30, 55.40, 38.93, 28.54; HRMS (ES+) <i>m</i>/<i>z</i> found 298.0754; C<sub>18</sub>H<sub>15</sub>ClO<sub>2</sub> (M<sup>+</sup>) requires 298.0761.</div></div><div id="sec4_1_3_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>E</i>)-1-(2-Chlorobenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>13c</b>)</h3><div class="NLM_p last">Yield 50%, yellow crystal. Mp: 124–126 °C. HPLC: 95.6%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.78 (s, 1H), 7.38 (d, <i>J</i> = 8.4 Hz, 1H), 7.12 (d, <i>J</i> = 7.8 Hz, 1H), 7.04 (dd, <i>J</i> = 8.1, 2.4 Hz, 2H), 6.96 (s, 1H), 6.72–6.80 (m, 1H), 6.54–6.58 (m, 1H), 3.76 (s, 3H), 3.09 (t, <i>J</i> = 6.6 Hz, 2H), 2.63 (t, <i>J</i> = 6.6 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 298.0760; C<sub>18</sub>H<sub>15</sub>ClO<sub>2</sub> (M<sup>+</sup>) requires 298.0761.</div></div><div id="sec4_1_3_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>E</i>)-1-(2,4-Dichlorobenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>14a</b>)</h3><div class="NLM_p last">Yield 42%, yellow powder. Mp: 118–120 °C. HPLC: 95.1%. IR (KBr) ν (cm<sup>–1</sup>): 3088, 3064, 3023, 3000, 2965, 2945, 2908, 2855, 2832, 1693, 1608, 1574, 1543, 1492, 1465, 1435, 1357, 1324, 1301, 1279, 1235, 1193, 1169, 1099, 1046, 904, 867, 826, 808, 748, 719, 592. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.73 (s, 1H), 7.31 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 7.11 (d, <i>J</i> = 8.4 Hz, 1H), 6.89 (dd, <i>J</i> = 8.4, 2.7 Hz, 1H), 6.77 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 6.56 (d, <i>J</i> = 2.7 Hz, 1H), 3.48 (s, 3H), 3.02 (t, <i>J</i> = 6.6 Hz, 2H), 2.65 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 200.53, 158.96, 136.76, 135.60, 134.82, 133.19, 132.01, 130.81, 129.41, 128.86, 126.37, 114.39, 110.59, 55.44, 39.02, 27.28; HRMS (ES+) <i>m</i>/<i>z</i> found 332.0368; C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.0371.</div></div><div id="sec4_1_3_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>E</i>)-1-(2,4-Dichlorobenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>14b</b>)</h3><div class="NLM_p last">Yield 40%, yellow powder. Mp: 122–124 °C. HPLC: 96.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.74 (s, 1H), 7.49 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.42–7.47 (m, 1H), 7.39 (s, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 7.20–7.25 (m, 1H), 6.61 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 3.84 (s, 3H), 3.02 (t, <i>J</i> = 6.6 Hz, 2H), 2.67 (t, <i>J</i> = 6.6 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 332.0370; C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.0371.</div></div><div id="sec4_1_3_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>E</i>)-1-(2,4-Dichlorobenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>14c</b>)</h3><div class="NLM_p last">Yield 47%, yellow powder. Mp: 126–128 °C. HPLC: 97.3%. IR (KBr) ν (cm<sup>–1</sup>): 3089, 3066, 2998, 2958, 2901, 2829, 1695, 1603, 1577, 1475, 1453, 1359, 1294, 1262, 1226, 1098, 1080, 1049, 1019, 996, 881, 861, 823, 771, 733, 579, 555, 448. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.45 (s, 1H), 7.31 (d, <i>J</i> = 7.8 Hz, 1H), 7.22 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.15 (s, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 6.54–6.62 (m, 1H), 3.80 (s, 3H), 3.01 (t, <i>J</i> = 6.3 Hz, 2H), 2.58 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.05, 156.29, 137.01, 135.59, 134.74, 133.63, 131.93, 130.94, 129.65, 128.86, 127.10, 126.76, 125.63, 121.31, 109.95, 55.60, 38.48, 20.71; HRMS (ES+) <i>m</i>/<i>z</i> found 332.0370; C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.0371.</div></div><div id="sec4_1_3_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>E</i>)-1-(3,4-Dichlorobenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>15a</b>)</h3><div class="NLM_p last">Yield 35%, yellow powder. Mp: 118–120 °C. HPLC: 96.8%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.54 (s, 1H), 7.35 (s, 1H), 7.18–7.26 (m, 2H), 7.04–7.12 (m, 2H), 6.64–6.72 (m, 1H), 3.69 (s, 3H), 2.96 (t, <i>J</i> = 6.3 Hz, 1H), 2.67 (t, <i>J</i> = 6.3 Hz, 1H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 200.53, 158.96, 136.76, 135.60, 134.82, 133.19, 132.01, 130.81, 129.41, 128.86, 126.37, 114.39, 110.59, 55.44, 39.02, 27.28; HRMS (ES+) <i>m</i>/<i>z</i> found 332.0370; C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.0371.</div></div><div id="sec4_1_3_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>E</i>)-1-(3,4-Dichlorobenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>15b</b>)</h3><div class="NLM_p last">Yield 42%, yellow crystal. Mp: 124–126 °C. HPLC: 96.2%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 7.54 (d, <i>J</i> = 8.4 Hz, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 1H), 7.42 (dd, <i>J</i> = 11.1, 2.1 Hz, 2H), 6.99–7.07 (m, 1H), 6.78 (s, 1H), 6.55 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 3.86 (s, 3H), 3.04 (t, <i>J</i> = 6.6 Hz, 2H), 2.62 (t, <i>J</i> = 6.6 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 332.0374; C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.0371.</div></div><div id="sec4_1_3_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (<i>E</i>)-1-(3,4-Dichlorobenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>15c</b>)</h3><div class="NLM_p last">Yield 52%, yellow crystal. Mp: 124–126 °C. HPLC: 95.8%. IR (KBr) ν (cm<sup>–1</sup>): 3445, 2998, 2961, 2914, 2831, 1686, 1542, 1473, 1453, 1385, 1351, 1290, 1262, 1226, 1182, 1131, 1078, 1022, 978, 897, 855, 810, 770, 704, 663, 581, 554, 491, 432. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.52 (s, 1H), 7.37 (s, 1H), 7.23 (dd, <i>J</i> = 7.8, 2.4 Hz, 1H), 7.05 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.89 (d, <i>J</i> = 8.1 Hz, 1H), 7.02 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 6.89 (d, <i>J</i> = 7.8 Hz, 1H), 3.88 (s, 3H), 3.09 (t, <i>J</i> = 6.3 Hz, 2H), 2.64 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 332.0370; C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.0371.</div></div><div id="sec4_1_3_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>E</i>)-1-(2,6-Dichlorobenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>16a</b>)</h3><div class="NLM_p last">Yield 30%, yellow powder. Mp: 120–122 °C. HPLC: 95.8%. IR (KBr) ν (cm<sup>–1</sup>): 3081, 3026, 2993, 2963, 2915, 2861, 2839, 1698, 1615, 1571, 1487, 1428, 1348, 1301, 1276, 1236, 1191, 1165, 1096, 1036, 992, 879, 860, 819, 779, 742, 700. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.57 (s, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 2H), 7.20 (d, <i>J</i> = 7.2 Hz, 1H), 7.14 (d, <i>J</i> = 8.7 Hz, 1H), 6.74 (dd, <i>J</i> = 8.4, 2.7 Hz, 1H), 6.30 (d, <i>J</i> = 2.7 Hz, 1H), 3.36 (s, 3H), 2.99 (t, <i>J</i> = 6.3 Hz, 1H), 2.69 (t, <i>J</i> = 6.3 Hz, 1H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 200.37, 157.87, 137.78, 134.66, 134.23, 133.81, 130.20, 129.27, 129.11, 128.75, 128.17, 115.48, 111.28, 54.79, 37.38, 26.76; HRMS (ES+) <i>m</i>/<i>z</i> found 332.0372; C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>O<sub>2</sub> (M<sup>+</sup>) requires 332.0371.</div></div><div id="sec4_1_3_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>E</i>)-1-(3-Hydroxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>16b</b>)</h3><div class="NLM_p last">Yield 35%, yellow crystal. Mp: 168–170 °C. HPLC: 96.9%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.54 (s, 1H), 7.30 (d, <i>J</i> = 8.7 Hz, 1H), 7.15 (d, <i>J</i> = 7.8 Hz, 1H), 7.00 (d, <i>J</i> = 7.8 Hz, 1H), 6.92 (s, 1H), 6.78 (d, <i>J</i> = 7.8 Hz, 2H), 6.59 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 3.86 (s, 3H), 3.00 (t, <i>J</i> = 6.3 Hz, 2H), 2.63 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 200.37, 157.87, 137.78, 134.66, 134.23, 133.81, 130.20, 129.27, 129.11, 128.75, 128.17, 115.48, 111.28, 54.79, 37,38, 26.76; HRMS (ES+) <i>m</i>/<i>z</i> found 280.1036; C<sub>18</sub>H<sub>16</sub>O<sub>3</sub> (M<sup>+</sup>) requires 280.1099.</div></div><div id="sec4_1_3_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>E</i>)-1-(3-Hydroxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>16c</b>)</h3><div class="NLM_p last">Yield 35%, yellow crystal. Mp: 160–162 °C. HPLC: 97.7%. IR (KBr) ν (cm<sup>–1</sup>): 3174, 2976, 2361, 1673, 1591, 1571, 1451, 1364, 1343, 1286, 1261, 1196, 1162, 1067, 1022, 1001, 974, 942, 906, 880, 867, 792, 732, 692, 592, 564, 532, 482, 462, 430. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 7.14 (d, <i>J</i> = 8.4 Hz, 1H), 7.00 (d, <i>J</i> = 8.4 Hz, 1H), 6.94–6.98 (m, 2H) 6.89 (s, 1H), 6.74–6.80 (m, 2H), 5.22 (s, 1H), 3.88 (s, 3H), 3.08 (t, <i>J</i> = 6.3 Hz, 2H), 2.58 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.37, 156.14, 155.50, 136.76, 135.19, 134.19, 133.80, 129.62, 126.98, 126.61, 122.27, 121.57, 116.07, 109.78, 55.57, 36.54, 19.29; HRMS (ES+) <i>m</i>/<i>z</i> found 280.1096; C<sub>18</sub>H<sub>16</sub>O<sub>3</sub> (M<sup>+</sup>) requires 280.1099.</div></div><div id="sec4_1_3_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>E</i>)-1-(4-Dimethylaminobenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>17a</b>)</h3><div class="NLM_p last">Yield 58%, yellow crystal. Mp: 118–119 °C. HPLC: 99.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.57 (s, 1H), 7.23 (d, <i>J</i> = 8.1 Hz, 2H), 7.14 (d, <i>J</i> = 8.4 Hz, 2H), 6.76 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 6.56 (d, <i>J</i> = 2.7 Hz, 2H), 3.68 (s, 3H), 3.10 (s, 6H), 2.89 (t, <i>J</i> = 6.3 Hz, 1H), 2.65 (t, <i>J</i> = 6.3 Hz, 1H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.16, 157.50, 151.00, 136.59, 134.70, 132.09, 130.59, 129.44, 128.63, 114.30, 112.74, 111.42, 55.28, 40.18, 37.56, 27.07; HRMS (ES+) <i>m</i>/<i>z</i> found 307.1576; C<sub>20</sub>H<sub>21</sub>NO<sub>2</sub> (M<sup>+</sup>) requires 307.1572.</div></div><div id="sec4_1_3_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>E</i>)-1-(4-Dimethylaminobenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>17b</b>)</h3><div class="NLM_p last">Yield 52%, yellow crystal. Mp: 128–130 °C. HPLC: 97.5%. IR (KBr) ν (cm<sup>–1</sup>): 2905, 2360, 1676, 1607, 1582, 1522, 1490, 1431, 1363, 1301, 1264, 1229, 1191, 1147, 1136, 1101, 1066, 1031, 1015, 945, 900, 867, 847, 821, 807, 718, 668, 662, 564, 510, 474. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.56 (s, 1H), 7.54 (s, 1H), 7.47 (s, 1H), 7.44 (s, 1H), 6.79 (d, <i>J</i> = 2.7 Hz, 1H), 6.65 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.58 (d, <i>J</i> = 8.7 Hz, 2H), 3.84 (s, 3H), 3.00 (s, 6H), 2.96 (t, <i>J</i> = 6.3 Hz, 2H), 2.57 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.98, 158.87, 150.74, 139.82, 134.69, 131.64, 129.83, 129.15, 126.28, 112.60, 111.91, 111.44, 55.26, 40.14, 37.32, 28.24; HRMS (ES+) <i>m</i>/<i>z</i> found 307.1575; C<sub>20</sub>H<sub>21</sub>NO<sub>2</sub> (M<sup>+</sup>) requires 307.1572.</div></div><div id="sec4_1_3_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>E</i>)-1-(4-Dimethylaminobenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>17c</b>)</h3><div class="NLM_p last">Yield 48%, yellow crystal. Mp: 98–100 °C. HPLC: 97.5%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 7.56(d, <i>J</i> = 8.1 Hz, 2H), 7.37 (d, <i>J</i> = 7.8 Hz, 1H), 6.79 (d, <i>J</i> = 2.7 Hz, 1H), 6.65 (dd, <i>J</i> = 8.7, 2.7 Hz, 3H), 3.92 (s, 3H), 3.12 (s, 6H), 3.06 (t, <i>J</i> = 6.3 Hz, 2H), 2.53 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 307.1589; C<sub>20</sub>H<sub>21</sub>NO<sub>2</sub> (M<sup>+</sup>) requires 307.1572.</div></div><div id="sec4_1_3_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>E</i>)-1-(3-Hydroxy-4-methoxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>18a</b>)</h3><div class="NLM_p last">Yield 42%, yellow crystal. Mp: 170–172 °C. HPLC: 95.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.59 (s, 1H), 7.16 (d, <i>J</i> = 7.6 Hz, 2H), 7.11 (s, 1H), 7.01 (s, 2H), 6.77 (d, <i>J</i> = 7.8 Hz, 2H), 5.71 (s, 1H), 3.89 (s, 3H), 3.57 (s, 3H), 2.95 (s, 1H), 2.59 (s, 3H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.91, 157.52, 147.55, 145.21, 135.37, 133.54, 132.31, 130.72, 128.74, 128.06, 123.32, 115.38, 114.97, 113.18, 110.32, 55.88, 55.24, 37.33, 26.89; HRMS (ES+) <i>m</i>/<i>z</i> found 310.1211; C<sub>19</sub>H<sub>18</sub>O<sub>4</sub> (M<sup>+</sup>) requires 310.1205.</div></div><div id="sec4_1_3_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>E</i>)-1-(3-Hydroxy-4-methoxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>18b</b>)</h3><div class="NLM_p last">Yield 48%, yellow crystal. Mp: 170–172 °C. HPLC: 96.4%. IR (KBr) ν (cm<sup>–1</sup>): 3556, 2999, 2939, 2902, 2839, 1681, 1613, 1585, 1570, 1510, 1484, 1436, 1367, 1332, 1277, 1245, 1196, 1161, 1129, 1094, 1039, 1021, 999, 926, 901, 873, 816, 796, 760, 727, 622, 562, 487, 424; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.50 (s, 1H), 7.38 (d, <i>J</i> = 8.4 Hz, 1H), 7.06 (d, <i>J</i> = 2.1 Hz, 1H), 7.01 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 6.78 (d, <i>J</i> = 2.1 Hz, 1H), 6.76 (d, <i>J</i> = 8.4 Hz, 1H), 6.62 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 5.55 (s, 1H), 3.90 (s, 3H), 3.83 (s, 3H), 2.98 (t, <i>J</i> = 6.3 Hz, 2H), 2.59 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.01, 159.30, 147.25, 145.21, 139.99, 133.34, 131.97, 130.22, 128.63, 125.18, 122.98, 115.05, 112.72, 112.07, 110.35, 55.86, 55.22, 37.08, 28.08; HRMS (ES+) <i>m</i>/<i>z</i> found 310.1204; C<sub>19</sub>H<sub>18</sub>O<sub>4</sub> (M<sup>+</sup>) requires 310.1205.</div></div><div id="sec4_1_3_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (<i>E</i>)-1-(3-Hydroxy-4-methoxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>18c</b>)</h3><div class="NLM_p last">Yield 43%, yellow crystal. Mp: 178–180 °C. HPLC: 99.7%. IR (KBr) ν (cm<sup>–1</sup>): 3315, 3005, 2961, 2940, 2905, 2882, 2840, 2733, 1681, 1590, 1506, 1471, 1441, 1370, 1344, 1283, 1251, 1173, 1130, 1068, 1027, 997, 971, 944, 908, 806, 780, 757, 730, 673, 615, 503, 434. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.57 (s, 1H), 7.05 (d, <i>J</i> = 7.8 Hz, 2H), 7.02 (dd, <i>J</i> = 7.8, 2.4 Hz, 2H), 6.97 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 6.76 (dd, <i>J</i> = 8.4, 2.7 Hz, 2H), 5.61 (s, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.05 (t, <i>J</i> = 6.6 Hz, 2H), 2.54 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.32, 156.13, 147.46, 145.12, 135.38, 134.20, 132.54, 128.30, 126.92, 126.50, 123.28, 121.31, 115.37, 110.24, 109.60, 55.86, 55.55, 36.59, 19.30; HRMS (ES+) <i>m</i>/<i>z</i> found 310.1204; C<sub>19</sub>H<sub>18</sub>O<sub>4</sub> (M<sup>+</sup>) requires 310.1205.</div></div><div id="sec4_1_3_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (<i>E</i>)-1-(4-Hydroxy-3-methoxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>19a</b>)</h3><div class="NLM_p last">Yield 49%, yellow crystal. Mp: 158–160 °C. HPLC: 99.3%. IR (KBr) ν (cm<sup>–1</sup>): 3359, 3002, 2945, 2841, 1677, 1612, 1573, 1516, 1489, 1444, 1383, 1306, 1284, 1247, 1230, 1204, 1166, 1121, 1096, 1044, 1025, 934, 801, 626, 548, 481, 422. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.60 (s, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 7.09 (s, 1H), 7.04 (d, <i>J</i> = 2.7 Hz, 2H), 6.83 (d, <i>J</i> = 8.4 Hz, 1H), 6.76 (dd, <i>J</i> = 8.4, 2.7 Hz, 1H), 5.97 (s, 1H), 3.71 (s, 3H), 3.64 (s, 3H), 2.96 (t, <i>J</i> = 6.3 Hz, 2H), 2.60 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.81, 157.46, 147.01, 146.15, 135.63, 133.70, 131.82, 130.81, 128.85, 126.79, 124.76, 114.65, 114.46, 113.31, 112.02, 55.77, 55.21, 37.36, 26.92; HRMS (ES+) <i>m</i>/<i>z</i> found 310.1209; C<sub>19</sub>H<sub>18</sub>O<sub>4</sub> (M<sup>+</sup>) requires 310.1205.</div></div><div id="sec4_1_3_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>E</i>)-1-(4-Hydroxy-3-methoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>19b</b>)</h3><div class="NLM_p last">Yield 52%, yellow crystal. Mp: 153–155 °C. HPLC: 98.6%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.53 (s, 1H), 7.45 (d, <i>J</i> = 8.7 Hz, 1H), 7.06 (s, 1H), 7.02 (s, 1H), 6.83 (s, 1H), 6.80 (s, 1H), 6.63 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 5.85 (s, 1H), 3.83 (s, 3H), 3.72 (s, 3H), 2.99 (t, <i>J</i> = 6.6 Hz, 2H), 2.60 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.67, 159.26, 146.65, 146.11, 140.16, 133.70, 131.36, 130.27, 127.33, 125.31, 124.44, 114.42, 112.73, 111.88, 111.60, 55.77, 55.27, 37.11, 28.13; HRMS (ES+) <i>m</i>/<i>z</i> found 310.1206; C<sub>19</sub>H<sub>18</sub>O<sub>4</sub> (M<sup>+</sup>) requires 310.1205.</div></div><div id="sec4_1_3_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (<i>E</i>)-1-(4-Hydroxy-3-methoxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>19c</b>)</h3><div class="NLM_p last">Yield 50%, yellow crystal. Mp: 160–162 °C. HPLC: 98.6%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.60 (s, 1H), 7.11 (d, <i>J</i> = 7.8 Hz, 1H), 7.02 (d, <i>J</i> = 7.8, 2.1 Hz, 2H), 6.99 (s, 1H), 6.80 (dd, <i>J</i> = 8.1, 2.1 Hz, 2H), 5.98–6.02 (m, 1H), 3.88 (s, 3H), 3.67 (s, 3H), 3.06 (t, <i>J</i> = 6.3 Hz, 2H), 2.55 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.38, 156.17, 146.96, 146.05, 135.77, 134.32, 131.79, 127.03, 126.91, 126.27, 124.97, 121.33, 114.40, 111.84, 109.46, 55.72, 55.53, 36.61, 19.32; HRMS (ES+) <i>m</i>/<i>z</i> found 310.1209; C<sub>19</sub>H<sub>18</sub>O<sub>4</sub> (M<sup>+</sup>) requires 310.1205.</div></div><div id="sec4_1_3_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (<i>E</i>)-1-(3,4-Dimethoxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>20a</b>)</h3><div class="NLM_p last">Yield 50%, yellow solid. Mp: 84–86 °C. HPLC: 97.2%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.62 (s, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 1H), 7.00 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.95 (s, 1H), 6.68 (d, <i>J</i> = 2.4 Hz, 2H), 6.62 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 3.85(s, 6H), 3.63 (s, 3H), 2.92 (t, <i>J</i> = 6.3 Hz, 2H), 2.61 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 324.1360; C<sub>20</sub>H<sub>20</sub>O<sub>4</sub>(M<sup>+</sup>) requires 324.1362.</div></div><div id="sec4_1_3_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (<i>E</i>)-1-(3,4-Dimethoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>20b</b>)</h3><div class="NLM_p last">Yield 50%, yellow powder. Mp: 114–116 °C. HPLC: 95.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.52 (s, 1H), 7.42 (d, <i>J</i> = 8.7 Hz, 1H), 7.07 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 7.03 (s, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.62 (dd, <i>J</i> = 8.4 Hz, 2.2 Hz, 1H), 3.90 (s, 3H), 3.85 (s, 6H), 2.99 (t, <i>J</i> = 6.3 Hz, 2H), 2.62 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 324.1361; C<sub>20</sub>H<sub>20</sub>O<sub>4</sub>(M<sup>+</sup>) requires 324.1362.</div></div><div id="sec4_1_3_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>E</i>)-1-(3,4-Dimethoxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>20c</b>)</h3><div class="NLM_p last">Yield 43%, yellow crystal. Mp: 114–116 °C. HPLC: 95.5%. IR (KBr) ν (cm<sup>–1</sup>): 3005, 2950, 2835, 2361, 1686, 1595, 1579, 1509, 1471, 1440, 1418, 1370, 1342, 1250, 1157, 1137, 1070, 1016, 968, 903, 860, 807, 793, 781, 768, 735, 695, 674, 623, 604, 553, 460, 437. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.61 (s, 1H), 7.00–7.10 (m, 4H), 6.78 (d, <i>J</i> = 8.4 Hz, 2H), 3.89 (s, 6H), 3.64 (s, 3H), 3.07 (t, <i>J</i> = 6.3 Hz, 2H), 2.56 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.08, 156.17, 150.04, 148.26, 135.43, 134.31, 132.08, 127.47, 127.05, 126.27, 124.48, 121.41, 112.02, 110.70, 109.47, 55.80, 55.57, 55.53, 36.59, 19.34; HRMS (ES+) <i>m</i>/<i>z</i> found 324.1364; C<sub>20</sub>H<sub>20</sub>O<sub>4</sub>(M<sup>+</sup>) requires 324.1362.</div></div><div id="sec4_1_3_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (<i>E</i>)-1-(3,5-Dimethoxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>21a</b>)</h3><div class="NLM_p last">Yield 48%, yellow crystal. Mp: 126–128 °C. HPLC: 95.7%. IR (KBr) ν (cm<sup>–1</sup>): 2955, 2833, 2360, 1691, 1584, 1491, 1459, 1361, 1341, 1318, 1299, 1279, 1233, 1201, 1163, 1099, 1068, 1038, 995, 914, 874, 843, 816, 805, 744, 714, 689, 546, 484, 423. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.62 (s, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 6.91 (d, <i>J</i> = 2.4 Hz, 1H), 6.77 (dd, <i>J</i> = 8.4, 2.7 Hz, 1H), 6.58 (d, <i>J</i> = 2.1 Hz, 2H), 6.39 (d, <i>J</i> = 2.1 Hz, 1H), 3.68 (s, 6H), 3.53 (s, 3H), 2.99 (t, <i>J</i> = 6.3 Hz, 2H), 2.62 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.61, 160.62, 157.45, 136.90, 135.22, 134.16, 133.14, 130.76, 128.79, 115.32, 113.51, 107.32, 101,64, 55.29, 55.15, 37.28, 26.87; HRMS (ES+) <i>m</i>/<i>z</i> found 324.1365; C<sub>20</sub>H<sub>20</sub>O<sub>4</sub>(M<sup>+</sup>) requires 324.1362.</div></div><div id="sec4_1_3_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (<i>E</i>)-1-(3,5-Dimethoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>21b</b>)</h3><div class="NLM_p last">Yield 53%, yellow crystal. Mp: 126–128 °C. HPLC: 98.8%. IR (KBr) ν (cm<sup>–1</sup>): 2959, 2836, 2362, 1687, 1594, 1498, 1448, 1424, 1373, 1336, 1309, 1263, 1252, 1222, 1205, 1154, 1093, 1053, 1027, 904, 850, 834, 694, 672 619, 563, 537. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.52 (s, 1H), 7.33 (d, <i>J</i> = 8.7 Hz, 1H), 6.78 (d, <i>J</i> = 2.4 Hz, 1H), 6.62 (d, <i>J</i> = 8.7 Hz, 1H), 6.58 (d, <i>J</i> = 8.7 Hz, 1H), 6.38 (d, <i>J</i> = 2.4 Hz, 1H), 3.83 (s, 3H), 3.69 (s, 6H), 3.01 (t, <i>J</i> = 6.3 Hz, 2H), 2.63 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.61, 160.59, 159.47, 140.09,137.32, 133.59, 133.23, 130.79, 124.82, 112.68, 111.98, 107.17, 101.37, 55.27, 37.00, 28.05; HRMS (ES+) <i>m</i>/<i>z</i> found 324.1363; C<sub>20</sub>H<sub>20</sub>O<sub>4</sub> (M<sup>+</sup>) requires 324.1362.</div></div><div id="sec4_1_3_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (<i>E</i>)-1-(3,5-Dimethoxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>21c</b>)</h3><div class="NLM_p last">Yield 50%, yellow powder. Mp: 126–128 °C. HPLC: 99.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.59 (s, 1H), 6.97–7.04 (m, 2H), 6.78 (dd, <i>J</i> = 6.6, 2.4 Hz, 1H), 6.54 (s, 2H), 6.39 (d, <i>J</i> = 2.2 Hz, 1H), 3.87 (s, 3H), 3.67 (s, 6H), 3.08 (t, <i>J</i> = 6.6 Hz, 2H), 2.58 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.09, 160,49, 156.07, 136.94, 135.27, 134.24, 133.79, 127.02, 126.38, 121.76, 109.74, 107.40, 101.67, 55.52, 55.24, 36.49, 19.30; HRMS (ES+) <i>m</i>/<i>z</i> found 324.1381; C<sub>20</sub>H<sub>20</sub>O<sub>4</sub> (M<sup>+</sup>) requires 324.1362.</div></div><div id="sec4_1_3_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (<i>E</i>)-1-(3,4,5-Trimethoxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>22a</b>)</h3><div class="NLM_p last">Yield 1.89 g (53%). Mp: 115–117 °C. HPLC: 99.6%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.58 (s, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 7.00 (s, 1H), 6.78 (dd, <i>J</i> = 8.4, 2.7 Hz, 1H), 6.73 (s, 2H), 3.86 (s, 3H), 3.70 (s, 6H), 3.56 (s, 3H), 2.98 (t, <i>J</i> = 6.6 Hz, 2H), 2.60 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.60, 157.39, 152.91, 138.97, 135.12, 133.22, 130.84, 129.99, 128.89, 114.89, 113.52, 107.16, 60.89, 55.95, 55.15, 37.25, 26.86; HRMS (ES+) <i>m</i>/<i>z</i> found 354.1466; C<sub>21</sub>H<sub>22</sub>O<sub>5</sub> (M<sup>+</sup>) requires 354.1467.</div></div><div id="sec4_1_3_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (<i>E</i>)-1-(3,4,5-Trimethoxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>22c</b>)</h3><div class="NLM_p last">Yield 53%, yellow crystal. Mp: 120–123 °C. HPLC: 99.2%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.56 (s, 1H), 7.04–7.10 (m, 2H), 6.78 (d, <i>J</i> = 8.7 Hz, 1H), 6.69 (s, 2H), 3.90 (s, 6H), 3.69 (s, 6H), 3.08 (t, <i>J</i> = 6.3 Hz, 2H), 2.57 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 202.17, 156.17, 152.84, 138.92, 135.26, 133.93, 133.22, 130.10, 127.15, 126.27, 121.63, 109.65, 107.22, 60.93, 55.94, 55.54, 36.52, 19.32; HRMS (ES+) <i>m</i>/<i>z</i> found 354.1469; C<sub>21</sub>H<sub>22</sub>O<sub>5</sub>(M<sup>+</sup>) requires 354.1467.</div></div><div id="sec4_1_3_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (<i>E</i>)-1-(2,3,4-Trimethoxybenzylidene)-5-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>23a</b>)</h3><div class="NLM_p last">Yield 50%, yellow crystal. Mp: 118–120 °C. HPLC: 96.5%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.84 (s, 1H), 7.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.06 (d, <i>J</i> = 9 Hz, 1H), 6.89 (d, <i>J</i> = 2.4 Hz, 1H), 6.75 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.50 (d, <i>J</i> = 8.7 Hz, 1H), 3.92 (s, 3H), 3.88 (s, 3H), 3.85 (s, 3H), 3.53 (s, 3H), 2.97 (t, <i>J</i> = 6.3 Hz, 2H), 2.62 (t, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 201.09, 157.47, 154.61, 153.49, 142.15, 134.05, 132.78, 131.26, 130.61, 128.73, 124.33, 121.93, 114.43, 113.16, 106.87, 61.45, 60.93, 55.99, 55.04, 37.57, 26.99; HRMS (ES+) <i>m</i>/<i>z</i> found 354.1464; C<sub>21</sub>H<sub>22</sub>O<sub>5</sub>(M<sup>+</sup>) requires 354.1467.</div></div><div id="sec4_1_3_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (<i>E</i>)-1-(2,3,4-Trimethoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>23b</b>)</h3><div class="NLM_p last">Yield 43%, yellow powder. Mp: 112–114 °C. HPLC: 96.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.73 (s, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 7.03 (d, <i>J</i> = 8.7 Hz, 1H), 6.77 (s, 1H), 6.57 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 6.37 (d, <i>J</i> = 8.7 Hz, 1H), 3.90 (s, 6H), 3.85 (s, 6H), 2.99 (t, <i>J</i> = 6.3 Hz, 2H), 2.62 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 354.1464; C<sub>21</sub>H<sub>22</sub>O<sub>5</sub>(M<sup>+</sup>) requires 354.1467.</div></div><div id="sec4_1_3_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>E</i>)-1-(2,3,4-Trimethoxybenzylidene)-7-methoxy-3,4-dihydronaphthalen-2(1<i>H</i>)-one (<b>23c</b>)</h3><div class="NLM_p last">Yield 46%, yellow solid. Mp: 78–80 °C. HPLC: 97.4%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.60 (s, 1H), 6.93–6.99 (m, 1H), 6.87 (d, <i>J</i> = 2.4 Hz, 1H), 6.73 (s, 1H), 6.68 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 6.50 (d, <i>J</i> = 8.4 Hz, 1H), 3.92 (s, 6H), 3.73 (s, 6H), 2.99 (t, <i>J</i> = 6.3 Hz, 2H), 2.61 (t, <i>J</i> = 6.3 Hz, 2H); HRMS (ES+) <i>m</i>/<i>z</i> found 354.1466; C<sub>21</sub>H<sub>22</sub>O<sub>5</sub>(M<sup>+</sup>) requires 354.1467.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Biology. Cytotoxicity Assay</h3><div class="NLM_p last">Cytotoxic effects were examined in the MDA-MB-435 human breast carcinoma, HCT-116 human colon carcinoma, and CEM human leukemia cell lines. Cells in logarithmic phase were diluted to a density of 40000–50000 cells/mL in culture medium based on growth characteristics. For each well of a 96-well microplate, 100 μL of cell dilution was seeded, allowed to attach overnight, and then exposed to varying concentrations (10<sup>–4</sup>–10<sup>–9</sup> M) of compounds for 72 h (37 °C, 5% CO<sub>2</sub> atmosphere). The number of living cells was estimated by the MTT assay. Absorbance at 570 nm was recorded on a Wellscan MK-2 multifunction microplate reader (Labsystems Inc.). Compounds were tested in triplicate in at least three independent assays. The IC<sub>50</sub> values were determined by a nonlinear regression analysis. Average values were reported.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Tubulin Polymerization Assay<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63, 64)</a></h3><div class="NLM_p last">Procine brain tubulin was purchased from cytoskeleton. Tubulin (>99% pure, 3 mg/mL) in 100 μL of general tubulin buffer (80 mM PIPES, pH 6.9, 0.5 mM EGTA, 2 mM MgCl<sub>2</sub>, 1 mM GTP, and 5% glycerol) at 0 °C was placed in a prewarmed half area 96-well plate at 37 °C in the presence of tested compounds at varying concentrations. The reaction was started by warming the samples at 37 °C. The mass of polymer formed was monitored by turbidimetry at 340 nm every 1 min for 60 min with a BioTek’s Synergy 4 multifunction microplate reader.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Cell Cycle Analysis</h3><div class="NLM_p last">For flow cytometric analysis of DNA content, 10<sup>6</sup> HCT-116 cells in exponential growth were treated with varying concentrations of compound <b>22b</b> for 24 h. After centrifugation, the cell pellet was fixed in 2 mL of citrate buffer. Fixed cells were treated with 1.5 mL of RNase A for 20 min. Samples were analyzed on a BD FACStar Plus cell sorter flow cytometer. The percentage of each phase of the cell cycle (G1, S, G2/M) was calculated on living cells. The percentage of apoptotic cells is referred to the cell populations characterized by the appearance of a sub-G1-peak.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> In Vivo Antitumor Activity</h3><div class="NLM_p last">Four-week-old female BALB/c nude mice (18–20 g) were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). The animals were maintained under specific pathogen-free conditions in Shanghai Institute of Pharmaceutical Industry. Once the HT-29 xenografts reached a size of around 100 mm<sup>3</sup>, mice were randomly assigned into corresponding groups and injected intraperitoneally at 0.1 mL per 20 g of body weight.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The drugs or vehicle were administered once a day. After completing the treatment schedule and the evaluation period, tumor-bearing mice were euthanized. Tumor volume (TV) was calculated by the formula: TV= (<i>ab</i><sup>2</sup>)/2 where <i>a</i> is the length and <i>b</i> is the width of the tumor nodules determined once per 4 days by caliper measurements and recorded along with body weights. The study was approved by Shanghai Institute of Pharmaceutical Industry.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Molecular Docking</h3><div class="NLM_p last">The X-ray structure of the DAMA–colchicine–tubulin complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0">1SA0</a>) was used as the tubulin protein template. All calculations were performed on an Origin 300 server. Docking was carried out with AutoDock program. A grid of 45 × 40 × 40 was used to ensure that the area probed was adequate for the ligands to explore all possible binding modes. Docking runs were performed using the Larmarckian genetic algorithm (LGA) with some modifications of the docking parameters. Each docking experiment was derived from 50 different runs that was set to terminate after a maximum of 10 000 000 energy evaluations or 370 000 generations, yielding 50 docked conformations. At the end of a docking job with multiple runs, AutoDock performed cluster analysis. Docking solutions with ligand all-atom rmsd values within 0.5 Å of each other were clustered together and ranked by the lowest energy representative. Low energy binding modes and the lowest energy conformation from clusters of five or more occurrences were selected for further refinement. These were then refined by SYBYL, with the binding mode that had the lowest complex energy after minimization being selected as the final binding mode.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> X-ray Crystallography</h3><div class="NLM_p last">Crystal data for <b>22b</b> are as follows: C<sub>21</sub>H<sub>22</sub>O<sub>5</sub>, MW 354.39; crystal size, 0.06 × 0.05 × 0.04 mm<sup>3</sup>; yellow, prism; space group <i>P</i>2(1)/<i>c</i>; monoclinic, <i>a</i> = 11.13(3) Å, <i>b</i> = 12.69(3) Å,<i>c</i> = 14.47(3) Å, α = γ = 90°, β = 111.59(3) °; <i>V</i> = 1900(8) Å; <i>Z</i> = 4; Dc = 1.239 g/cm<sup>3</sup>; <i>F</i>(000) = 752; <i>m</i> = 0.088 mm<sup>–1</sup>; range for data collection, 2.53–26.16; reflections collected 6490; unique reflections 3326 [<i>R</i><sub>int</sub> = 0.1003]; data/restraints/parameters 3326/0/240; goodness-of-fit on <i>F</i><sup>2</sup> 1.056; <i>R</i> indices (all data), R1 = 0.0824, wR2 = 0.1960; final <i>R</i> indices [<i>I</i> > 2σ(<i>I</i>)], R1 = 0.0628, wR2 = 0.1785; CCDC, 761109.</div></div><div id="secz" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Statistical Analysis</h3><div class="NLM_p last">The differences between different treatments were analyzed, using the two-sided Student’s <i>t</i> test. <i>P</i> values lower than 0.05 were considered significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm300596s" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83828" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83828" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Can-Hui Zheng</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Second Military Medical University, 325 Guohe Road,
Shanghai 200433, People’s Republic of China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3556545b5d405c6a4f5d505b52754c545d5a5a1b565a581b565b15595f52070505030500050d754c545d5a5a1b565a581b565b154f5d5a404c5a405f405b07050503754c545d5a5a1b565a581b565b"><span class="__cf_email__" data-cfemail="82e1e3eceaf7ebddf8eae7ece5c2fbe3eaededace1edeface1ec">[email protected]</span> <span class="__cf_email__" data-cfemail="630f0904515353555356535b231a020b0c0c4d000c0e4d000d">[email protected]</span> <span class="__cf_email__" data-cfemail="364c5e59434f59435c435804060600764f575e59591855595b185558">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia-Guo Lv</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Second Military Medical University, 325 Guohe Road,
Shanghai 200433, People’s Republic of China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7e1d1f10160b172104161b10193e071f161111501d1113501d105e1214194c4e4e484e4b4e463e071f161111501d1113501d105e0416110b07110b140b104c4e4e483e071f161111501d1113501d10"><span class="__cf_email__" data-cfemail="791a1817110c102603111c171e390018111616571a1614571a17">[email protected]</span> <span class="__cf_email__" data-cfemail="472b2d20757777717772777f073e262f28286924282a692429">[email protected]</span> <span class="__cf_email__" data-cfemail="502a383f25293f253a253e62606066102931383f3f7e333f3d7e333e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">You-Jun Zhou</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Second Military Medical University, 325 Guohe Road,
Shanghai 200433, People’s Republic of China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e083818e889589bf9a88858e87a09981888f8fce838f8dce838ec08c8a87d2d0d0d6d0d5d0d8a09981888f8fce838f8dce838ec09a888f95998f958a958ed2d0d0d6a09981888f8fce838f8dce838e"><span class="__cf_email__" data-cfemail="97f4f6f9ffe2fec8edfff2f9f0d7eef6fff8f8b9f4f8fab9f4f9">[email protected]</span> <span class="__cf_email__" data-cfemail="f39f9994c1c3c3c5c3c6c3cbb38a929b9c9cdd909c9edd909d">[email protected]</span> <span class="__cf_email__" data-cfemail="5b2133342e22342e312e35696b6b6d1b223a33343475383436753835">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Liu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Second Military Medical University, 325 Guohe Road,
Shanghai 200433, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-Hui Ren</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Second Military Medical University, 325 Guohe Road,
Shanghai 200433, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Zhou</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Second Military Medical University, 325 Guohe Road,
Shanghai 200433, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Li</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Second Military Medical University, 325 Guohe Road,
Shanghai 200433, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ju Zhu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Second Military Medical University, 325 Guohe Road,
Shanghai 200433, People’s Republic of China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6361-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The work was supported by National Natural Science Foundation of China (Grant No. 21172260), the Key Program for Basic Research of Shanghai “Technology Innovation Action Plan” (Grant No. 09JC1417500), Shanghai Natural Science Foundation (Grant No. 09ZR1438800), and National Natural Science Foundation of China (Grant No. 30901859).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i85" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i85"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i86" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i86"> Abbreviations Used</h2><tr><td class="NLM_term">VDA</td><td class="NLM_def"><p class="first last">vascular disrupting agent</p></td></tr><tr><td class="NLM_term">CA-4</td><td class="NLM_def"><p class="first last">combretastatin A-4</p></td></tr><tr><td class="NLM_term">CA-4P</td><td class="NLM_def"><p class="first last">combretastatin A-4 phosphate</p></td></tr><tr><td class="NLM_term">CSI</td><td class="NLM_def"><p class="first last">colchicine site inhibitor</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">PIPES</td><td class="NLM_def"><p class="first last">piperazine-<i>N</i>,<i>N</i>′-bis[2-ethanesulfonic acid]sequisodium salt</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">ethylene glycol bis(2-aminoethyl ether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid</p></td></tr><tr><td class="NLM_term">WBC</td><td class="NLM_def"><p class="first last">white blood cell</p></td></tr><tr><td class="NLM_term">LY</td><td class="NLM_def"><p class="first last">lymphocyte</p></td></tr><tr><td class="NLM_term">PLT</td><td class="NLM_def"><p class="first last">platelet</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine transaminase</p></td></tr><tr><td class="NLM_term">ALP</td><td class="NLM_def"><p class="first last">alkaline phosphatase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 65 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lg-KqfhottRvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahindroo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chern, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, U. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C. C.</span><span> </span><span class="NLM_article-title">Structure–activity and crystallographic analysis of benzophenone derivatives—the potential anticancer agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=101-105&author=H.+P.+Hsiehauthor=J.+P.+Liouauthor=Y.+T.+Linauthor=N.+Mahindrooauthor=J.+Y.+Changauthor=Y.+N.+Yangauthor=S.+S.+Chernauthor=U.+K.+Tanauthor=C.+W.+Changauthor=T.+W.+Chenauthor=C.+H.+Linauthor=Y.+Y.+Changauthor=C.+C.+Wang&title=Structure%E2%80%93activity+and+crystallographic+analysis+of+benzophenone+derivatives%E2%80%94the+potential+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLin%26aufirst%3DY.%2BT.%26aulast%3DMahindroo%26aufirst%3DN.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DYang%26aufirst%3DY.%2BN.%26aulast%3DChern%26aufirst%3DS.%2BS.%26aulast%3DTan%26aufirst%3DU.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DT.%2BW.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DY.%2BY.%26aulast%3DWang%26aufirst%3DC.%2BC.%26atitle%3DStructure%25E2%2580%2593activity%2520and%2520crystallographic%2520analysis%2520of%2520benzophenone%2520derivatives%25E2%2580%2594the%2520potential%2520anticancer%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D101%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Belotti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drudis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsotti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitelli, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taraboletti, G.</span><span> </span><span class="NLM_article-title">The microtubule-affecting drug paclitaxel has antiangiogenic activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1843</span><span class="NLM_x">–</span> <span class="NLM_lpage">1849</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=9816139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1SitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=1843-1849&author=D.+Belottiauthor=V.+Verganiauthor=T.+Drudisauthor=P.+Borsottiauthor=M.+R.+Pitelliauthor=G.+Vialeauthor=R.+Giavazziauthor=G.+Taraboletti&title=The+microtubule-affecting+drug+paclitaxel+has+antiangiogenic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The microtubule-affecting drug paclitaxel has antiangiogenic activity</span></div><div class="casAuthors">Belotti, Dorina; Vergani, Veronica; Drudis, Teresa; Borsotti, Patrizia; Pitelli, Maria Rosa; Viale, Giuseppe; Giavazzi, Raffaella; Taraboletti, Giulia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1843-1849</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endothelial cell migration is a crit. event during angiogenesis, and inhibitors of cell motility can affect the angiogenic process.  Paclitaxel, a microtubule-stabilizing antineoplastic cytotoxic drug, inhibits motility and invasiveness of several cell types.  The aim of this study was to investigate the effect of paclitaxel on endothelial cell functions and on angiogenesis.  In vivo, paclitaxel (20-28 mg/kg i.v.) significantly inhibited the angiogenic response induced by tumor cell supernatant embedded in a pellet of reconstituted basement membrane (Matrigel) injected s.c. into C57BL/6N mice.  In vitro, paclitaxel inhibited endothelial cell proliferation, motility, invasiveness, and cord formation on Matrigel in a dose-dependent manner.  The antiangiogenic activity of paclitaxel was not linked to its cytotoxicity, since inhibition of endothelial cell chemotaxis and invasiveness occurred at drug concns. which did not affect endothelial cell proliferation.  Another cytotoxic drug, cisplatin, that inhibited endothelial cell proliferation in vitro, did not affect angiogenesis in vivo.  These data indicate that paclitaxel has a strong antiangiogenic activity, a property that might contribute to its antineoplastic activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEwI_-XSTB_7Vg90H21EOLACvtfcHk0ljrl36WiOIdaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1SitLo%253D&md5=fa2918912bb43c219952c4c4003c73f5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBelotti%26aufirst%3DD.%26aulast%3DVergani%26aufirst%3DV.%26aulast%3DDrudis%26aufirst%3DT.%26aulast%3DBorsotti%26aufirst%3DP.%26aulast%3DPitelli%26aufirst%3DM.%2BR.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DTaraboletti%26aufirst%3DG.%26atitle%3DThe%2520microtubule-affecting%2520drug%2520paclitaxel%2520has%2520antiangiogenic%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1996%26volume%3D2%26spage%3D1843%26epage%3D1849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mekhail, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markman, M.</span><span> </span><span class="NLM_article-title">Paclitaxel in cancer therapy</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1517%2F14656566.3.6.755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12036415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1CqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=755-766&author=T.+M.+Mekhailauthor=M.+Markman&title=Paclitaxel+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel in cancer therapy</span></div><div class="casAuthors">Mekhail, Tarek M.; Markman, Maurie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-766</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  The last decade witnessed the introduction of exciting new chemotherapeutic agents.  Among these, paclitaxel emerged as one of the most powerful compds.  Paclitaxel promotes the polymn. of tubulin, thereby causing cell death by disrupting the normal microtubule dynamics required for cell division and vital interphase processes.  Mechanisms of acquired resistance to paclitaxel include alterations of tubulin structure and the amplification of membrane phosphoglycoproteins that function as drug-efflux pumps.  Toxicities assocd. with paclitaxel include hypersensitivity reaction, neurotoxicity and hematol. toxicities.  Toxicities may be both dose- and schedule-dependent.  Paclitaxel has activity against a broad band of tumor types, including breast, ovarian, lung, head and neck cancers.  Paclitaxel also has activity in other malignancies that are refractory to conventional chemotherapy, including previously-treated lymphoma and small cell lung cancers and esophageal, gastric endometrial, bladder and germ cell tumors.  Paclitaxel is also active against AIDS-assocd. Kaposi's sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbdrcIMqjxiLVg90H21EOLACvtfcHk0ljrl36WiOIdaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1CqsrY%253D&md5=258be69b5cce3cc7c4654cd65229a3e4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14656566.3.6.755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.3.6.755%26sid%3Dliteratum%253Aachs%26aulast%3DMekhail%26aufirst%3DT.%2BM.%26aulast%3DMarkman%26aufirst%3DM.%26atitle%3DPaclitaxel%2520in%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2002%26volume%3D3%26spage%3D755%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, R. C.</span><span> </span><span class="NLM_article-title">The clinical-pharmacology and use of antimicrotubule agents in cancer chemotherapeutics</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1016%2F0163-7258%2891%2990086-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=1687171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK38XhvVOgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1991&pages=35-84&author=E.+K.+Rowinskyauthor=R.+C.+Donehower&title=The+clinical-pharmacology+and+use+of+antimicrotubule+agents+in+cancer+chemotherapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics</span></div><div class="casAuthors">Rowinsky, Eric K.; Donehower, Ross C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-84</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    </div><div class="casAbstract">A review with >500 refs.  Mechanisms of antineoplastic action and resistance and clin. pharmacol., therapeutic applications, and clin. toxicities of selected antimicrotubule agents (vincristine, vinblastine, vindesine, vinorelbine, and taxol) are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTPZ9qEQhDorVg90H21EOLACvtfcHk0ljrl36WiOIdaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvVOgt7o%253D&md5=575a2df3b5700d2587ca1ab45e1a6645</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0163-7258%2891%2990086-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0163-7258%252891%252990086-2%26sid%3Dliteratum%253Aachs%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DDonehower%26aufirst%3DR.%2BC.%26atitle%3DThe%2520clinical-pharmacology%2520and%2520use%2520of%2520antimicrotubule%2520agents%2520in%2520cancer%2520chemotherapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D1991%26volume%3D52%26spage%3D35%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Nam, N. H.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 analogues as antimitotic antitumor agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1697</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2174%2F0929867033457151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12871118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1Wgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=1697-1722&author=N.+H.+Nam&title=Combretastatin+A-4+analogues+as+antimitotic+antitumor+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 analogues as antimitotic antitumor agents</span></div><div class="casAuthors">Nam, Nguyen-Hai</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1697-1722</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is a major target for anticancer drug discovery.  As a result, antimitotic agents constitute an important class of the current anticancer drugs.  Hundreds of tubulin inhibitors, naturally occurring, semisynthetic or synthetic, have been reported.  Among these, combretastatin A-4 (CA-4), isolated from a South African tree Combretum caffrum, is one of the most potent antimitotic agents.  CA-4 shows strong cytotoxicity against a variety of cancer cells, including multi-drug resistant cancer cell lines.  It has also been demonstrated to exert highly selective effects in proliferating endothelial cells.  CA-4 disodium phosphate (CA4DP), a water-sol. prodrug of CA-4, shows potent antivascular and antitumor effects in a wide variety of preclin. tumor models.  Consequently, a no. of CA-4 analogs has been synthesized and evaluated.  In this paper, the structure-activity relationships and pharmacol. properties of the CA-4 derivs. as a class of potent antimitotic anticancer agents are reviewed and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcRUgR4DDrfbVg90H21EOLACvtfcHk0lje21s3ZLSwTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1Wgurk%253D&md5=7eeed63b294477bb55c7392ab3948d77</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F0929867033457151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867033457151%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DN.%2BH.%26atitle%3DCombretastatin%2520A-4%2520analogues%2520as%2520antimitotic%2520antitumor%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2003%26volume%3D10%26spage%3D1697%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Bhattacharyya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, M.</span><span> </span><span class="NLM_article-title">Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1002%2Fmed.20097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=17464966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=155-183&author=B.+Bhattacharyyaauthor=D.+Pandaauthor=S.+Guptaauthor=M.+Banerjee&title=Anti-mitotic+activity+of+colchicine+and+the+structural+basis+for+its+interaction+with+tubulin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin</span></div><div class="casAuthors">Bhattacharyya, Bhabatarak; Panda, Dulal; Gupta, Suvroma; Banerjee, Mithu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-183</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In this review, an attempt has been made to throw light on the mechanism of action of colchicine and its different analogs as anti-cancer agents.  Colchicine interacts with tubulin and perturbs the assembly dynamics of microtubules.  Though its use has been limited because of its toxicity, colchicine can still be used as a lead compd. for the generation of potent anti-cancer drugs.  Colchicine binds to tubulin in a poorly reversible manner with high activation energy.  The binding interaction is favored entropically.  In contrast, binding of its simple analogs AC or DAAC is enthalpically favored and commences with comparatively low activation energy.  Colchicine-tubulin interaction, which is normally pH dependent, has been found to be independent of pH in the presence of microtubule-assocd. proteins, salts or upon cleavage of carboxy termini of tubulin.  Biphasic kinetics of colchicines-tubulin interaction has been explained in light of the variation in the residues around the drug-binding site on β-tubulin.  Using the crystal structure of the tubulin-DAMAcolchicine complex, a detailed discussion on the pharmacophore concept that explains the variation of affinity for different colchicine site inhibitors (CSI) has been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9F4KA4GVMr7Vg90H21EOLACvtfcHk0lje21s3ZLSwTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVSjsA%253D%253D&md5=720f26c98a40dd91634dbe558d982e98</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fmed.20097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20097%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharyya%26aufirst%3DB.%26aulast%3DPanda%26aufirst%3DD.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DM.%26atitle%3DAnti-mitotic%2520activity%2520of%2520colchicine%2520and%2520the%2520structural%2520basis%2520for%2520its%2520interaction%2520with%2520tubulin%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D155%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, R. C.</span><span> </span><span class="NLM_article-title">Drug therapy—paclitaxel (Taxol)</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1056%2FNEJM199504133321507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=7885406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A280%3ADyaK2M7ptFKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1995&pages=1004-1014&author=E.+K.+Rowinskyauthor=R.+C.+Donehower&title=Drug+therapy%E2%80%94paclitaxel+%28Taxol%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel (taxol)</span></div><div class="casAuthors">Rowinsky E K; Donehower R C</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1004-14</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDsoUwRBKuB62q3xNe7a7QfW6udTcc2ebTVk8QL9GeMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7ptFKisg%253D%253D&md5=918362934f39ee3362db9d2bed1c71cb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJM199504133321507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199504133321507%26sid%3Dliteratum%253Aachs%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DDonehower%26aufirst%3DR.%2BC.%26atitle%3DDrug%2520therapy%25E2%2580%2594paclitaxel%2520%2528Taxol%2529%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1995%26volume%3D332%26spage%3D1004%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kruczynski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, B. T.</span><span> </span><span class="NLM_article-title">Vinflunine, the latest vinca alkaloid in clinical development: a review of its preclinical anticancer properties</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1016%2FS1040-8428%2801%2900183-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=11682323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A280%3ADC%252BD3MrnsVGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=159-173&author=A.+Kruczynskiauthor=B.+T.+Hill&title=Vinflunine%2C+the+latest+vinca+alkaloid+in+clinical+development%3A+a+review+of+its+preclinical+anticancer+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties</span></div><div class="casAuthors">Kruczynski A; Hill B T</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-73</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">Vinflunine is a new Vinca alkaloid uniquely fluorinated, by the use of superacid chemistry, in a little exploited region of the catharanthine moiety.  In vitro investigations have confirmed the mitotic-arresting and tubulin-interacting properties of vinflunine shared by other Vinca alkaloids.  However, differences in terms of the inhibitory effects of vinflunine on microtubules dynamics and its tubulin binding affinities have been identified which appear to distinguish it from the other Vinca alkaloids.  Vinflunine induced smaller spirals with a shorter relaxation time, effects, which might be associated with reduced neurotoxicity.  Studies investigating the in vitro cytotoxicity of vinflunine in combination therapy have revealed a high level of synergy when vinflunine was combined with either cisplatin, mitomycin C, doxorubicin or 5-fluorouracil.  Furthermore, although vinflunine appears to participate in P-glycoprotein-mediated drug resistance mechanisms, it has proved only a weak substrate for this protein and a far less potent inducer of resistance than vinorelbine.  Vinflunine was identified in preclinical studies as having marked antitumour activity in vivo against a large panel of experimental tumour models, with tumour regressions being recorded in human renal and small cell lung cancer tumour xenografts.  Overall its level of activity was superior to that of vinorelbine in many of the experimental models used.  Interestingly, an in vivo study using a well vascularised adenocarcinoma of the colon has suggested that vinflunine mediates its antitumour activity at least in part via an antivascular mechanism, even at sub-cytotoxic doses.  Therefore, these data provide a favourable preclinical profile for vinflunine, supporting its promising candidacy for clinical development.  Phase I evaluations of vinflunine have been completed in Europe and phase II clinical trials are now ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2XApFJuUMRYkFb3mqPUYDfW6udTcc2ebTVk8QL9GeMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MrnsVGlsQ%253D%253D&md5=65fa3755e13ca2227f3e12e00877874a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1040-8428%2801%2900183-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1040-8428%252801%252900183-4%26sid%3Dliteratum%253Aachs%26aulast%3DKruczynski%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DB.%2BT.%26atitle%3DVinflunine%252C%2520the%2520latest%2520vinca%2520alkaloid%2520in%2520clinical%2520development%253A%2520a%2520review%2520of%2520its%2520preclinical%2520anticancer%2520properties%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2001%26volume%3D40%26spage%3D159%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Altaha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, J.</span><span> </span><span class="NLM_article-title">Epothilones: a novel class of non-taxane microtubule-stabilizing agents</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1707</span><span class="NLM_x">–</span> <span class="NLM_lpage">1712</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2174%2F1381612023394043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12171542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD38XlslKhtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1707-1712&author=R.+Altahaauthor=T.+Fojoauthor=E.+Reedauthor=J.+Abraham&title=Epothilones%3A+a+novel+class+of+non-taxane+microtubule-stabilizing+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilones: a novel class of non-taxane microtubule-stabilizing agents</span></div><div class="casAuthors">Altaha, Ramin; Fojo, Tito; Reed, Eddie; Abraham, Jame</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1707-1712</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  The epothilones are a novel class of non-taxane microtubule-stabilizing agents obtained from the fermn. of the cellulose degrading myxobacteria, Sorangium cellulosum.  Preclin. studies have shown that the epothilones are more potent than the taxanes and active in some taxane-resistant models.  Similar to paclitaxel and other taxanes, the epothilones block cells in mitosis, resulting in cell death.  The chief components of the fermn. process are epothilones A and B, with epothilones C and D found in smaller amts.  Trace amts. of other epothilones have also been detected.  Pre-clin. studies have shown that epothilone B is the most active form, exhibiting significantly higher antitumor activity than paclitaxel and docetaxel.  Several phase I and phase II clin. trials are ongoing with epothilone B and BMS 247550, an epothilone B analog.  Preliminary reports indicate these agents are active against human cancers in heavily pre-treated patients.  The epothilones appear to be well tolerated, with a side effect profile that is similar to that reported with the taxanes.  This article will review some basic aspects of epothilone chem. and biol., and pre-clin. and preliminary clin. experience with epothilone B and its analog, BMS 247550.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtxmpHV7S5fbVg90H21EOLACvtfcHk0liz3vUPIqIwww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlslKhtro%253D&md5=8a817f51e738385550307f4a034253ab</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1381612023394043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612023394043%26sid%3Dliteratum%253Aachs%26aulast%3DAltaha%26aufirst%3DR.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DReed%26aufirst%3DE.%26aulast%3DAbraham%26aufirst%3DJ.%26atitle%3DEpothilones%253A%2520a%2520novel%2520class%2520of%2520non-taxane%2520microtubule-stabilizing%2520agents%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2002%26volume%3D8%26spage%3D1707%26epage%3D1712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannakakou, P.</span><span> </span><span class="NLM_article-title">Targeting microtubules for cancer chemotherapy</span> <span class="citation_source-journal">Curr. Med. Chem.: Anti-Cancer Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2174%2F1568011053352569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=15720262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-71&author=J.+Zhouauthor=P.+Giannakakou&title=Targeting+microtubules+for+cancer+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting microtubules for cancer chemotherapy</span></div><div class="casAuthors">Zhou, Jun; Giannakakou, Paraskevi</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chem. compds. that interfere with microtubules such as the vinca alkaloids and taxanes are important chemotherapeutic agents for the treatment of cancer.  As knowledge of microtubule-targeting drugs increases, the mechanism underlying the anticancer activity of these agents may mainly lie in their inhibitory effects on spindle microtubule dynamics, rather than in their effects on microtubule polymer mass.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell cycle progression at mitosis and eventually leading to apoptotic cell death.  The effectiveness of microtubule-targeting drugs for cancer therapy has been impaired by various side effects, notably neurol. and hematol. toxicities.  Drug resistance is another notorious factor that thwarts the effectiveness of these agents, as with many other cancer chemotherapeutics.  Several new microtubule-targeting agents have shown potent activity against the proliferation of various cancer cells, including cells that display resistance to the existing microtubule-targeting drugs.  Continued investigation of the mechanisms of action of microtubule-targeting drugs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance may provide more effective therapeutic options for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI0IucAUr4V7Vg90H21EOLACvtfcHk0liz3vUPIqIwww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D&md5=e5d34ca2c4d4adf0e6975989da8aaee8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1568011053352569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011053352569%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGiannakakou%26aufirst%3DP.%26atitle%3DTargeting%2520microtubules%2520for%2520cancer%2520chemotherapy%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Tron, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirali, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagliai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busacca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of combretastatin A4: present and future directions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3033</span><span class="NLM_x">–</span> <span class="NLM_lpage">3044</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0512903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFyjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3033-3044&author=G.+C.+Tronauthor=T.+Piraliauthor=G.+Sorbaauthor=F.+Pagliaiauthor=S.+Busaccaauthor=A.+A.+Genazzani&title=Medicinal+chemistry+of+combretastatin+A4%3A+present+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of combretastatin A4: Present and future directions</span></div><div class="casAuthors">Tron, Gian Cesare; Pirali, Tracey; Sorba, Giovanni; Pagliai, Francesca; Busacca, Sara; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3033-3044</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with refs.  A review on the medicinal chem. of combretastatin A4 (CA-4), a compd. with antitumor properties.  The mechanism of action of CA-4, including its ability to inhibit tubulin polymn., is discussed, along with selected analogs of CA-4 modified on the arom. rings A and B, substituted Ph rings, heterocycling rings, non-substituted arom. rings, modifications on the double bond, and analogs where the olefinic group is replaced by a ring.  Some issues related to the pharmacol. of CA-4 and future directions in research are considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGNHvpiUH4mbVg90H21EOLACvtfcHk0liz3vUPIqIwww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFyjuro%253D&md5=be023d8f1f059f952308bb06196459da</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm0512903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512903%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DPagliai%26aufirst%3DF.%26aulast%3DBusacca%26aufirst%3DS.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DMedicinal%2520chemistry%2520of%2520combretastatin%2520A4%253A%2520present%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3033%26epage%3D3044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walicke, P. A.</span><span> </span><span class="NLM_article-title">A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=189-197&author=D.+W.+Siemannauthor=D.+J.+Chaplinauthor=P.+A.+Walicke&title=A+review+and+update+of+the+current+status+of+the+vasculature-disabling+agent+combretastatin-A4+phosphate+%28CA4P%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DWalicke%26aufirst%3DP.%2BA.%26atitle%3DA%2520review%2520and%2520update%2520of%2520the%2520current%2520status%2520of%2520the%2520vasculature-disabling%2520agent%2520combretastatin-A4%2520phosphate%2520%2528CA4P%2529%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, S.</span><span> </span><span class="NLM_article-title">Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1334</span><span class="NLM_x">–</span> <span class="NLM_lpage">1344</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1038%2Fsj.bjc.6601261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=14520469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1Cmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2003&pages=1334-1344&author=K.+Horiauthor=S.+Saito&title=Microvascular+mechanisms+by+which+the+combretastatin+A-4+derivative+AC7700+%28AVE8062%29+induces+tumour+blood+flow+stasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis</span></div><div class="casAuthors">Hori, K.; Saito, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1334-1344</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors previously reported that a novel combretastatin A-4 deriv., AC7700, has remarkable antitumor effects because of an irreversible stasis of tumor blood flow (TBF) and subsequent loss of nutrient supply to tumor tissue.  Since early 2002, under the new designation AVE8062, AC7700 has undergone clin. trials in Europe and the US.  Questions remain, however, concerning how AC7700 blocks TBF and why the TBF stasis does not recover.  In this study, using a rat tumor LY80, a variant of Yoshida sarcoma, the authors examd. whether TBF cessation after AC7700 administration is due to a direct action of the agent on tumor blood vessels.  The authors constructed electrodes that can drop a small quantity of the drug soln. directly at the site of blood flow measurement and inserted them s.c. and into the tumor.  The authors compared the blood flow responses of normal vessels and tumor vessels after administration of 10-μl doses of various concns. (0.2, 1, 10, and 50 mg ml-1) of the AC7700 soln.  In addn., the authors assessed TBF stasis after i.v. and intra-arterial 10 mg kg-1 AC7700 administration in an LY80-induced kidney tumor.  To det. why the TBF stasis is irreversible, the authors obsd. AC7700-induced changes in host arterioles and the tumor vascular network of the Sato lung carcinoma using a vital microscopic rat transparent chamber.  Since an increase in tumor interstitial fluid pressure brings about a decrease in TBF, the authors also measured 10 mg kg-1 AC7700-induced changes in this pressure.  The sensitivity of the blood flow response after intratumoral application of AC7700 was markedly higher in normal vessels relative to tumor vessels.  Intra-arterial administration of AC7700 did not have stronger effects on TBF stasis than did i.v. administration.  Intravital microscopy showed that AC7700 induced a powerful and long-lasting constriction of host arterioles, so that complete stasis of blood flow occurred in downstream vessels, which supplied blood to tumors.  Owing to this stasis, the lumens of numerous tumor vessels narrowed or completely disappeared, and numerous erythrocytes stagnated in drainage vessels of the tumor vascular network.  Hemolysis of these erythrocytes occurred after 2-3 h, resulting in complete thrombosis.  There was no indication of reperfusion in vessels showing hemolysis.  This hemolysis is thought to be the main cause for the irreversibility of TBF stasis.  Since the tumor interstitial fluid pressure decreased after i.v. AC7700 administration, the possibility of stasis of TBF being caused by tumor vascular compression was excluded.  All these results strongly suggest that the main target of AC7700 is host arterioles and that the stasis of TBF induced by AC7700 is not triggered by a direct action of the drug on tumor vessels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplroi2amwQXbVg90H21EOLACvtfcHk0lhR2N7E62W8iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1Cmu70%253D&md5=68c723d7334ac342d2c5c1b7c06b5294</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601261%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DS.%26atitle%3DMicrovascular%2520mechanisms%2520by%2520which%2520the%2520combretastatin%2520A-4%2520derivative%2520AC7700%2520%2528AVE8062%2529%2520induces%2520tumour%2520blood%2520flow%2520stasis%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D89%26spage%3D1334%26epage%3D1344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Shan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y.</span><span> </span><span class="NLM_article-title">Developments of combretastatin A-4 derivatives as anticancer agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2174%2F092986711794480221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=21143124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsl2lt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=523-538&author=Y.+Shanauthor=J.+Zhangauthor=Z.+Liuauthor=M.+Wangauthor=Y.+Dong&title=Developments+of+combretastatin+A-4+derivatives+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Developments of combretastatin A-4 derivatives as anticancer agents</span></div><div class="casAuthors">Shan, Y.; Zhang, J.; Liu, Z.; Wang, M.; Dong, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-538</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is one of several members of a small family of globular proteins.  It offers a potential target for anticancer drug design and development.  Combretastatin A-4 (CA-4) is a potent anticancer and antiangiogenesis natural substance isolated from Combretum caffrum.  Modifications on the Ca-4 structure have led to a great no. of novel CA-4 derivs. as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer.  In this review, the recent developments of novel CA-4 derivs. via the modifications on the A- and B-ring and the double bond as anticancer agents are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUzBhk-7FdB7Vg90H21EOLACvtfcHk0lhR2N7E62W8iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsl2lt70%253D&md5=81b78f1ee900478f3771ba7e9b7ef1d9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F092986711794480221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794480221%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DY.%26atitle%3DDevelopments%2520of%2520combretastatin%2520A-4%2520derivatives%2520as%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D523%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Theeramunkong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massarotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aprile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caprioglio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaninetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teruggi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirali, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tron, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span> </span><span class="NLM_article-title">Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4977</span><span class="NLM_x">–</span> <span class="NLM_lpage">4986</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200555r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlaitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4977-4986&author=S.+Theeramunkongauthor=A.+Caldarelliauthor=A.+Massarottiauthor=S.+Aprileauthor=D.+Caprioglioauthor=R.+Zaninettiauthor=A.+Teruggiauthor=T.+Piraliauthor=G.+Grosaauthor=G.+C.+Tronauthor=A.+A.+Genazzani&title=Regioselective+Suzuki+coupling+of+dihaloheteroaromatic+compounds+as+a+rapid+strategy+to+synthesize+potent+rigid+combretastatin+analogues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective Suzuki Coupling of Dihaloheteroaromatic Compounds as a Rapid Strategy To Synthesize Potent Rigid Combretastatin Analogues</span></div><div class="casAuthors">Theeramunkong, Sewan; Caldarelli, Antonio; Massarotti, Alberto; Aprile, Silvio; Caprioglio, Diego; Zaninetti, Roberta; Teruggi, Alessia; Pirali, Tracey; Grosa, Giorgio; Tron, Gian Cesare; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4977-4986</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combretastatin A-4 (CA-4) is a potent tubulin depolymg. agent able to inhibit tumor growth and with antivascular effects.  Although it is in clin. trials, the search for novel analogs that may display better/different features is still ongoing.  In this manuscript we describe the synthesis of novel constrained analogs of CA-4 obtained in only two synthetic steps exploiting a regioselective Suzuki coupling of dihalogenated heteroarom. and alicyclic compds.  All the compds. synthesized have been evaluated for cytotoxicity and for their ability to inhibit tubulin assembly.  One of them, I, displayed low nanomolar cytotoxicity and proved to have a pharmacodynamic profile similar to that of CA-4 and a better pharmacokinetic profile, but most important of all, this synthetic strategy may pave the way for the easy and rapid generation of novel rigid analogs of combretastatins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCcsEeiXLwXLVg90H21EOLACvtfcHk0lhR2N7E62W8iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlaitbs%253D&md5=235e7be73c6f7f974bd9e129381933cd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm200555r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200555r%26sid%3Dliteratum%253Aachs%26aulast%3DTheeramunkong%26aufirst%3DS.%26aulast%3DCaldarelli%26aufirst%3DA.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DCaprioglio%26aufirst%3DD.%26aulast%3DZaninetti%26aufirst%3DR.%26aulast%3DTeruggi%26aufirst%3DA.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DGrosa%26aufirst%3DG.%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DRegioselective%2520Suzuki%2520coupling%2520of%2520dihaloheteroaromatic%2520compounds%2520as%2520a%2520rapid%2520strategy%2520to%2520synthesize%2520potent%2520rigid%2520combretastatin%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4977%26epage%3D4986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz-Lopez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez Cara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrion, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4248</span><span class="NLM_x">–</span> <span class="NLM_lpage">4258</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100245q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4248-4258&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=O.+Cruz-Lopezauthor=C.+Lopez+Caraauthor=M.+D.+Carrionauthor=A.+Brancaleauthor=E.+Hamelauthor=L.+Chenauthor=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Synthesis+and+antitumor+activity+of+1%2C5-disubstituted+1%2C2%2C4-triazoles+as+cis-restricted+combretastatin+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm100245q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100245q%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DCruz-Lopez%26aufirst%3DO.%26aulast%3DLopez%2BCara%26aufirst%3DC.%26aulast%3DCarrion%26aufirst%3DM.%2BD.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520antitumor%2520activity%2520of%25201%252C5-disubstituted%25201%252C2%252C4-triazoles%2520as%2520cis-restricted%2520combretastatin%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4248%26epage%3D4258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Congiu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocco, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onnis, V.</span><span> </span><span class="NLM_article-title">Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">989</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=989-993&author=C.+Congiuauthor=M.+T.+Coccoauthor=V.+Onnis&title=Design%2C+synthesis%2C+and+in+vitro+antitumor+activity+of+new+1%2C4-diarylimidazole-2-ones+and+their+2-thione+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCongiu%26aufirst%3DC.%26aulast%3DCocco%26aufirst%3DM.%2BT.%26aulast%3DOnnis%26aufirst%3DV.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520in%2520vitro%2520antitumor%2520activity%2520of%2520new%25201%252C4-diarylimidazole-2-ones%2520and%2520their%25202-thione%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D989%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesberger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overmoyer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makkar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stambler, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCrae, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remick, S. C.</span><span> </span><span class="NLM_article-title">A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">3408</span><span class="NLM_x">–</span> <span class="NLM_lpage">3416</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=3408-3416&author=A.+Dowlatiauthor=K.+Robertsonauthor=M.+Cooneyauthor=W.+P.+Petrosauthor=M.+Stratfordauthor=J.+Jesbergerauthor=N.+Rafieauthor=B.+Overmoyerauthor=V.+Makkarauthor=B.+Stamblerauthor=A.+Taylorauthor=J.+Waasauthor=J.+S.+Lewinauthor=K.+R.+McCraeauthor=S.+C.+Remick&title=A+phase+I+pharmacokinetic+and+translational+study+of+the+novel+vascular+targeting+agent+combretastatin+A-4+phosphate+on+a+single-dose+intravenous+schedule+in+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DK.%26aulast%3DCooney%26aufirst%3DM.%26aulast%3DPetros%26aufirst%3DW.%2BP.%26aulast%3DStratford%26aufirst%3DM.%26aulast%3DJesberger%26aufirst%3DJ.%26aulast%3DRafie%26aufirst%3DN.%26aulast%3DOvermoyer%26aufirst%3DB.%26aulast%3DMakkar%26aufirst%3DV.%26aulast%3DStambler%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DWaas%26aufirst%3DJ.%26aulast%3DLewin%26aufirst%3DJ.%2BS.%26aulast%3DMcCrae%26aufirst%3DK.%2BR.%26aulast%3DRemick%26aufirst%3DS.%2BC.%26atitle%3DA%2520phase%2520I%2520pharmacokinetic%2520and%2520translational%2520study%2520of%2520the%2520novel%2520vascular%2520targeting%2520agent%2520combretastatin%2520A-4%2520phosphate%2520on%2520a%2520single-dose%2520intravenous%2520schedule%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D3408%26epage%3D3416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbraith, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sena, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gumbrell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. M.</span><span> </span><span class="NLM_article-title">Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2815</span><span class="NLM_x">–</span> <span class="NLM_lpage">2822</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1200%2FJCO.2003.05.185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12807934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=2815-2822&author=G.+J.+S.+Rustinauthor=S.+M.+Galbraithauthor=H.+Andersonauthor=M.+Stratfordauthor=L.+K.+Folkesauthor=L.+Senaauthor=L.+Gumbrellauthor=P.+M.+Price&title=Phase+I+clinical+trial+of+weekly+combretastatin+A4+phosphate%3A+clinical+and+pharmacokinetic+results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results</span></div><div class="casAuthors">Rustin, Gordon J. S.; Galbraith, Susan M.; Anderson, Helen; Stratford, Michael; Folkes, Lisa K.; Sena, Luiza; Gumbrell, Lindsey; Price, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2815-2822</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors.  The drug was delivered by a 10-min weekly infusion for 3 wk followed by a week gap, with intrapatient dose escalation.  Dose escalation was accomplished by doubling until grade 2 toxicity was seen.  The starting dose was 5 mg/m2.  Thirty-four patients received 167 infusions.  CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized to the glucuronide.  CA4 area under the curve (AUC) increased from 0.169 at 5 mg/m2 to 3.29 μmol/h/L at 114 mg/m2.  The mean CA4 AUC in eight patients at 68 mg/m2 was 2.33 μmol/h/L compared with 5.8 μmol/h/L at 25 mg/kg (the lowest ED) in the mouse.  The only toxicity that possibly was related to the drug dose up to 40 mg/m2 was tumor pain.  Dose-limiting toxicity was reversible ataxia at 114 mg/m2, vasovagal syncope and motor neuropathy at 88 mg/m2, and fatal ischemia in previously irradiated bowel at 52 mg/m2.  Other drug-related grade 2 or higher toxicities seen in more than one patient were pain, lymphopenia, fatigue, anemia, diarrhea, hypertension, hypotension, vomiting, visual disturbance, and dyspnea.  One patient at 68 mg/m2 had improvement in liver metastases of adrenocortical carcinoma.  CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg/m2; these are doses at which tumor blood flow redn. has been recorded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqITxI8x4o-zLVg90H21EOLACvtfcHk0lhLbkGTXa69SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKjsLk%253D&md5=1543943847e0f14e61addc1d38ce3100</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.05.185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.05.185%26sid%3Dliteratum%253Aachs%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26aulast%3DGalbraith%26aufirst%3DS.%2BM.%26aulast%3DAnderson%26aufirst%3DH.%26aulast%3DStratford%26aufirst%3DM.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DSena%26aufirst%3DL.%26aulast%3DGumbrell%26aufirst%3DL.%26aulast%3DPrice%26aufirst%3DP.%2BM.%26atitle%3DPhase%2520I%2520clinical%2520trial%2520of%2520weekly%2520combretastatin%2520A4%2520phosphate%253A%2520clinical%2520and%2520pharmacokinetic%2520results%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D2815%26epage%3D2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Stevenson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haller, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giantonio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span> </span><span class="NLM_article-title">Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4428</span><span class="NLM_x">–</span> <span class="NLM_lpage">4438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1200%2FJCO.2003.12.986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=14645433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVajsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4428-4438&author=J.+P.+Stevensonauthor=M.+Rosenauthor=W.+J.+Sunauthor=M.+Gallagherauthor=D.+G.+Hallerauthor=D.+Vaughnauthor=B.+Giantonioauthor=R.+Zimmerauthor=W.+P.+Petrosauthor=M.+Stratfordauthor=D.+Chaplinauthor=S.+L.+Youngauthor=M.+Schnallauthor=P.+J.+O%E2%80%99Dwyer&title=Phase+I+trial+of+the+antivascular+agent+combretastatin+A4+phosphate+on+a+5-day+schedule+to+patients+with+cancer%3A+magnetic+resonance+imaging+evidence+for+altered+tumor+blood+flow"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow</span></div><div class="casAuthors">Stevenson, James P.; Rosen, Mark; Sun, Weijing; Gallagher, Maryann; Haller, Daniel G.; Vaughn, David; Giantonio, Bruce; Zimmer, Ross; Petros, William P.; Stratford, Michael; Chaplin, David; Young, Scott L.; Schnall, Mitchell; O'Dwyer, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4428-4438</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Combretastatin A4 (CA4) phosphate (CA4P) inhibits microtubule polymn. and is toxic to proliferating endothelial cells in vitro.  It causes reversible vascular shutdown in established tumors in vivo, consistent with an antivascular mechanism of action.  The present study investigated escalating doses of CA4P administered i.v. to patients with advanced cancer.  Patients and Methods: Patients with solid malignancies and good performance status received CA4P as a 10-min infusion daily for 5 days repeated every 3 wk.  Pharmacokinetic sampling was performed during cycle 1.  Patients receiving ≥ 52 mg/m2/d had serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies to measure changes in tumor perfusion with CA4P treatment.  Results: Thirty-seven patients received 133 treatment cycles.  CA4P dose levels ranged from 6 mg/m2 to 75 mg/m2 daily.  Severe pain at sites of known tumor was dose limiting at 75 mg/m2.  Dose-limiting cardiopulmonary toxicity (syncope and dyspnea or hypoxia) was noted as well in two patients treated at 75 mg/m2.  Other toxicities included hypotension, ataxia, dyspnea, nausea or vomiting, headache, and transient sensory neuropathy.  Plasma CA4P and CA4 area under the concn.-time curve and maximal concn. values increased linearly with dose.  Tumor perfusion, as measured by the first-order rate const. of gadolinium plasma to tissue transfer during DCE-MRI studies, was found to decrease in eight of 10 patients.  Relationships were also demonstrated between perfusion changes and pharmacokinetic indexes.  A partial response was obsd. in a patient with metastatic soft tissue sarcoma, and 14 patients exhibited disease stability for a min. of two cycles.  Conclusion: Doses of CA4P on a daily times five schedule of 52 to 65 mg/m2 were reasonably well-tolerated.  The 52 mg/m2 dose is recommended for further study based on cumulative phase 1 experience with CA4P.  Antitumor efficacy was obsd., and the use of DCE-MRI provided a valuable noninvasive measure of the vascular effects of CA4P treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC3zNAd2c3FrVg90H21EOLACvtfcHk0lhLbkGTXa69SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVajsrk%253D&md5=c5498364f4125668879a02622fa52c29</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.12.986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.12.986%26sid%3Dliteratum%253Aachs%26aulast%3DStevenson%26aufirst%3DJ.%2BP.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DW.%2BJ.%26aulast%3DGallagher%26aufirst%3DM.%26aulast%3DHaller%26aufirst%3DD.%2BG.%26aulast%3DVaughn%26aufirst%3DD.%26aulast%3DGiantonio%26aufirst%3DB.%26aulast%3DZimmer%26aufirst%3DR.%26aulast%3DPetros%26aufirst%3DW.%2BP.%26aulast%3DStratford%26aufirst%3DM.%26aulast%3DChaplin%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DS.%2BL.%26aulast%3DSchnall%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520antivascular%2520agent%2520combretastatin%2520A4%2520phosphate%2520on%2520a%25205-day%2520schedule%2520to%2520patients%2520with%2520cancer%253A%2520magnetic%2520resonance%2520imaging%2520evidence%2520for%2520altered%2520tumor%2520blood%2520flow%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4428%26epage%3D4438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Beerepoot, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radema, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span> </span><span class="NLM_article-title">Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1491</span><span class="NLM_x">–</span> <span class="NLM_lpage">1498</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1200%2FJCO.2005.02.7458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=16574998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFyksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=1491-1498&author=L.+V.+Beerepootauthor=S.+A.+Rademaauthor=E.+O.+Witteveenauthor=T.+Thomasauthor=C.+Wheelerauthor=S.+Kempinauthor=E.+E.+Voest&title=Phase+I+clinical+evaluation+of+weekly+administration+of+the+novel+vascular-targeting+agent%2C+ZD6126%2C+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors</span></div><div class="casAuthors">Beerepoot, Laurens V.; Radema, Sandra A.; Witteveen, Els O.; Thomas, Tawnie; Wheeler, Catherine; Kempin, Sanford; Voest, Emile E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1491-1498</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: ZD6126 is a novel vascular-targeting agent that induces selective effects on the morphol. of endothelial cells by disrupting the tubulin cytoskeleton.  This leads to cell detachment and tumor vessel congestion, resulting in extensive central necrosis in a range of tumor xenograft models.  Results from a phase I dose-escalation study of ZD6126 are reported.  Patients and Methods: Thirty-two patients with advanced cancer received weekly ZD6126 infusion (5 to 28 mg/m2).  Assessments for safety and pharmacokinetics were performed.  Circulating endothelial cells (CECs) were quantified as a pharmacodynamic marker of vascular damage.  Results: Maximum concns. of the active species were obsd. 5 to 25 min from the start of infusion, and decayed in a biexponential manner with a half-life of 1 to 3 h.  Maximum serum concn. and area under the time-concn. curve increased with dose in a linear fashion across the dose range of 5 to 28 mg/m2.  One patient treated at 10 mg/m2 with a history of ischemic heart disease experienced acute myocardial infarction 2 wk after drug discontinuation.  Four others had asymptomatic creatine phosphokinase-muscle-brain elevation.  Maximum-tolerated dose (MTD) was reached at 20 mg/m2/wk.  Dose-limiting toxicities at 28 mg/m2 were hypoxia caused by pulmonary embolism and an asymptomatic decrease in left ventricular ejection fraction.  No objective antitumor responses were obsd.  CEC levels increased in the hours after infusion, indicating potential effect of the compd. on the vasculature.  Conclusion: ZD6126 administered as a weekly infusion was clin. well tolerated.  The MTD was reached at 20 mg/m2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN6AH51OrSh7Vg90H21EOLACvtfcHk0lgmTnHuyhY8CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFyksbg%253D&md5=1e9c22f9719fc1717eb3ffb51f1ee066</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.02.7458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.02.7458%26sid%3Dliteratum%253Aachs%26aulast%3DBeerepoot%26aufirst%3DL.%2BV.%26aulast%3DRadema%26aufirst%3DS.%2BA.%26aulast%3DWitteveen%26aufirst%3DE.%2BO.%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DWheeler%26aufirst%3DC.%26aulast%3DKempin%26aufirst%3DS.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26atitle%3DPhase%2520I%2520clinical%2520evaluation%2520of%2520weekly%2520administration%2520of%2520the%2520novel%2520vascular-targeting%2520agent%252C%2520ZD6126%252C%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D1491%26epage%3D1498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barge, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DelProposto, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLuca, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evelhoch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, C.</span><span> </span><span class="NLM_article-title">Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=159-167&author=P.+M.+LoRussoauthor=S.+M.+Gadgeelauthor=A.+Wozniakauthor=A.+J.+Bargeauthor=H.+K.+Jonesauthor=Z.+S.+DelPropostoauthor=P.+A.+DeLucaauthor=J.+L.+Evelhochauthor=S.+A.+Boernerauthor=C.+Wheeler&title=Phase+I+clinical+evaluation+of+ZD6126%2C+a+novel+vascular-targeting+agent%2C+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DBarge%26aufirst%3DA.%2BJ.%26aulast%3DJones%26aufirst%3DH.%2BK.%26aulast%3DDelProposto%26aufirst%3DZ.%2BS.%26aulast%3DDeLuca%26aufirst%3DP.%2BA.%26aulast%3DEvelhoch%26aufirst%3DJ.%2BL.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DWheeler%26aufirst%3DC.%26atitle%3DPhase%2520I%2520clinical%2520evaluation%2520of%2520ZD6126%252C%2520a%2520novel%2520vascular-targeting%2520agent%252C%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D159%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Delmonte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sessa, C.</span><span> </span><span class="NLM_article-title">AVE8062: a new combretastatin derivative vascular disrupting agent</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1541</span><span class="NLM_x">–</span> <span class="NLM_lpage">1548</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1541-1548&author=A.+Delmonteauthor=C.+Sessa&title=AVE8062%3A+a+new+combretastatin+derivative+vascular+disrupting+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DSessa%26aufirst%3DC.%26atitle%3DAVE8062%253A%2520a%2520new%2520combretastatin%2520derivative%2520vascular%2520disrupting%2520agent%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1541%26epage%3D1548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Salmon, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemann, D. W.</span><span> </span><span class="NLM_article-title">Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4090</span><span class="NLM_x">–</span> <span class="NLM_lpage">4094</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1078-0432.CCR-06-0163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=16818709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVaksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4090-4094&author=H.+W.+Salmonauthor=D.+W.+Siemann&title=Effect+of+the+second-generation+vascular+disrupting+agent+OXi4503+on+tumor+vascularity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity</span></div><div class="casAuthors">Salmon, Howard W.; Siemann, Dietmar W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4090-4094</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: As first-generation small-mol. vascular disrupting agents (VDA) have begun to enter clin. trials, second-generation agents are under active development.  One such agent is the combretastatin A4 disodium phosphate (CA4P) analog OXi4503 (CA1P).  Exptl. Design: C3H/HeJ mice bearing KHT sarcomas were treated with CA4P and OXi4503 and the effect on tumor vasculature was detd. by evaluating the extent of vascular shutdown (Hoechst-33342 vessel staining) and tumor perfusion inhibition (dynamic contrast-enhanced magnetic resonance imaging).  Dynamic contrast-enhanced magnetic resonance imaging and tumor necrosis end points also were used to examine the pathophysiol. tumor effects following repeated exposures to these agents.  Results: Single doses of either agent (CA4P, 100 mg/kg; OXi4503, 25 mg/kg) resulted in an 80% to 90% redn. in tumor perfusion 4 h after treatment.  Whereas recovery in tumor perfusion was obsd. 48 h posttreatment, this recovery was significantly slower in mice treated with OXi4503.  Tumors re-treated with either VDA 72 h after the first drug exposure showed a similar redn. and recovery in tumor perfusion.  Histol. evidence showed the presence of a smaller viable rim after exposure to OXi4503 than that obsd. after CA4P treatment.  Furthermore, the extent of recovery of tumor necrosis 72 h after drug treatment was less for OXi4053.  Conclusions: The present studies show that the second-generation VDA OXi4503 possesses significant antivascular effects in solid tumors.  Importantly, the vasculature of tumors of mice that had received an initial dose this agent was as responsive to a subsequent treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgCf_4-SNSdrVg90H21EOLACvtfcHk0lgmTnHuyhY8CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVaksrY%253D&md5=fe8670c2b50177c5e8510454fe1bb34c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0163%26sid%3Dliteratum%253Aachs%26aulast%3DSalmon%26aufirst%3DH.%2BW.%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26atitle%3DEffect%2520of%2520the%2520second-generation%2520vascular%2520disrupting%2520agent%2520OXi4503%2520on%2520tumor%2520vascularity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D4090%26epage%3D4094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Patterson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1078-0432.CCR-11-2414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=22235096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1415-1425&author=D.+M.+Pattersonauthor=M.+Zweifelauthor=M.+R.+Middletonauthor=P.+M.+Priceauthor=L.+K.+Folkesauthor=M.+R.+L.+Stratfordauthor=P.+Rossauthor=S.+Halfordauthor=J.+Petersauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=A.+R.+Padhaniauthor=G.+J.+S.+Rustin&title=Phase+I+clinical+and+pharmacokinetic+evaluation+of+the+vascular-disrupting+agent+OXi4503+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Patterson, Dan M.; Zweifel, Martin; Middleton, Mark R.; Price, Patricia M.; Folkes, Lisa K.; Stratford, Michael R. L.; Ross, Phil; Halford, Sarah; Peters, Jane; Balkissoon, Jai; Chaplin, Dai J.; Padhani, Anwar R.; Rustin, Gordon J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1415-1425</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Preclin. studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clin. evaluated vascular-disrupting agents.  Exptl. Design: Escalating doses of OXi4503 were given i.v. over 10 min on days 1, 8, and 15 every 28 days to patients with advanced solid tumors.  RESULTS: Doses were escalated in single-patient cohorts from 0.06 to 1.92 mg/m2, then expanded cohorts to 15.4 mg/m2 in 43 patients.  Common adverse drug reactions were hypertension, tumor pain, anemia, lymphopenia, and easily controllable nausea/vomiting and fatigue.  Five patients experienced different drug-related dose-limiting toxicities, atrial fibrillation, increased troponin, blurred vision, diplopia, and tumor lysis.  Prophylactic amlodipine failed to prevent adverse events.  Pharmacokinetics showed dose-dependent linear increases in peak plasma concns. and area under the curve value of OXi4503.  One partial response was seen in a heavily pretreated patient with ovarian cancer.  Dynamic contrast-enhanced MRI confirmed a dose effect and showed significant antivascular effects in 10 of 13 patients treated at doses of 11 mg/m2 or higher.  CONCLUSIONS: The max. tolerated dose was 8.5 mg/m2 but escalation to 14 mg/m2 was possible with only temporary reversible cerebrovascular toxicity by excluding hypertensive patients.  As a tumor response was seen at 14 mg/m2 and max. tumor perfusion redns. were seen at doses of 11 mg/m2 or higher, the recommended phase II dose is from 11 to 14 mg/m2.  Clin Cancer Res; 18(5); 1415-25.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgz59a0dQud7Vg90H21EOLACvtfcHk0likFnR5DV4Kkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wlurc%253D&md5=9414d480dc5eef26ec066054dc96b124</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2414%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BM.%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DPrice%26aufirst%3DP.%2BM.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DRoss%26aufirst%3DP.%26aulast%3DHalford%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DJ.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520I%2520clinical%2520and%2520pharmacokinetic%2520evaluation%2520of%2520the%2520vascular-disrupting%2520agent%2520OXi4503%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1415%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Lippert, J. W.</span><span> </span><span class="NLM_article-title">Vascular disrupting agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=605-615&author=J.+W.+Lippert&title=Vascular+disrupting+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLippert%26aufirst%3DJ.%2BW.%26atitle%3DVascular%2520disrupting%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D605%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Cai, S. X.</span><span> </span><span class="NLM_article-title">Small molecule vascular disrupting agents: potential new drugs for cancer treatment</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=79-101&author=S.+X.+Cai&title=Small+molecule+vascular+disrupting+agents%3A+potential+new+drugs+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DS.%2BX.%26atitle%3DSmall%2520molecule%2520vascular%2520disrupting%2520agents%253A%2520potential%2520new%2520drugs%2520for%2520cancer%2520treatment%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D79%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Griggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesketh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindle, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, E. D.</span><span> </span><span class="NLM_article-title">Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">835</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1054%2Fbjoc.2000.1653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=11259100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVGrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2001&pages=832-835&author=J.+Griggsauthor=R.+Heskethauthor=G.+A.+Smithauthor=K.+M.+Brindleauthor=J.+C.+Metcalfeauthor=G.+A.+Thomasauthor=E.+D.+Williams&title=Combretastatin-A4+disrupts+neovascular+development+in+non-neoplastic+tissue"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue</span></div><div class="casAuthors">Griggs, J.; Hesketh, R.; Smith, G. A.; Brindle, K. M.; Metcalfe, J. C.; Thomas, G. A.; Williams, E. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">832-835</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Combretastatin-A4 phosphate (cis-CA-4) is a tubulin-binding agent currently undergoing clin. trials as an anti-tumor drug.  We have investigated whether CA-4 functions as a tumor-specific anti-vascular agent using the hyperplastic thyroid as a novel in vivo model of neovascularization.  CA-4 elicited pathol. changes in normal tissue, manifested as the induction of multiple, discrete intravascular thrombi.  These vascular-damaging effects indicate that CA-4P does not function as a tumor-specific agent but targets neovasculature irresp. of the primary angiogenic stimulus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGyDxpgfxzrVg90H21EOLACvtfcHk0likFnR5DV4Kkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVGrt7g%253D&md5=ce21a9cfa07aea8e9c41f9ca7a917c4f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2000.1653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2000.1653%26sid%3Dliteratum%253Aachs%26aulast%3DGriggs%26aufirst%3DJ.%26aulast%3DHesketh%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DG.%2BA.%26aulast%3DBrindle%26aufirst%3DK.%2BM.%26aulast%3DMetcalfe%26aufirst%3DJ.%2BC.%26aulast%3DThomas%26aufirst%3DG.%2BA.%26aulast%3DWilliams%26aufirst%3DE.%2BD.%26atitle%3DCombretastatin-A4%2520disrupts%2520neovascular%2520development%2520in%2520non-neoplastic%2520tissue%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D84%26spage%3D832%26epage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hasani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighl, N.</span><span> </span><span class="NLM_article-title">Classification and toxicities of vascular disrupting agents</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.3816%2FCLC.2011.n.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=21273175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlektbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=18-25&author=A.+Hasaniauthor=N.+Leighl&title=Classification+and+toxicities+of+vascular+disrupting+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Classification and toxicities of vascular disrupting agents</span></div><div class="casAuthors">Hasani, Arman; Leighl, Natasha</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-25</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">CIG Media Group, LP</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are an exciting new group of targeted therapies under active clin. research in many solid tumors, in particular, lung cancer.  Small-mol. VDAs are the focus of current clin. research, and consist of the flavonoids and the tubulin-binding agents.  Toxicities of single-agent VDAs are characterized by acute, transient, and generally noncumulative side effects including headaches, nausea and vomiting, tumor pain, hypertension, and tachycardia.  Flavonoid agents can also cause infusion site pain, visual disturbances, electrocardiac abnormalities, and symptoms consistent with an acute release of serotonin.  Tubulin-binding agents can result in cardiac ischemia, abdominal pain, neuromotor abnormalities and cerebellar ataxia, and acute hemodynamic changes.  Clin. trials investigating VDAs in combination with traditional chemotherapy have also shown the potential for significant pharmacol. and adverse toxicity interactions.  Further research will need to focus on pharmacokinetic and pharmacodynamic parameters to optimize dosing schedules, det. effective combinations with chemotherapy, and minimize toxicities assocd. with VDAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFp5v18P6467Vg90H21EOLACvtfcHk0likFnR5DV4Kkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlektbo%253D&md5=22784c563952161686eb2b4f7294ee68</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3816%2FCLC.2011.n.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLC.2011.n.002%26sid%3Dliteratum%253Aachs%26aulast%3DHasani%26aufirst%3DA.%26aulast%3DLeighl%26aufirst%3DN.%26atitle%3DClassification%2520and%2520toxicities%2520of%2520vascular%2520disrupting%2520agents%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2011%26volume%3D12%26spage%3D18%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeves, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1093%2Fannonc%2Fmdq708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=21273348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2036-2041&author=M.+Zweifelauthor=G.+C.+Jaysonauthor=N.+S.+Reedauthor=R.+Osborneauthor=B.+Hassanauthor=J.+Ledermannauthor=G.+Shreevesauthor=L.+Poupardauthor=S.+P.+Luauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=G.+J.+S.+Rustin&title=Phase+II+trial+of+combretastatin+A4+phosphate%2C+carboplatin%2C+and+paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span></div><div class="casAuthors">Zweifel M; Jayson G C; Reed N S; Osborne R; Hassan B; Ledermann J; Shreeves G; Poupard L; Lu S-P; Balkissoon J; Chaplin D J; Rustin G J S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2036-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.  PATIENTS AND METHODS:  Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks.  RESULTS:  Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited.  Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia.  Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine.  The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%.  CONCLUSIONS:  The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P.  A planned randomised trial will test this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKPQKWSYY7Sqe0F5ixvZgXfW6udTcc2ebxk9MI2I9U6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D&md5=6b960ad4dcccdbbc67ffa9398e85d2be</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq708%26sid%3Dliteratum%253Aachs%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DReed%26aufirst%3DN.%2BS.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DHassan%26aufirst%3DB.%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DShreeves%26aufirst%3DG.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%2BP.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520II%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%252C%2520carboplatin%252C%2520and%2520paclitaxel%2520in%2520patients%2520with%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2036%26epage%3D2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Rustin, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeves, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span> </span><span class="NLM_article-title">A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1038%2Fsj.bjc.6605650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=20389300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1OnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=1355-1360&author=G.+J.+Rustinauthor=G.+Shreevesauthor=P.+D.+Nathanauthor=A.+Gayaauthor=T.+S.+Ganesanauthor=D.+Wangauthor=J.+Boxallauthor=L.+Poupardauthor=D.+J.+Chaplinauthor=M.+R.+L.+Stratfordauthor=J.+Balkissoonauthor=M.+Zweifel&title=A+phase+Ib+trial+of+CA4P+%28combretastatin+A-4+phosphate%29%2C+carboplatin%2C+and+paclitaxel+in+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer</span></div><div class="casAuthors">Rustin, G. J.; Shreeves, G.; Nathan, P. D.; Gaya, A.; Ganesan, T. S.; Wang, D.; Boxall, J.; Poupard, L.; Chaplin, D. J.; Stratford, M. R. L.; Balkissoon, J.; Zweifel, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1355-1360</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The vascular disrupting agent combretastatin A4 phosphate (CA4P) causes major regression of animal tumors when given as combination therapy.  Methods: Patients with advanced cancer refractory to std. therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin.  Results: Combretastatin A4 phosphate was escalated from 36 to 54 mg m-2 with the carboplatin area under the concn. curve (AUC) 4-5, from 27 to 54 mg m-2 with paclitaxel 135-175 mg m-2, and from 54 to 72 mg m-2 with carboplatin AUC 5 and paclitaxel 175 mg m-2.  Grade 3 or 4 neutropenia was seen in 17%, and thrombocytopenia only in 4% of 46 patients.  Grade 1-3 hypertension (26% of patients) and grade 1-3 tumor pain (65% of patients) were the most typical non-haematol. toxicities.  Dose-limiting toxicity of grade 3 hypertension or grade 3 ataxia was seen in two patients at 72 mg m-2.  Responses were seen in 10 of 46 (22%) patients with ovarian, esophageal, small-cell lung cancer, and melanoma.  Conclusion: The combination of CA4P with carboplatin and paclitaxel was well tolerated in the majority of patients with adequate premedication and had antitumor activity in patients who were heavily pretreated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxlNCzTLZmbVg90H21EOLACvtfcHk0lg8GRwf38wNCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1OnurY%253D&md5=00921730bb1bce41c4f3cac0c7501402</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605650%26sid%3Dliteratum%253Aachs%26aulast%3DRustin%26aufirst%3DG.%2BJ.%26aulast%3DShreeves%26aufirst%3DG.%26aulast%3DNathan%26aufirst%3DP.%2BD.%26aulast%3DGaya%26aufirst%3DA.%26aulast%3DGanesan%26aufirst%3DT.%2BS.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBoxall%26aufirst%3DJ.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DZweifel%26aufirst%3DM.%26atitle%3DA%2520phase%2520Ib%2520trial%2520of%2520CA4P%2520%2528combretastatin%2520A-4%2520phosphate%2529%252C%2520carboplatin%252C%2520and%2520paclitaxel%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26spage%3D1355%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Ciric, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sersa, G.</span><span> </span><span class="NLM_article-title">Radiotherapy in combination with vascular-targeted therapies</span> <span class="citation_source-journal">Radiol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2478%2Fv10019-010-0025-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=22933894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1GgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=67-78&author=E.+Ciricauthor=G.+Sersa&title=Radiotherapy+in+combination+with+vascular-targeted+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy in combination with vascular-targeted therapies</span></div><div class="casAuthors">Ciric, Eva; Sersa, Gregor</div><div class="citationInfo"><span class="NLM_cas:title">Radiology and Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">67-78</span>CODEN:
                <span class="NLM_cas:coden">RONCEM</span>;
        ISSN:<span class="NLM_cas:issn">1318-2099</span>.
    
            (<span class="NLM_cas:orgname">Radiology and Oncology</span>)
        </div><div class="casAbstract">A review.  Background. Given the crit. role of tumor vasculature in tumor development, considerable efforts have been spent on developing therapeutic strategies targeting the tumor vascular network.  A variety of agents have been developed, with two general approaches being pursued.  Antiangiogenic agents (AAs) aim to interfere with the process of angiogenesis, preventing new tumor blood vessel formation.  Vascular-disrupting agents (VDAs) target existing tumor vessels causing tumor ischemia and necrosis.  Despite their great therapeutic potential, it has become clear that their greatest clin. utility may lie in combination with conventional anticancer therapies.  Radiotherapy is a widely used treatment modality for cancer with its distinct therapeutic challenges.  Thus, combining the two approaches seems reasonable.  Conclusions. Strong biol. rationale exist for combining vascular-targeted therapies with radiation.  AAs and VDAs were shown to alter the tumor microenvironment in such a way as to enhance responses to radiation.  The results of preclin. and early clin. studies have confirmed the therapeutic potential of this new treatment strategy in the clin. setting.  However, concerns about increased normal tissue toxicity, have been raised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRfiUGL_14qbVg90H21EOLACvtfcHk0lg8GRwf38wNCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1GgsLo%253D&md5=7f880fc4134cae459e1f8b108c1efbc2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2478%2Fv10019-010-0025-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2478%252Fv10019-010-0025-9%26sid%3Dliteratum%253Aachs%26aulast%3DCiric%26aufirst%3DE.%26aulast%3DSersa%26aufirst%3DG.%26atitle%3DRadiotherapy%2520in%2520combination%2520with%2520vascular-targeted%2520therapies%26jtitle%3DRadiol.%2520Oncol.%26date%3D2010%26volume%3D44%26spage%3D67%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaya, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dancey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Othman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellsted, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, P.-s.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedley, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Violet, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malaroda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green,, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buscombe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begent, R. H.</span><span> </span><span class="NLM_article-title">A phase I trial of radioimmunotherapy with (131)I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4484</span><span class="NLM_x">–</span> <span class="NLM_lpage">4492</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1078-0432.CCR-09-0035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=19549771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFajt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4484-4492&author=T.+Meyerauthor=A.+M.+Gayaauthor=G.+Danceyauthor=M.+R.+L.+Stratfordauthor=S.+Othmanauthor=S.+K.+Sharmaauthor=D.+Wellstedauthor=N.+J.+Taylorauthor=J.+J.+Stirlingauthor=L.+Poupardauthor=L.+K.+Folkesauthor=P.-s.+Chanauthor=R.+B.+Pedleyauthor=K.+A.+Chesterauthor=K.+Owenauthor=J.+A.+Violetauthor=A.+Malarodaauthor=A.+J.+Green%2Cauthor=J.+Buscombeauthor=A.+R.+Padhaniauthor=G.+J.+Rustinauthor=R.+H.+Begent&title=A+phase+I+trial+of+radioimmunotherapy+with+%28131%29I-A5B7+anti-CEA+antibody+in+combination+with+combretastatin-A4-phosphate+in+advanced+gastrointestinal+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas</span></div><div class="casAuthors">Meyer, Tim; Gaya, Andrew M.; Dancey, Gairin; Stratford, Michael R. L.; Othman, Shokri; Sharma, Surinder K.; Wellsted, David; Taylor, N. Jane; Stirling, J. James; Poupard, Linda; Folkes, Lisa K.; Chan, Pei-san; Pedley, R. Barbara; Chester, Kerry A.; Owen, Karen; Violet, John A.; Malaroda, Alessandra; Green, Alan J.; Buscombe, John; Padhani, Anwar R.; Rustin, Gordon J.; Begent, Richard H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4484-4492</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In preclin. models, radioimmunotherapy with 131I-A5B7 anti-carcinoembryonic antigen (CEA) antibody (131I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone.  We conducted a phase I trial detg. the dose-limiting toxicity (DLT), max. tolerated dose, efficacy, and mechanism of this combination in patients with gastrointestinal adenocarcinomas.  Exptl. Design: Patients had CEA of 10 to 1,000 μg/L, QTc ≤450 ms, no cardiac arrhythmia/ischemia, and adequate hematol./biochem.  Tumor was suitable for blood flow anal. by dynamic contrast enhanced-magnetic resonance imaging (MRI).  The starting dose was 1,800 MBq/m2 of 131I-A5B7 on day 1 and 45 mg/m2 CA4P given 48 and 72 h post-131I-A5B7, then weekly for up to seven weeks.  RESULTS: Twelve patients were treated, with mean age of 63 years (range, 32-77).  Two of six patients at the first dose level had DLTs (grade 4 neutropenia).  The dose was reduced to 1,600 MBq/m2, and CA4P escalated to 54 mg/m2.  Again, two of six patients had DLTs (neutropenia).  Of ten assessable patients, three had stable disease and seven had progressive disease.  Single-photon emission computed tomog. confirmed tumor antibody uptake in all 10 patients.  DCE-MRI confirmed falls in kinetic parameters (Ktrans/IAUGC60) in 9 of 12 patients.  The change of both pharmacokinetic parameters reached a level expected to produce efficacy in one patient who had a minor response on computed tomog. and a reduced serum tumor marker level.  CONCLUSIONS: This is believed to be the first trial reporting the combination of radioimmunotherapy and vascular disruptive agent; each component was shown to function, and myelosuppression was dose-limiting.  Optimal dose and timing of CA4P, and moderate improvements in the performance of radioimmunotherapy seem necessary for efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9depZ77fXn7Vg90H21EOLACvtfcHk0lhKxuMh9mctcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFajt7o%253D&md5=4b579ec5d7a3ec78afe3c41441409d5e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0035%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DGaya%26aufirst%3DA.%2BM.%26aulast%3DDancey%26aufirst%3DG.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DOthman%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DWellsted%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DN.%2BJ.%26aulast%3DStirling%26aufirst%3DJ.%2BJ.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DChan%26aufirst%3DP.-s.%26aulast%3DPedley%26aufirst%3DR.%2BB.%26aulast%3DChester%26aufirst%3DK.%2BA.%26aulast%3DOwen%26aufirst%3DK.%26aulast%3DViolet%26aufirst%3DJ.%2BA.%26aulast%3DMalaroda%26aufirst%3DA.%26aulast%3DGreen%252C%26aufirst%3DA.%2BJ.%26aulast%3DBuscombe%26aufirst%3DJ.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%26aulast%3DBegent%26aufirst%3DR.%2BH.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520radioimmunotherapy%2520with%2520%2528131%2529I-A5B7%2520anti-CEA%2520antibody%2520in%2520combination%2520with%2520combretastatin-A4-phosphate%2520in%2520advanced%2520gastrointestinal%2520carcinomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4484%26epage%3D4492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Atkinson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falconer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siller, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, J. H.</span><span> </span><span class="NLM_article-title">Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">6902</span><span class="NLM_x">–</span> <span class="NLM_lpage">6912</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F0008-5472.CAN-10-1440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=20663911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2rsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=6902-6912&author=J.+M.+Atkinsonauthor=R.+A.+Falconerauthor=D.+R.+Edwardsauthor=C.+J.+Penningtonauthor=C.+S.+Sillerauthor=S.+D.+Shnyderauthor=M.+C.+Bibbyauthor=L.+H.+Pattersonauthor=P.+M.+Loadmanauthor=J.+H.+Gill&title=Development+of+a+novel+tumor-targeted+vascular+disrupting+agent+activated+by+membrane-type+matrix+metalloproteinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases</span></div><div class="casAuthors">Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, Dylan R.; Pennington, Caroline J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6902-6912</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage.  Several VDAs have progressed into early clin. trials, but their therapeutic value seems to be compromised by systemic toxicity.  In this report, we describe the design and characterization of a novel VDA, ICT2588, that is nontoxic until activated specifically in the tumor by membrane-type 1 matrix metalloproteinase (MT1-MMP).  HT1080 cancer cells expressing MT1-MMP were selectively chemosensitive to ICT2588, whereas MCF7 cells that did not express MT1-MMP were nonresponsive.  Preferential hydrolysis of ICT2588 to its active metabolite (ICT2552) was obsd. in tumor homogenates of HT1080 relative to MCF7 homogenates, mouse plasma, and liver homogenate.  ICT2588 activation was inhibited by the MMP inhibitor ilomastat.  In HT1080 tumor-bearing mice, ICT2588 administration resulted in the formation of the active metabolite, diminution of tumor vasculature, and hemorrhagic necrosis of the tumor.  The antitumor activity of ICT2588 was superior to its active metabolite, exhibiting reduced toxicity, improved therapeutic index, enhanced pharmacodynamic effect, and greater efficacy.  Coadministration of ICT2588 with doxorubicin resulted in a significant antitumor response (22.6 d growth delay), which was superior to the administration of ICT2588 or doxorubicin as a single agent, including complete tumor regressions.  Our findings support the clin. development of ICT2588, which achieves selective VDA targeting based on MT-MMP activation in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYqbra5OjQWbVg90H21EOLACvtfcHk0lhKxuMh9mctcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2rsb7I&md5=e41bcd4a06c42051f1a406a58425b24e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1440%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DJ.%2BM.%26aulast%3DFalconer%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DD.%2BR.%26aulast%3DPennington%26aufirst%3DC.%2BJ.%26aulast%3DSiller%26aufirst%3DC.%2BS.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DBibby%26aufirst%3DM.%2BC.%26aulast%3DPatterson%26aufirst%3DL.%2BH.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DGill%26aufirst%3DJ.%2BH.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520tumor-targeted%2520vascular%2520disrupting%2520agent%2520activated%2520by%2520membrane-type%2520matrix%2520metalloproteinases%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D6902%26epage%3D6912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rischin, D.</span><span> </span><span class="NLM_article-title">Phase I, pharmacokinetic, and pharmacodynamic evaluation of BNC105P, a novel anticancer agent that is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=27&author=J.+Desaiauthor=S.+Wongauthor=G.+Chongauthor=D.+Bibbyauthor=A.+Leskeauthor=G.+Kremmidiotisauthor=M.+Rosenauthor=D.+Rischin&title=Phase+I%2C+pharmacokinetic%2C+and+pharmacodynamic+evaluation+of+BNC105P%2C+a+novel+anticancer+agent+that+is+both+a+vascular+disrupting+agent+%28VDA%29+and+an+inhibitor+of+cancer+cell+proliferation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DChong%26aufirst%3DG.%26aulast%3DBibby%26aufirst%3DD.%26aulast%3DLeske%26aufirst%3DA.%26aulast%3DKremmidiotis%26aufirst%3DG.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DRischin%26aufirst%3DD.%26atitle%3DPhase%2520I%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamic%2520evaluation%2520of%2520BNC105P%252C%2520a%2520novel%2520anticancer%2520agent%2520that%2520is%2520both%2520a%2520vascular%2520disrupting%2520agent%2520%2528VDA%2529%2520and%2520an%2520inhibitor%2520of%2520cancer%2520cell%2520proliferation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26spage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavranos, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, B.</span><span> </span><span class="NLM_article-title">BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">–</span> <span class="NLM_lpage">1573</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1535-7163.MCT-09-0815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=20515948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1562-1573&author=G.+Kremmidiotisauthor=A.+F.+Leskeauthor=T.+C.+Lavranosauthor=D.+Beaumontauthor=J.+Gasicauthor=A.+Hallauthor=M.+O%E2%80%99Callaghanauthor=C.+A.+Matthewsauthor=B.+Flynn&title=BNC105%3A+a+novel+tubulin+polymerization+inhibitor+that+selectively+disrupts+tumor+vasculature+and+displays+single-agent+antitumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy</span></div><div class="casAuthors">Kremmidiotis, Gabriel; Leske, Annabell F.; Lavranos, Tina C.; Beaumont, Donna; Gasic, Jelena; Hall, Allison; O'Callaghan, Michael; Matthews, Clayton A.; Flynn, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1562-1573</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis.  Tumor vascular disruption is a therapeutic strategy of great potential; however, VDAs currently under development display a narrow therapeutic margin, with cardiovascular toxicity posing a dose-limiting obstacle.  Discovery of new VDAs, which display a wider therapeutic margin, may allow attainment of improved clin. outcomes.  To identify such compds., we used an in vitro selectivity screening approach that exploits the fact that tumor endothelial cells are in a const. state of activation and angiogenesis and do not undergo senescence.  Our effort yielded the compd. BNC105.  This compd. acts as a tubulin polymn. inhibitor and displays 80-fold higher potency against endothelial cells that are actively proliferating or are engaged in the formation of in vitro capillaries compared with nonproliferating endothelial cells or endothelium found in stable capillaries.  This selectivity was not obsd. with CA4, a VDA currently under evaluation in phase III clin. trials.  BNC105 is more potent and offers a wider therapeutic window.  CA4 produces 90% vascular disruption at its no obsd. adverse event level (NOAEL), whereas BNC105 causes 95% vascular disruption at 1/8th of its NOAEL.  Tissue distribution anal. of BNC105 in tumor-bearing mice showed that while the drug is cleared from all tissues 24 h after administration, it is still present at high concns. within the solid tumor mass.  Furthermore, BNC105 treatment causes tumor regressions with complete tumor clearance in 20% of treated animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLcKlwS1G0NrVg90H21EOLACvtfcHk0lhKxuMh9mctcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsLk%253D&md5=94a9f916319585f07bd4b8467b1b5a89</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0815%26sid%3Dliteratum%253Aachs%26aulast%3DKremmidiotis%26aufirst%3DG.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DLavranos%26aufirst%3DT.%2BC.%26aulast%3DBeaumont%26aufirst%3DD.%26aulast%3DGasic%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DC.%2BA.%26aulast%3DFlynn%26aufirst%3DB.%26atitle%3DBNC105%253A%2520a%2520novel%2520tubulin%2520polymerization%2520inhibitor%2520that%2520selectively%2520disrupts%2520tumor%2520vasculature%2520and%2520displays%2520single-agent%2520antitumor%2520efficacy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1562%26epage%3D1573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Flynn, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavranos, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostewicz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morizzi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span> </span><span class="NLM_article-title">Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[<i>b</i>]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6014</span><span class="NLM_x">–</span> <span class="NLM_lpage">6027</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200454y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6014-6027&author=B.+L.+Flynnauthor=G.+S.+Gillauthor=D.+W.+Grobelnyauthor=J.+H.+Chaplinauthor=D.+Paulauthor=A.+F.+Leskeauthor=T.+C.+Lavranosauthor=D.+K.+Chalmersauthor=S.+A.+Charmanauthor=E.+Kostewiczauthor=D.+M.+Shacklefordauthor=J.+Morizziauthor=E.+Hamelauthor=M.+K.+Jungauthor=G.+Kremmidiotis&title=Discovery+of+7-hydroxy-6-methoxy-2-methyl-3-%283%2C4%2C5-trimethoxybenzoyl%29benzo%5Bb%5Dfuran+%28BNC105%29%2C+a+tubulin+polymerization+inhibitor+with+potent+antiproliferative+and+tumor+vascular+disrupting+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm200454y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200454y%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DB.%2BL.%26aulast%3DGill%26aufirst%3DG.%2BS.%26aulast%3DGrobelny%26aufirst%3DD.%2BW.%26aulast%3DChaplin%26aufirst%3DJ.%2BH.%26aulast%3DPaul%26aufirst%3DD.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DLavranos%26aufirst%3DT.%2BC.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DKostewicz%26aufirst%3DE.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DJung%26aufirst%3DM.%2BK.%26aulast%3DKremmidiotis%26aufirst%3DG.%26atitle%3DDiscovery%2520of%25207-hydroxy-6-methoxy-2-methyl-3-%25283%252C4%252C5-trimethoxybenzoyl%2529benzo%255Bb%255Dfuran%2520%2528BNC105%2529%252C%2520a%2520tubulin%2520polymerization%2520inhibitor%2520with%2520potent%2520antiproliferative%2520and%2520tumor%2520vascular%2520disrupting%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6014%26epage%3D6027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span> </span><span class="NLM_article-title">Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2</span> <span class="citation_source-journal">Can. J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">2390</span><span class="NLM_x">–</span> <span class="NLM_lpage">2396</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1987&pages=2390-2396&author=G.+R.+Pettitauthor=S.+B.+Singh&title=Isolation%2C+structure%2C+and+synthesis+of+combretastatin+A-2%2C+A-3%2C+and+B-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DIsolation%252C%2520structure%252C%2520and%2520synthesis%2520of%2520combretastatin%2520A-2%252C%2520A-3%252C%2520and%2520B-2%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D1987%26volume%3D65%26spage%3D2390%26epage%3D2396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Cushman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarathnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of analogs of (<i>Z</i>)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethane as potential cytotoxic and antimitotic agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2293</span><span class="NLM_x">–</span> <span class="NLM_lpage">2306</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00090a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2293-2306&author=M.+Cushmanauthor=D.+Nagarathnamauthor=D.+Gopalauthor=H.+M.+Heauthor=C.+M.+Linauthor=E.+Hamel&title=Synthesis+and+evaluation+of+analogs+of+%28Z%29-1-%284-methoxyphenyl%29-2-%283%2C4%2C5-trimethoxyphenyl%29ethane+as+potential+cytotoxic+and+antimitotic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm00090a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00090a021%26sid%3Dliteratum%253Aachs%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DGopal%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DH.%2BM.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520analogs%2520of%2520%2528Z%2529-1-%25284-methoxyphenyl%2529-2-%25283%252C4%252C5-trimethoxyphenyl%2529ethane%2520as%2520potential%2520cytotoxic%2520and%2520antimitotic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2293%26epage%3D2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Gaukroger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadfield, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, A. T.</span><span> </span><span class="NLM_article-title">Structural requirements for the interaction of combretastatins with tubulin: How important is the trimethoxy unit?</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">3033</span><span class="NLM_x">–</span> <span class="NLM_lpage">3037</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=3033-3037&author=K.+Gaukrogerauthor=J.+A.+Hadfieldauthor=N.+J.+Lawrenceauthor=S.+Nolanauthor=A.+T.+McGown&title=Structural+requirements+for+the+interaction+of+combretastatins+with+tubulin%3A+How+important+is+the+trimethoxy+unit%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaukroger%26aufirst%3DK.%26aulast%3DHadfield%26aufirst%3DJ.%2BA.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DNolan%26aufirst%3DS.%26aulast%3DMcGown%26aufirst%3DA.%2BT.%26atitle%3DStructural%2520requirements%2520for%2520the%2520interaction%2520of%2520combretastatins%2520with%2520tubulin%253A%2520How%2520important%2520is%2520the%2520trimethoxy%2520unit%253F%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2003%26volume%3D1%26spage%3D3033%26epage%3D3037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Jordan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadfield, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, A. T.</span><span> </span><span class="NLM_article-title">Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1002%2F%28SICI%291098-1128%28199807%2918%3A4%3C259%3A%3AAID-MED3%3E3.0.CO%3B2-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=9664292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVeisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=259-296&author=A.+Jordanauthor=J.+A.+Hadfieldauthor=N.+J.+Lawrenceauthor=A.+T.+McGown&title=Tubulin+as+a+target+for+anticancer+drugs%3A+agents+which+interact+with+the+mitotic+spindle"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle</span></div><div class="casAuthors">Jordan, Allan; Hadfield, John A.; Lawrence, Nicholas J.; Mcgown, Alan T.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-296</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 193 refs.  Tubulin is the biochem. target for several clin. used anticancer drugs, including paclitaxel and the vinca alkaloids vincristine and vinblastine.  This review describes both the natural and synthetic agents which are known to interact with tubulin.  Syntheses of the more complex agents are referenced and the potential clin. use of the compds. is discussed.  This review describes the biochem. of tubulin, microtubules, and the mitotic spindle.  The agents are discussed in relation to the type of binding site on the protein with which they interact.  These are the colchicine, vinca alkaloid, rhizoxin/maytansine, and tubulin sulfhydryl binding sites.  Also included are the agents which either bind at other sites or unknown sites on tubulin.  The literature is reviewed up to Oct. 1997.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXj350MJMOy7Vg90H21EOLACvtfcHk0lgrNDWF-lfmwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVeisLY%253D&md5=c11865c6792d7989270ba2d7e891e1ed</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28199807%2918%3A4%3C259%3A%3AAID-MED3%3E3.0.CO%3B2-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528199807%252918%253A4%253C259%253A%253AAID-MED3%253E3.0.CO%253B2-U%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DA.%26aulast%3DHadfield%26aufirst%3DJ.%2BA.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DMcGown%26aufirst%3DA.%2BT.%26atitle%3DTubulin%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%253A%2520agents%2520which%2520interact%2520with%2520the%2520mitotic%2520spindle%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1998%26volume%3D18%26spage%3D259%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Lawrence, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadfield, J. A.</span><span> </span><span class="NLM_article-title">Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4</span> <span class="citation_source-journal">J. Fluorine Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1016%2FS0022-1139%2803%2900117-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1yqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2003&pages=101-108&author=N.+J.+Lawrenceauthor=L.+A.+Hepworthauthor=D.+Rennisonauthor=A.+T.+McGownauthor=J.+A.+Hadfield&title=Synthesis+and+anticancer+activity+of+fluorinated+analogues+of+combretastatin+A-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4</span></div><div class="casAuthors">Lawrence, Nicholas J.; Hepworth, Lucy A.; Rennison, David; McGown, Alan T.; Hadfield, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorine Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-108</span>CODEN:
                <span class="NLM_cas:coden">JFLCAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-1139</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The synthesis of a series of fluorinated benzaldehydes and their use in the Wittig synthesis of fluoro-substituted stilbenes is described. 3,5-Difluoro-4-hydroxybenzaldehyde and 3-fluoro-4-methoxybenzaldehyde are prepd. by Duff formylation of 3,5-difluorophenol and 2-fluoroanisole, resp.  2-Methoxy-3,4-difluorobenzaldehyde was obtained by Friedel-Crafts formylation of 2,3-difluoroanisole with α,α-dichloromethyl Me ether.  The aldehydes were used to make a series of fluorinated analogs of the anticancer combretastatins A-1, A-2 and A-4.  The in vitro anticancer properties of the fluoro combretastatins are reported.  The most active fluoro analog 3-deoxy-3-fluoro-combretastatin A-4 (Z-2) retains the potent cell growth inhibitory properties of CA-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUjL6IaBeQ2LVg90H21EOLACvtfcHk0lgrNDWF-lfmwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1yqs7s%253D&md5=7276d416c796d7221358e488d55c0abb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0022-1139%2803%2900117-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-1139%252803%252900117-9%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DHepworth%26aufirst%3DL.%2BA.%26aulast%3DRennison%26aufirst%3DD.%26aulast%3DMcGown%26aufirst%3DA.%2BT.%26aulast%3DHadfield%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520and%2520anticancer%2520activity%2520of%2520fluorinated%2520analogues%2520of%2520combretastatin%2520A-4%26jtitle%3DJ.%2520Fluorine%2520Chem.%26date%3D2003%26volume%3D123%26spage%3D101%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettitt, R. K.</span><span> </span><span class="NLM_article-title">Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (<i>Z</i>)- and (<i>E</i>)-combretastatin A-4</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4087</span><span class="NLM_x">–</span> <span class="NLM_lpage">4099</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0205797" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4087-4099&author=G.+R.+Pettitauthor=M.+R.+Rhodesauthor=D.+L.+Heraldauthor=E.+Hamelauthor=J.+M.+Schmidtauthor=R.+K.+Pettitt&title=Antineoplastic+agents.+445.+Synthesis+and+evaluation+of+structural+modifications+of+%28Z%29-+and+%28E%29-combretastatin+A-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm0205797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0205797%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DRhodes%26aufirst%3DM.%2BR.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DPettitt%26aufirst%3DR.%2BK.%26atitle%3DAntineoplastic%2520agents.%2520445.%2520Synthesis%2520and%2520evaluation%2520of%2520structural%2520modifications%2520of%2520%2528Z%2529-%2520and%2520%2528E%2529-combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4087%26epage%3D4099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Hatanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohsumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, T.</span><span> </span><span class="NLM_article-title">Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3371</span><span class="NLM_x">–</span> <span class="NLM_lpage">3374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3371-3374&author=T.+Hatanakaauthor=K.+Fujitaauthor=K.+Ohsumiauthor=R.+Nakagawaauthor=Y.+Fukudaauthor=Y.+Niheiauthor=Y.+Sugaauthor=Y.+Akiyamaauthor=T.+Tsuji&title=Novel+B-ring+modified+combretastatin+analogues%3A+syntheses+and+antineoplastic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DOhsumi%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DNihei%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DT.%26atitle%3DNovel%2520B-ring%2520modified%2520combretastatin%2520analogues%253A%2520syntheses%2520and%2520antineoplastic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3371%26epage%3D3374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Maya, A. B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, B. d.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelaez Lamamie de Clairac, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caballero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barasoain, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medarde, M.</span><span> </span><span class="NLM_article-title">Design, synthesis and cytotoxic activities of naphthyl analogues of combretastatin A-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2549</span><span class="NLM_x">–</span> <span class="NLM_lpage">2551</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2549-2551&author=A.+B.+S.+Mayaauthor=B.+d.+Reyauthor=R.+Pelaez+Lamamie+de+Clairacauthor=E.+Caballeroauthor=I.+Barasoainauthor=J.+M.+Andreuauthor=M.+Medarde&title=Design%2C+synthesis+and+cytotoxic+activities+of+naphthyl+analogues+of+combretastatin+A-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaya%26aufirst%3DA.%2BB.%2BS.%26aulast%3DRey%26aufirst%3DB.%2Bd.%26aulast%3DPelaez%2BLamamie%2Bde%2BClairac%26aufirst%3DR.%26aulast%3DCaballero%26aufirst%3DE.%26aulast%3DBarasoain%26aufirst%3DI.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DMedarde%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520cytotoxic%2520activities%2520of%2520naphthyl%2520analogues%2520of%2520combretastatin%2520A-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2549%26epage%3D2551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Pérez-Melero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maya, A. B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Rey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peláez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caballero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medarde, M.</span><span> </span><span class="NLM_article-title">A new family of quinoline and quinoxaline analogues of combretastatins</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3771</span><span class="NLM_x">–</span> <span class="NLM_lpage">3774</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=3771-3774&author=C.+P%C3%A9rez-Meleroauthor=A.+B.+S.+Mayaauthor=B.+del+Reyauthor=R.+Pel%C3%A1ezauthor=E.+Caballeroauthor=M.+Medarde&title=A+new+family+of+quinoline+and+quinoxaline+analogues+of+combretastatins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Melero%26aufirst%3DC.%26aulast%3DMaya%26aufirst%3DA.%2BB.%2BS.%26aulast%3Ddel%2BRey%26aufirst%3DB.%26aulast%3DPel%25C3%25A1ez%26aufirst%3DR.%26aulast%3DCaballero%26aufirst%3DE.%26aulast%3DMedarde%26aufirst%3DM.%26atitle%3DA%2520new%2520family%2520of%2520quinoline%2520and%2520quinoxaline%2520analogues%2520of%2520combretastatins%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D3771%26epage%3D3774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Medarde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maya, A. B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Melero, C.</span><span> </span><span class="NLM_article-title">Naphthalene combretastatin analogues: Synthesis, cytotoxicity and antitubulin activity</span> <span class="citation_source-journal">J. Enzyme Inhib. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1080%2F14756360412331280473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=15662956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=521-540&author=M.+Medardeauthor=A.+B.+S.+Mayaauthor=C.+Perez-Melero&title=Naphthalene+combretastatin+analogues%3A+Synthesis%2C+cytotoxicity+and+antitubulin+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthalene combretastatin analogs: Synthesis, cytotoxicity and antitubulin activity</span></div><div class="casAuthors">Medarde, Manuel; Maya, Ana B. S.; Perez-Melero, Concepcion</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">521-540</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Synthesis and evaluation of new combretastatin analogs with varied modifications on the bridge and the arom. rings, have shown that the 2-naphthyl moiety is a good surrogate for the 3-hydroxy-4-methoxyphenyl (B-ring) of combretastatin A-4.  Other bicyclic systems, such as 6(7)-quinolyl and 5-indolyl, can replace the B-ring, but they produce less potent analogs in the cytotoxicity and tubulin polymn. inhibition assays.  Other modifications are detrimental for the potency of the studied analogs.  The combretastatin 2-naphthyl deriv., 2-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]naphthalene, and the related 6-quinolyl combretastatin analog are the most potent among the derivs. of this type.  Previous and new results in this family of combretastatin analogs are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL-veEQ785ZrVg90H21EOLACvtfcHk0lj730yaqSxMKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqsg%253D%253D&md5=7f457aee0291399ca5b85289cd0f2339</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1080%2F14756360412331280473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756360412331280473%26sid%3Dliteratum%253Aachs%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DMaya%26aufirst%3DA.%2BB.%2BS.%26aulast%3DPerez-Melero%26aufirst%3DC.%26atitle%3DNaphthalene%2520combretastatin%2520analogues%253A%2520Synthesis%252C%2520cytotoxicity%2520and%2520antitubulin%2520activity%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2004%26volume%3D19%26spage%3D521%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span> </span><span class="NLM_article-title">Concise synthesis and structure–activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4247</span><span class="NLM_x">–</span> <span class="NLM_lpage">4257</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049802l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4247-4257&author=J.+P.+Liouauthor=Y.+L.+Changauthor=F.+M.+Kuoauthor=C.+W.+Changauthor=H.+Y.+Tsengauthor=C.+C.+Wangauthor=Y.+N.+Yangauthor=J.+Y.+Changauthor=S.+J.+Leeauthor=H.+P.+Hsieh&title=Concise+synthesis+and+structure%E2%80%93activity+relationships+of+combretastatin+A-4+analogues%2C+1-aroylindoles+and+3-aroylindoles%2C+as+novel+classes+of+potent+antitubulin+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm049802l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049802l%26sid%3Dliteratum%253Aachs%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DKuo%26aufirst%3DF.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DTseng%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DY.%2BN.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DConcise%2520synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520combretastatin%2520A-4%2520analogues%252C%25201-aroylindoles%2520and%25203-aroylindoles%252C%2520as%2520novel%2520classes%2520of%2520potent%2520antitubulin%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4247%26epage%3D4257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Sriram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grohmann, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strecker, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wootton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franken, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trawick, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinney, K. G.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">8161</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=8161-8171&author=M.+Sriramauthor=J.+J.+Hallauthor=N.+C.+Grohmannauthor=T.+E.+Streckerauthor=T.+Woottonauthor=A.+Frankenauthor=M.+L.+Trawickauthor=K.+G.+Pinney&title=Design%2C+synthesis+and+biological+evaluation+of+dihydronaphthalene+and+benzosuberene+analogs+of+the+combretastatins+as+inhibitors+of+tubulin+polymerization+in+cancer+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSriram%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DJ.%2BJ.%26aulast%3DGrohmann%26aufirst%3DN.%2BC.%26aulast%3DStrecker%26aufirst%3DT.%2BE.%26aulast%3DWootton%26aufirst%3DT.%26aulast%3DFranken%26aufirst%3DA.%26aulast%3DTrawick%26aufirst%3DM.%2BL.%26aulast%3DPinney%26aufirst%3DK.%2BG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520dihydronaphthalene%2520and%2520benzosuberene%2520analogs%2520of%2520the%2520combretastatins%2520as%2520inhibitors%2520of%2520tubulin%2520polymerization%2520in%2520cancer%2520chemotherapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D8161%26epage%3D8171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Andreani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granaiola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locatelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morigi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rambaldi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varoli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, M. W.</span><span> </span><span class="NLM_article-title">Antitumor activity of substituted <i>E</i>-3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6922</span><span class="NLM_x">–</span> <span class="NLM_lpage">6924</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0607808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6922-6924&author=A.+Andreaniauthor=S.+Burnelliauthor=M.+Granaiolaauthor=A.+Leoniauthor=A.+Locatelliauthor=R.+Morigiauthor=M.+Rambaldiauthor=L.+Varoliauthor=M.+W.+Kunkel&title=Antitumor+activity+of+substituted+E-3-%283%2C4%2C5-trimethoxybenzylidene%29-1%2C3-dihydroindol-2-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm0607808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0607808%26sid%3Dliteratum%253Aachs%26aulast%3DAndreani%26aufirst%3DA.%26aulast%3DBurnelli%26aufirst%3DS.%26aulast%3DGranaiola%26aufirst%3DM.%26aulast%3DLeoni%26aufirst%3DA.%26aulast%3DLocatelli%26aufirst%3DA.%26aulast%3DMorigi%26aufirst%3DR.%26aulast%3DRambaldi%26aufirst%3DM.%26aulast%3DVaroli%26aufirst%3DL.%26aulast%3DKunkel%26aufirst%3DM.%2BW.%26atitle%3DAntitumor%2520activity%2520of%2520substituted%2520E-3-%25283%252C4%252C5-trimethoxybenzylidene%2529-1%252C3-dihydroindol-2-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6922%26epage%3D6924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Li, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Z. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackett, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werbovetz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnsamuel, J.</span><span> </span><span class="NLM_article-title">Conformationally restricted analogs of combretastatin A-4 derived from SU5416</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5382</span><span class="NLM_x">–</span> <span class="NLM_lpage">5385</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=5382-5385&author=P.+K.+Liauthor=Z.+L.+Xiaoauthor=Z.+G.+Huauthor=B.+Panditauthor=Y.+J.+Sunauthor=D.+L.+Sackettauthor=K.+Werbovetzauthor=A.+Lewisauthor=J.+Johnsamuel&title=Conformationally+restricted+analogs+of+combretastatin+A-4+derived+from+SU5416"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%2BK.%26aulast%3DXiao%26aufirst%3DZ.%2BL.%26aulast%3DHu%26aufirst%3DZ.%2BG.%26aulast%3DPandit%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DY.%2BJ.%26aulast%3DSackett%26aufirst%3DD.%2BL.%26aulast%3DWerbovetz%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DA.%26aulast%3DJohnsamuel%26aufirst%3DJ.%26atitle%3DConformationally%2520restricted%2520analogs%2520of%2520combretastatin%2520A-4%2520derived%2520from%2520SU5416%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D5382%26epage%3D5385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span> </span><span class="NLM_article-title">Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">1228</span><span class="NLM_x">–</span> <span class="NLM_lpage">1238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1111%2Fj.1476-5381.2009.00112.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=19302593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2009&pages=1228-1238&author=X.+Renauthor=M.+Daiauthor=L.-P.+Linauthor=P.-K.+Liauthor=J.+Ding&title=Anti-angiogenic+and+vascular+disrupting+effects+of+C9%2C+a+new+microtubule-depolymerizing+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent</span></div><div class="casAuthors">Ren, Xuan; Dai, Mei; Lin, Li-Ping; Li, Pui-Kai; Ding, Jian</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1228-1238</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: The crit. role of blood supply in the growth of solid tumors makes blood vessels an ideal target for anti-tumor drug discovery.  The anti-angiogenic and vascular disrupting activities of C9, a newly synthesized microtubule-depolymg. agent, were investigated with several in vitro and in vivo models.  Possible mechanisms involved in its activity were also assessed.  Exptl. approach: Microtubule-depolymg. actions were assessed by surface plasmon resonance binding, competitive inhibition and cytoskeleton immunofluorescence.  Anti-angiogenic and vascular disrupting activities were tested on proliferation, migration, tube formation with human umbilical vein endothelial cells, and in rat aortic ring, chick chorioallantoic membrane and Matrigel plug assays.  Western blots and Rho activation assays were employed to examine the role of Raf-MEK-ERK (mitogen-activated ERK kinase, extracellular signal-regulated kinase) and Rho/Rho kinase signaling.  Key results: C9 inhibited proliferation, migration and tube formation of endothelial cells and inhibited angiogenesis in aortic ring and chick chorioallantoic membrane assays.  C9 induced disassembly of microtubules in endothelial cells and down-regulated Raf-MEK-ERK signaling activated by pro-angiogenic factors.  In addn., C9 disrupted capillary-like networks and newly formed vessels in vitro and rapidly decreased perfusion of neovasculature in vivo.  Endothelial cell contraction and membrane blebbing induced by C9 in neovasculature was dependent on the Rho/Rho kinase pathway.  Conclusions and implications: Anti-angiogenic and vascular disruption by C9 was assocd. with changes in morphol. and function of endothelial cells, involving the Raf-MEK-ERK and Rho/Rho kinase signaling pathways.  These findings strongly suggest that C9 is a new microtubule-binding agent that could effectively target tumor vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojex2iPcTR5LVg90H21EOLACvtfcHk0lhgxxG7vOKBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWmtbc%253D&md5=12d6a380c08e9244adef040586f2d0a9</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00112.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00112.x%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DL.-P.%26aulast%3DLi%26aufirst%3DP.-K.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DAnti-angiogenic%2520and%2520vascular%2520disrupting%2520effects%2520of%2520C9%252C%2520a%2520new%2520microtubule-depolymerizing%2520agent%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D156%26spage%3D1228%26epage%3D1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Rischin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span> </span><span class="NLM_article-title">Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1078-0432.CCR-11-0937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=21690571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5152-5160&author=D.+Rischinauthor=D.+C.+Bibbyauthor=G.+Chongauthor=G.+Kremmidiotisauthor=A.+F.+Leskeauthor=C.+A.+Matthewsauthor=S.+S.+Wongauthor=M.+A.+Rosenauthor=J.+Desai&title=Clinical%2C+pharmacodynamic%2C+and+pharmacokinetic+evaluation+of+BNC105P%3A+a+phase+I+trial+of+a+novel+vascular+disrupting+agent+and+inhibitor+of+cancer+cell+proliferation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation</span></div><div class="casAuthors">Rischin, Danny; Bibby, David C.; Chong, Geoff; Kremmidiotis, Gabriel; Leske, Annabell F.; Matthews, Clayton A.; Wong, Shirley S.; Rosen, Mark A.; Desai, Jayesh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5152-5160</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and pharmacodynamic (PD) effects of BNC105P, an inhibitor of tubulin polymn. that has vascular disrupting and antiproliferative effects.  Exptl. Design: BNC105P was administered as a 10-min infusion on days 1 and 8 of a 21-day cycle in a first-in-human phase I study.  A dynamic accelerated dose titrn. method was used for dose escalation.  Plasma concns. of BNC105P (phosphate prodrug) and BNC105 (active agent) were detd.  PD assessments were carried out using dynamic contrast enhanced (DCE)-MRI and anal. of a blood-borne biomarker.  RESULTS: Twenty-one subjects with advanced solid tumors were enrolled on 6 dose levels (range: 2.1-18.9 mg/m2).  The recommended dose level was 16 mg/m2 and was well tolerated.  BNC105P (prodrug) rapidly converted to BNC105 with a half-life of 0.13 h.  Plasma concns. of BNC105 generally increased in proportion to dose with a half-life of 0.57 h.  Pharmacodymanically active plasma levels were obtained with a dose dependant redn. in the levels of polymd. tubulin (on-target action) being obsd. in PBMCs.  DCE-MRI also indicated blood flow changes in the tumor lesions of a no. of subjects.  CONCLUSIONS: BNC105P has a favorable toxicity profile at the recommended dose of 16 mg/m2 and is assocd. with PD changes consistent with its known mechanism of action.  Phase II studies in renal cancer and mesothelioma have commenced.  Clin Cancer Res; 17(15); 5152-60.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofFtL953e-x7Vg90H21EOLACvtfcHk0liO5N1CWPIchA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbk%253D&md5=277c9745f593ee87871faa0915b93dc0</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0937%26sid%3Dliteratum%253Aachs%26aulast%3DRischin%26aufirst%3DD.%26aulast%3DBibby%26aufirst%3DD.%2BC.%26aulast%3DChong%26aufirst%3DG.%26aulast%3DKremmidiotis%26aufirst%3DG.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DMatthews%26aufirst%3DC.%2BA.%26aulast%3DWong%26aufirst%3DS.%2BS.%26aulast%3DRosen%26aufirst%3DM.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26atitle%3DClinical%252C%2520pharmacodynamic%252C%2520and%2520pharmacokinetic%2520evaluation%2520of%2520BNC105P%253A%2520a%2520phase%2520I%2520trial%2520of%2520a%2520novel%2520vascular%2520disrupting%2520agent%2520and%2520inhibitor%2520of%2520cancer%2520cell%2520proliferation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5152%26epage%3D5160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Li, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span> </span><span class="NLM_article-title">Imidazolone-amide bridges and their effects on tubulin polymerization in cis-locked vinylogous combretastatin-A4 analogues: synthesis and biological evaluation</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3579</span><span class="NLM_x">–</span> <span class="NLM_lpage">3584</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=3579-3584&author=Y.+W.+Liauthor=J.+Liuauthor=N.+Liuauthor=D.+Shiauthor=X.+T.+Zhouauthor=J.+G.+Lvauthor=J.+Zhuauthor=C.+H.+Zhengauthor=Y.+J.+Zhou&title=Imidazolone-amide+bridges+and+their+effects+on+tubulin+polymerization+in+cis-locked+vinylogous+combretastatin-A4+analogues%3A+synthesis+and+biological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%2BT.%26aulast%3DLv%26aufirst%3DJ.%2BG.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DC.%2BH.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26atitle%3DImidazolone-amide%2520bridges%2520and%2520their%2520effects%2520on%2520tubulin%2520polymerization%2520in%2520cis-locked%2520vinylogous%2520combretastatin-A4%2520analogues%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D3579%26epage%3D3584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Li, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Study on the binding modes of the colchicine-site inhibitors and construction of their structural model</span> <span class="citation_source-journal">Acta Chim. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1735</span><span class="NLM_x">–</span> <span class="NLM_lpage">1739</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2008&pages=1735-1739&author=Y.+W.+Liauthor=Y.+J.+Zhouauthor=J.+Zhuauthor=C.+H.+Zhengauthor=J.+Chenauthor=C.+Q.+Shengauthor=J.+G.+Luauthor=H.+Tangauthor=Y.+N.+Liauthor=J.+Zhang&title=Study+on+the+binding+modes+of+the+colchicine-site+inhibitors+and+construction+of+their+structural+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSheng%26aufirst%3DC.%2BQ.%26aulast%3DLu%26aufirst%3DJ.%2BG.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DStudy%2520on%2520the%2520binding%2520modes%2520of%2520the%2520colchicine-site%2520inhibitors%2520and%2520construction%2520of%2520their%2520structural%2520model%26jtitle%3DActa%2520Chim.%2520Sin.%26date%3D2008%26volume%3D66%26spage%3D1735%26epage%3D1739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Nguyen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermone, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaharevitz, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wipf, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gussio, R.</span><span> </span><span class="NLM_article-title">A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6107</span><span class="NLM_x">–</span> <span class="NLM_lpage">6116</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050502t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1WitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6107-6116&author=T.+L.+Nguyenauthor=C.+McGrathauthor=A.+R.+Hermoneauthor=J.+C.+Burnettauthor=D.+W.+Zaharevitzauthor=B.+W.+Dayauthor=P.+Wipfauthor=E.+Hamelauthor=R.+Gussio&title=A+common+pharmacophore+for+a+diverse+set+of+colchicine+site+inhibitors+using+a+structure-based+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach</span></div><div class="casAuthors">Nguyen, Tam Luong; McGrath, Connor; Hermone, Ann R.; Burnett, James C.; Zaharevitz, Daniel W.; Day, Billy W.; Wipf, Peter; Hamel, Ernest; Gussio, Rick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6107-6116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modulating the structure and function of tubulin and microtubules is an important route to anticancer therapeutics, and therefore, small mols. that bind to tubulin and cause mitotic arrest are of immense interest.  A large no. of synthetic and natural compds. with diverse structures have been shown to bind at the colchicine site, one of the major binding sites on tubulin, and inhibit tubulin assembly.  Using the recently detd. x-ray structure of the tubulin:colchicinoid complex as the template, we employed docking studies to det. the binding modes of a set of structurally diverse colchicine site inhibitors.  These binding models were subsequently used to construct a comprehensive, structure-based pharmacophore that in combination with mol. dynamics simulations confirms and extends our understanding of binding interactions at the colchicine site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp40uoXQZMHULVg90H21EOLACvtfcHk0liO5N1CWPIchA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1WitL8%253D&md5=443f25ca9212b379813d91ccdf820c5a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm050502t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050502t%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BL.%26aulast%3DMcGrath%26aufirst%3DC.%26aulast%3DHermone%26aufirst%3DA.%2BR.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26aulast%3DZaharevitz%26aufirst%3DD.%2BW.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DGussio%26aufirst%3DR.%26atitle%3DA%2520common%2520pharmacophore%2520for%2520a%2520diverse%2520set%2520of%2520colchicine%2520site%2520inhibitors%2520using%2520a%2520structure-based%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6107%26epage%3D6116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Yao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span> </span><span class="NLM_article-title">Synthesis and antifungal activities of novel 2-aminotetralin derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">5293</span><span class="NLM_x">–</span> <span class="NLM_lpage">5300</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0701167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5293-5300&author=B.+Yaoauthor=H.+T.+Jiauthor=Y.+B.+Caoauthor=Y.+J.+Zhouauthor=J.+Zhuauthor=J.+G.+Luauthor=Y.+W.+Liauthor=J.+Chenauthor=C.+H.+Zhengauthor=Y.+Y.+Jiangauthor=R.+M.+Liangauthor=H.+Tang&title=Synthesis+and+antifungal+activities+of+novel+2-aminotetralin+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm0701167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0701167%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DH.%2BT.%26aulast%3DCao%26aufirst%3DY.%2BB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%2BG.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DC.%2BH.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DLiang%26aufirst%3DR.%2BM.%26aulast%3DTang%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520antifungal%2520activities%2520of%2520novel%25202-aminotetralin%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5293%26epage%3D5300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">App, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2588</span><span class="NLM_x">–</span> <span class="NLM_lpage">2603</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980123i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2588-2603&author=L.+Sunauthor=N.+Tranauthor=F.+Tangauthor=H.+Appauthor=P.+Hirthauthor=G.+McMahonauthor=C.+Tang&title=Synthesis+and+biological+evaluations+of+3-substituted+indolin-2-ones%3A+a+novel+class+of+tyrosine+kinase+inhibitors+that+exhibit+selectivity+toward+particular+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases</span></div><div class="casAuthors">Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2588-2603</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs).  These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells.  By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells.  Structure-activity anal. for these compds. and their relative potency and selectivity to inhibit particular RTKs has detd. that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones contg. bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compd. contg. an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs.  Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs.  The structure-activity anal. supports the use of subsets of these compds. as specific chem. leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoPixq8Am5rVg90H21EOLACvtfcHk0liO5N1CWPIchA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D&md5=536302b717170a630008dac14832204c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm980123i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980123i%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DApp%26aufirst%3DH.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%25203-substituted%2520indolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520tyrosine%2520kinase%2520inhibitors%2520that%2520exhibit%2520selectivity%2520toward%2520particular%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2588%26epage%3D2603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Petit, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karajannis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shido, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span> </span><span class="NLM_article-title">The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1951</span><span class="NLM_x">–</span> <span class="NLM_lpage">1961</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=1951-1961&author=I.+Petitauthor=M.+A.+Karajannisauthor=L.+Vincentauthor=L.+Youngauthor=J.+Butlerauthor=A.+T.+Hooperauthor=K.+Shidoauthor=H.+Stellerauthor=D.+J.+Chaplinauthor=E.+Feldmanauthor=S.+Rafii&title=The+microtubule-targeting+agent+CA4P+regresses+leukemic+xenografts+by+disrupting+interaction+with+vascular+cells+and+mitochondrial-dependent+cell+death"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetit%26aufirst%3DI.%26aulast%3DKarajannis%26aufirst%3DM.%2BA.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DL.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DHooper%26aufirst%3DA.%2BT.%26aulast%3DShido%26aufirst%3DK.%26aulast%3DSteller%26aufirst%3DH.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DFeldman%26aufirst%3DE.%26aulast%3DRafii%26aufirst%3DS.%26atitle%3DThe%2520microtubule-targeting%2520agent%2520CA4P%2520regresses%2520leukemic%2520xenografts%2520by%2520disrupting%2520interaction%2520with%2520vascular%2520cells%2520and%2520mitochondrial-dependent%2520cell%2520death%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D1951%26epage%3D1961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Cushman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarathnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborti, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">2579</span><span class="NLM_x">–</span> <span class="NLM_lpage">2588</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00112a036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK3MXkvFWksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=2579-2588&author=M.+Cushmanauthor=D.+Nagarathnamauthor=D.+Gopalauthor=A.+K.+Chakrabortiauthor=C.+M.+Linauthor=E.+Hamel&title=Synthesis+and+evaluation+of+stilbene+and+dihydrostilbene+derivatives+as+potential+anticancer+agents+that+inhibit+tubulin+polymerization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization</span></div><div class="casAuthors">Cushman, Mark; Nagarathnam, Dhanapalan; Gopal, D.; Chakraborti, Asit K.; Lin, Chii M.; Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2579-88</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">cis- And trans-dihydrostilbenes and some N-arylbenzylamines were synthesized and evaluated for their cytotoxicity in five cancer cell cultures A-549 lung carcinoma, NCF-7 breast carcinoma, HT-δ colon adenocarcinoma, SKMEL-5 melanoma and MLM melanoma.  Several cis-stilbenes, structurally similar to combretastatins, were highly cytotoxic in all five cell lines, and active as inhibitors of tubulin polymn.  The most active compds. also inhibited the binding of colchicine to tubulin.  The most potent of the new compds., both as a tubulin polymn. inhibitor and as a cytotoxic agent, was (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene (I) which was almost as potent as combrestatins A-4, the most active of the combrestatins, as a tubulin polymn. inhibitor.  I was a approx. 140 times more cytotoxic against HT-29:adenocarcinoma cells and about 10 times more cytotoxic against MCF-η breast carcinoma cells than combrestatin A-4, but it was about 20 times less cytotoxic against A-549 lung carcinoma cells, 30 times less cytotoxic against SKMEL-5 melanoma cells, and 7 times less cytotoxic against NLM melanoma cells than combrestatin A-4.  The relative potencies for the cis, dihydro, and trans compds., resp., as inhibitors of tubulin polymn. are in agreement with the relative potencies previously obsd. for combretastatin A-Δ, dihydrocombrestatin A-4, and trans-combrestatin A-4.  The relative potencies were also reflected as a result of the cytotoxicity assays.  Structure-activity relationships of this group of compds. are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUMaB6teYTTrVg90H21EOLACvtfcHk0ljFkF20ihdB6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkvFWksLc%253D&md5=fe12d2c046d97aa417a1b7ece35d3414</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm00112a036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00112a036%26sid%3Dliteratum%253Aachs%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DGopal%26aufirst%3DD.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520stilbene%2520and%2520dihydrostilbene%2520derivatives%2520as%2520potential%2520anticancer%2520agents%2520that%2520inhibit%2520tubulin%2520polymerization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D2579%26epage%3D2588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, W. J.</span><span> </span><span class="NLM_article-title">Highly potent triazole-based tubulin polymerization inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061142s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=749-754&author=Q.+Zhangauthor=Y.+Y.+Pengauthor=X.+I.+Wangauthor=S.+M.+Keenanauthor=S.+Aroraauthor=W.+J.+Welsh&title=Highly+potent+triazole-based+tubulin+polymerization+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm061142s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061142s%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DY.%2BY.%26aulast%3DWang%26aufirst%3DX.%2BI.%26aulast%3DKeenan%26aufirst%3DS.%2BM.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26atitle%3DHighly%2520potent%2520triazole-based%2520tubulin%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D749%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span> <span class="citation_source-journal">Cell Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1385%2FCBB%3A38%3A1%3A1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12663938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=1-21&author=E.+Hamel&title=Evaluation+of+antimitotic+agents+by+quantitative+comparisons+of+their+effects+on+the+polymerization+of+purified+tubulin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span></div><div class="casAuthors">Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Most antimitotic compds. have highly specific interactions with tubulin, the major protein component of microtubules.  It is, therefore, often desirable to characterize interactions of these agents with tubulin.  In particular, quant. comparisons between new and old ("std.") agents, between different classes of agent, and between structural analogs (e.g., for a structure-activity relationship study) are important.  Because antimitotic drugs have a variety of effects on tubulin and bind at multiple distinct sites on the protein, the tubulin assembly reaction is probably the only universally applicable reaction that can be analyzed.  In my lab., we use the assembly of purified tubulin induced by higher concns. of monosodium glutamate as our basic assay system.  This report presents a detailed description of our current routine assay, including the effects of a variety of reaction components on the reaction.  In addn., the variety of effects that reaction components can have on the quant. results obtained with drugs, using the colchicine site drug combretastatin A-4 as a model compd., is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLvDICXLUiYbVg90H21EOLACvtfcHk0ljFkF20ihdB6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D&md5=c37c365cc707e237f43feffca64d706b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1385%2FCBB%3A38%3A1%3A1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FCBB%253A38%253A1%253A1%26sid%3Dliteratum%253Aachs%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DEvaluation%2520of%2520antimitotic%2520agents%2520by%2520quantitative%2520comparisons%2520of%2520their%2520effects%2520on%2520the%2520polymerization%2520of%2520purified%2520tubulin%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2003%26volume%3D38%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Bailly, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bal, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finet, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hildebrand, M.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wattez, N.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5437</span><span class="NLM_x">–</span> <span class="NLM_lpage">5444</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030903d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5437-5444&author=C.+Baillyauthor=C.+Balauthor=P.+Barbierauthor=S.+Combesauthor=J.-P.+Finetauthor=M.-P.+Hildebrandauthor=V.+Peyrotauthor=N.+Wattez&title=Synthesis+and+biological+evaluation+of+4-arylcoumarin+analogues+of+combretastatins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm030903d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030903d%26sid%3Dliteratum%253Aachs%26aulast%3DBailly%26aufirst%3DC.%26aulast%3DBal%26aufirst%3DC.%26aulast%3DBarbier%26aufirst%3DP.%26aulast%3DCombes%26aufirst%3DS.%26aulast%3DFinet%26aufirst%3DJ.-P.%26aulast%3DHildebrand%26aufirst%3DM.-P.%26aulast%3DPeyrot%26aufirst%3DV.%26aulast%3DWattez%26aufirst%3DN.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25204-arylcoumarin%2520analogues%2520of%2520combretastatins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5437%26epage%3D5444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Babu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strobel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockway, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickols, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjoholm, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegfried, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiakos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span> </span><span class="NLM_article-title">Acetyl analogs of combretastatin A-4: synthesis and biological studies</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2359</span><span class="NLM_x">–</span> <span class="NLM_lpage">2367</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=2359-2367&author=B.+Babuauthor=M.+Leeauthor=L.+Leeauthor=R.+Strobelauthor=O.+Brockwayauthor=A.+Nickolsauthor=R.+Sjoholmauthor=S.+Tzouauthor=S.+Chavdaauthor=D.+Destaauthor=G.+Fraleyauthor=A.+Siegfriedauthor=W.+Penningtonauthor=R.+M.+Hartleyauthor=C.+Westbrookauthor=S.+L.+Mooberryauthor=K.+Kiakosauthor=J.+A.+Hartleyauthor=M.+Lee&title=Acetyl+analogs+of+combretastatin+A-4%3A+synthesis+and+biological+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBabu%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DStrobel%26aufirst%3DR.%26aulast%3DBrockway%26aufirst%3DO.%26aulast%3DNickols%26aufirst%3DA.%26aulast%3DSjoholm%26aufirst%3DR.%26aulast%3DTzou%26aufirst%3DS.%26aulast%3DChavda%26aufirst%3DS.%26aulast%3DDesta%26aufirst%3DD.%26aulast%3DFraley%26aufirst%3DG.%26aulast%3DSiegfried%26aufirst%3DA.%26aulast%3DPennington%26aufirst%3DW.%26aulast%3DHartley%26aufirst%3DR.%2BM.%26aulast%3DWestbrook%26aufirst%3DC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DKiakos%26aufirst%3DK.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DM.%26atitle%3DAcetyl%2520analogs%2520of%2520combretastatin%2520A-4%253A%2520synthesis%2520and%2520biological%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D2359%26epage%3D2367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengzheng  Wang</span>, <span class="hlFld-ContribAuthor ">Kun  Fang</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Shuqiang  Chen</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Zhenyuan  Miao</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Yao</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, and <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>  . </span><span class="cited-content_cbyCitation_article-title">Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (16)
                                     , 6678-6696. <a href="https://doi.org/10.1021/acs.jmedchem.5b00910" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00910</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00910%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DScaffold%252BDiversity%252BInspired%252Bby%252Bthe%252BNatural%252BProduct%252BEvodiamine%25253A%252BDiscovery%252Bof%252BHighly%252BPotent%252Band%252BMultitargeting%252BAntitumor%252BAgents%26aulast%3DWang%26aufirst%3DShengzheng%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D14062015%26date%3D19082015%26date%3D27082015%26date%3D30072015%26volume%3D58%26issue%3D16%26spage%3D6678%26epage%3D6696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junhang  Jiang</span>, <span class="hlFld-ContribAuthor ">Canhui  Zheng</span>, <span class="hlFld-ContribAuthor ">Kongkai  Zhu</span>, <span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Nannan  Sun</span>, <span class="hlFld-ContribAuthor ">Chongqing  Wang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Ju  Zhu</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, and <span class="hlFld-ContribAuthor ">Youjun  Zhou</span>  . </span><span class="cited-content_cbyCitation_article-title">Quantum Chemistry Calculation-Aided Structural Optimization of Combretastatin A-4-like Tubulin Polymerization Inhibitors: Improved Stability and Biological Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (5)
                                     , 2538-2546. <a href="https://doi.org/10.1021/acs.jmedchem.5b00118" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00118%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DQuantum%252BChemistry%252BCalculation-Aided%252BStructural%252BOptimization%252Bof%252BCombretastatin%252BA-4-like%252BTubulin%252BPolymerization%252BInhibitors%25253A%252BImproved%252BStability%252Band%252BBiological%252BActivity%26aulast%3DJiang%26aufirst%3DJunhang%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D23012015%26date%3D26022015%26date%3D12032015%26date%3D17022015%26volume%3D58%26issue%3D5%26spage%3D2538%26epage%3D2546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. V. Ramana  Reddy</span>, <span class="hlFld-ContribAuthor ">Muralidhar R.  Mallireddigari</span>, <span class="hlFld-ContribAuthor ">Venkat R.  Pallela</span>, <span class="hlFld-ContribAuthor ">Stephen C.  Cosenza</span>, <span class="hlFld-ContribAuthor ">Vinay K.  Billa</span>, <span class="hlFld-ContribAuthor ">Balaiah  Akula</span>, <span class="hlFld-ContribAuthor ">D. R. C. Venkata  Subbaiah</span>, <span class="hlFld-ContribAuthor ">E. Vijaya  Bharathi</span>, <span class="hlFld-ContribAuthor ">Amol  Padgaonkar</span>, <span class="hlFld-ContribAuthor ">Hua  Lv</span>, <span class="hlFld-ContribAuthor ">James M.  Gallo</span>, and <span class="hlFld-ContribAuthor ">E. Premkumar  Reddy</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of (E)-N-Aryl-2-arylethenesulfonamide Analogues as Potent and Orally Bioavailable Microtubule-Targeted Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (13)
                                     , 5562-5586. <a href="https://doi.org/10.1021/jm400575x" title="DOI URL">https://doi.org/10.1021/jm400575x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400575x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400575x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B%252528E%252529-N-Aryl-2-arylethenesulfonamide%252BAnalogues%252Bas%252BPotent%252Band%252BOrally%252BBioavailable%252BMicrotubule-Targeted%252BAnticancer%252BAgents%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BRamana%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D18042013%26date%3D25062013%26date%3D11072013%26date%3D10062013%26volume%3D56%26issue%3D13%26spage%3D5562%26epage%3D5586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad Sadegh  Asgari</span>, <span class="hlFld-ContribAuthor ">Parviz  Rashidi Ranjbar</span>, <span class="hlFld-ContribAuthor ">Rahmatollah  Rahimi</span>, <span class="hlFld-ContribAuthor ">Mohammad  Mahdavi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Arylidene – Isoquinolinones bearing Combretastatin Skeleton by Cyclocarbopalladation/cross coupling Tandem Heck‐Suzuki Miaura Reactions using nano catalyst <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c797a38797be">[email protected]</a>‐IL‐SPION. </span><span class="cited-content_cbyCitation_journal-name">Applied Organometallic Chemistry</span><span> <strong>2020,</strong> <em>34 </em>
                                    (2)
                                     <a href="https://doi.org/10.1002/aoc.5279" title="DOI URL">https://doi.org/10.1002/aoc.5279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/aoc.5279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Faoc.5279%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Organometallic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BArylidene%252B%2525E2%252580%252593%252BIsoquinolinones%252Bbearing%252BCombretastatin%252BSkeleton%252Bby%252BCyclocarbopalladation%25252Fcross%252Bcoupling%252BTandem%252BHeck%2525E2%252580%252590Suzuki%252BMiaura%252BReactions%252Busing%252Bnano%252Bcatalyst%252BPd%252540Py%2525E2%252580%252590IL%2525E2%252580%252590SPION%26aulast%3DAsgari%26aufirst%3DMohammad%2BSadegh%26date%3D2020%26date%3D2019%26volume%3D34%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junhang  Jiang</span>, <span class="hlFld-ContribAuthor ">Qingsen  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiapeng  Guo</span>, <span class="hlFld-ContribAuthor ">Shaoyu  Fang</span>, <span class="hlFld-ContribAuthor ">Ruolan  Zhou</span>, <span class="hlFld-ContribAuthor ">Ju  Zhu</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Youjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Canhui  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 7-methoxy-1-(3,4,5-trimethoxyphenyl)-4,5-dihydro-2H-benzo[e]indazoles as new colchicine site inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (18)
                                     , 2632-2634. <a href="https://doi.org/10.1016/j.bmcl.2019.07.042" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.07.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.07.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.07.042%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B7-methoxy-1-%2525283%25252C4%25252C5-trimethoxyphenyl%252529-4%25252C5-dihydro-2H-benzo%25255Be%25255Dindazoles%252Bas%252Bnew%252Bcolchicine%252Bsite%252Binhibitors%26aulast%3DJiang%26aufirst%3DJunhang%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2632%26epage%3D2634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junhang  Jiang</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Chongqing  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaoyu  Fang</span>, <span class="hlFld-ContribAuthor ">Ruolan  Zhou</span>, <span class="hlFld-ContribAuthor ">Jian  Hu</span>, <span class="hlFld-ContribAuthor ">Ju  Zhu</span>, <span class="hlFld-ContribAuthor ">Youjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Canhui  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">1-Phenyl-dihydrobenzoindazoles as novel colchicine site inhibitors: Structural basis and antitumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>177 </em>, 448-456. <a href="https://doi.org/10.1016/j.ejmech.2019.04.040" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.04.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.04.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.04.040%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1-Phenyl-dihydrobenzoindazoles%252Bas%252Bnovel%252Bcolchicine%252Bsite%252Binhibitors%25253A%252BStructural%252Bbasis%252Band%252Bantitumor%252Befficacy%26aulast%3DJiang%26aufirst%3DJunhang%26date%3D2019%26volume%3D177%26spage%3D448%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anastasia A.  Beloglazkina</span>, <span class="hlFld-ContribAuthor ">Birgit  Wobith</span>, <span class="hlFld-ContribAuthor ">Elena S.  Barskaia</span>, <span class="hlFld-ContribAuthor ">Nikolay A.  Zefirov</span>, <span class="hlFld-ContribAuthor ">Alexander G.  Majouga</span>, <span class="hlFld-ContribAuthor ">Elena K.  Beloglazkina</span>, <span class="hlFld-ContribAuthor ">Nikolay V.  Zyk</span>, <span class="hlFld-ContribAuthor ">Sergei A.  Kuznetsov</span>, <span class="hlFld-ContribAuthor ">Olga N.  Zefirova</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological testing of (5Z)-2-aryl-5-arylmethylidene-3,5-dihydro-4H-imidazol-4-ones as antimitotic agents. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2016,</strong> <em>25 </em>
                                    (6)
                                     , 1239-1249. <a href="https://doi.org/10.1007/s00044-016-1566-2" title="DOI URL">https://doi.org/10.1007/s00044-016-1566-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-016-1566-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-016-1566-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DSynthesis%252Band%252Bbiological%252Btesting%252Bof%252B%2525285Z%252529-2-aryl-5-arylmethylidene-3%25252C5-dihydro-4H-imidazol-4-ones%252Bas%252Bantimitotic%252Bagents%26aulast%3DBeloglazkina%26aufirst%3DAnastasia%2BA.%26date%3D2016%26date%3D2016%26volume%3D25%26issue%3D6%26spage%3D1239%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Ya-Juan  Qin</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Yin</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>, <span class="hlFld-ContribAuthor ">Lin-Guo  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Combined Molecular Docking, 3D-QSAR, and Pharmacophore Model: Design of Novel Tubulin Polymerization Inhibitors by Binding to Colchicine-binding Site. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2015,</strong> <em>86 </em>
                                    (4)
                                     , 731-745. <a href="https://doi.org/10.1111/cbdd.12545" title="DOI URL">https://doi.org/10.1111/cbdd.12545</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12545%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DCombined%252BMolecular%252BDocking%25252C%252B3D-QSAR%25252C%252Band%252BPharmacophore%252BModel%25253A%252BDesign%252Bof%252BNovel%252BTubulin%252BPolymerization%252BInhibitors%252Bby%252BBinding%252Bto%252BColchicine-binding%252BSite%26aulast%3DLi%26aufirst%3DDong-Dong%26date%3D2015%26date%3D2015%26volume%3D86%26issue%3D4%26spage%3D731%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun-Hang  Jiang</span>, <span class="hlFld-ContribAuthor ">Can-Hui  Zheng</span>, <span class="hlFld-ContribAuthor ">Chong-Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Tian</span>, <span class="hlFld-ContribAuthor ">Chao  Yang</span>, <span class="hlFld-ContribAuthor ">Yun-Long  Song</span>, <span class="hlFld-ContribAuthor ">Yong  Hu</span>, <span class="hlFld-ContribAuthor ">Ju  Zhu</span>, <span class="hlFld-ContribAuthor ">You-Yun  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 5,6,7-trimethoxy-1-benzylidene-3,4-dihydro-naphthalen-2-one as tubulin-polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2015,</strong> <em>26 </em>
                                    (5)
                                     , 607-609. <a href="https://doi.org/10.1016/j.cclet.2015.03.022" title="DOI URL">https://doi.org/10.1016/j.cclet.2015.03.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2015.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2015.03.022%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B5%25252C6%25252C7-trimethoxy-1-benzylidene-3%25252C4-dihydro-naphthalen-2-one%252Bas%252Btubulin-polymerization%252Binhibitors%26aulast%3DJiang%26aufirst%3DJun-Hang%26date%3D2015%26volume%3D26%26issue%3D5%26spage%3D607%26epage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siwen  Li</span>, <span class="hlFld-ContribAuthor ">Aqin  Wang</span>, <span class="hlFld-ContribAuthor ">Fan  Gu</span>, <span class="hlFld-ContribAuthor ">Zhaohui  Wang</span>, <span class="hlFld-ContribAuthor ">Caiping  Tian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Qian</span>, <span class="hlFld-ContribAuthor ">Liping  Tang</span>, <span class="hlFld-ContribAuthor ">Yueqing  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel harmine derivatives for tumor targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2015,</strong> <em>6 </em>
                                    (11)
                                     , 8988-9001. <a href="https://doi.org/10.18632/oncotarget.3276" title="DOI URL">https://doi.org/10.18632/oncotarget.3276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.3276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.3276%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DNovel%252Bharmine%252Bderivatives%252Bfor%252Btumor%252Btargeted%252Btherapy%26aulast%3DLi%26aufirst%3DSiwen%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D11%26spage%3D8988%26epage%3D9001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya-Juan  Qin</span>, <span class="hlFld-ContribAuthor ">Yu-jing  Li</span>, <span class="hlFld-ContribAuthor ">Ai-Qin  Jiang</span>, <span class="hlFld-ContribAuthor ">Meng-Ru  Yang</span>, <span class="hlFld-ContribAuthor ">Qi-Zhang  Zhu</span>, <span class="hlFld-ContribAuthor ">Hong  Dong</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>94 </em>, 447-457. <a href="https://doi.org/10.1016/j.ejmech.2015.02.058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.02.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.02.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.02.058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpyrazoline-containing%252Bderivatives%252Bas%252Bpotential%252Btubulin%252Bassembling%252Binhibitors%26aulast%3DQin%26aufirst%3DYa-Juan%26date%3D2015%26volume%3D94%26spage%3D447%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Batakrishna  Jana</span>, <span class="hlFld-ContribAuthor ">Jayita  Sarkar</span>, <span class="hlFld-ContribAuthor ">Prasenjit  Mondal</span>, <span class="hlFld-ContribAuthor ">Surajit  Barman</span>, <span class="hlFld-ContribAuthor ">Saswat  Mohapatra</span>, <span class="hlFld-ContribAuthor ">Debmalya  Bhunia</span>, <span class="hlFld-ContribAuthor ">Krishnangsu  Pradhan</span>, <span class="hlFld-ContribAuthor ">Abhijit  Saha</span>, <span class="hlFld-ContribAuthor ">Anindyasundar  Adak</span>, <span class="hlFld-ContribAuthor ">Subhajit  Ghosh</span>, <span class="hlFld-ContribAuthor ">Surajit  Ghosh</span>. </span><span class="cited-content_cbyCitation_article-title">A short GC rich DNA derived from microbial origin targets tubulin/microtubules and induces apoptotic death of cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2015,</strong> <em>51 </em>
                                    (60)
                                     , 12024-12027. <a href="https://doi.org/10.1039/C5CC03432A" title="DOI URL">https://doi.org/10.1039/C5CC03432A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5CC03432A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5CC03432A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DA%252Bshort%252BGC%252Brich%252BDNA%252Bderived%252Bfrom%252Bmicrobial%252Borigin%252Btargets%252Btubulin%25252Fmicrotubules%252Band%252Binduces%252Bapoptotic%252Bdeath%252Bof%252Bcancer%252Bcells%26aulast%3DJana%26aufirst%3DBatakrishna%26date%3D2015%26date%3D2015%26volume%3D51%26issue%3D60%26spage%3D12024%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramandeep  Kaur</span>, <span class="hlFld-ContribAuthor ">Gurneet  Kaur</span>, <span class="hlFld-ContribAuthor ">Rupinder Kaur  Gill</span>, <span class="hlFld-ContribAuthor ">Richard  Soni</span>, <span class="hlFld-ContribAuthor ">Jitender  Bariwal</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in tubulin polymerization inhibitors: An overview. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>87 </em>, 89-124. <a href="https://doi.org/10.1016/j.ejmech.2014.09.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.09.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.09.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bin%252Btubulin%252Bpolymerization%252Binhibitors%25253A%252BAn%252Boverview%26aulast%3DKaur%26aufirst%3DRamandeep%26date%3D2014%26volume%3D87%26spage%3D89%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng-Yang  Chang</span>, <span class="hlFld-ContribAuthor ">Yi-Chia  Chen</span>, <span class="hlFld-ContribAuthor ">Shin-Ying  Lin</span>, <span class="hlFld-ContribAuthor ">Chieh-Kai  Chan</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot synthesis of sulfonyl (E)-stilbenes by nitrobenzene-mediated dimerizative desulfonation of benzylic sulfones. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2014,</strong> <em>70 </em>
                                    (9)
                                     , 1740-1747. <a href="https://doi.org/10.1016/j.tet.2014.01.045" title="DOI URL">https://doi.org/10.1016/j.tet.2014.01.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2014.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2014.01.045%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DOne-pot%252Bsynthesis%252Bof%252Bsulfonyl%252B%252528E%252529-stilbenes%252Bby%252Bnitrobenzene-mediated%252Bdimerizative%252Bdesulfonation%252Bof%252Bbenzylic%252Bsulfones%26aulast%3DChang%26aufirst%3DMeng-Yang%26date%3D2014%26volume%3D70%26issue%3D9%26spage%3D1740%26epage%3D1747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mitko  Miliovsky</span>, <span class="hlFld-ContribAuthor ">Ivan  Svinyarov</span>, <span class="hlFld-ContribAuthor ">Yavor  Mitrev</span>, <span class="hlFld-ContribAuthor ">Yana  Evstatieva</span>, <span class="hlFld-ContribAuthor ">Dilyana  Nikolova</span>, <span class="hlFld-ContribAuthor ">Maya  Chochkova</span>, <span class="hlFld-ContribAuthor ">Milen G.  Bogdanov</span>. </span><span class="cited-content_cbyCitation_article-title">A novel one-pot synthesis and preliminary biological activity evaluation of cis-restricted polyhydroxy stilbenes incorporating protocatechuic acid and cinnamic acid fragments. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>66 </em>, 185-192. <a href="https://doi.org/10.1016/j.ejmech.2013.05.040" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.05.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.05.040%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bnovel%252Bone-pot%252Bsynthesis%252Band%252Bpreliminary%252Bbiological%252Bactivity%252Bevaluation%252Bof%252Bcis-restricted%252Bpolyhydroxy%252Bstilbenes%252Bincorporating%252Bprotocatechuic%252Bacid%252Band%252Bcinnamic%252Bacid%252Bfragments%26aulast%3DMiliovsky%26aufirst%3DMitko%26date%3D2013%26volume%3D66%26spage%3D185%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of CA-4 and its analogues that entered clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) (CH<sub>3</sub>)<sub>2</sub>SO<sub>2</sub>, NaOH; (ii) Na, EtOH; (iii) substituted benzylidene, AcOH/piperidine, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of compound <b>22b</b>: (A) ORTEP drawing of compound <b>22b</b>; (B) superposition of <b>22b</b> (green) with the docking modes of CA4 (gray) bound to the colchicine of tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell cycle distribution of human cancer HCT-116 cells treated for 24 h with different amounts of <b>22b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Predicted binding modes with DAMA-colchicine at the β-tubulin binding site: (A) CA-4 (green) and <b>22b</b> (red); (B) <b>22b</b> (red) and <b>23b</b> (blue). P1 and P2 are two hydrophobic pockets in the interface between α- and β-tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Acute toxicity testing for compound <b>22b</b> and CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/medium/jm-2012-00596s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibition of human xenograft growth in vivo by compound <b>22b</b> and CA-4. HT-29 tumor-bearing nude mice were administered vehicle alone or 100, 150, 300 mg/kg compound <b>22b</b> or 30, 50 mg/kg CA-4 intraperitoneally once a day. The figure shows the tumor volume of <b>22b</b> (A) and CA-4 (B) recorded at the indicated days after treatments. Data are expressed as mean ± SEM of tumor volume at each time point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-12/jm300596s/production/images/large/jm-2012-00596s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300596s&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38233" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38233" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 65 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lhf37jQAl8sNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahindroo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chern, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, U. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C. C.</span><span> </span><span class="NLM_article-title">Structure–activity and crystallographic analysis of benzophenone derivatives—the potential anticancer agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=101-105&author=H.+P.+Hsiehauthor=J.+P.+Liouauthor=Y.+T.+Linauthor=N.+Mahindrooauthor=J.+Y.+Changauthor=Y.+N.+Yangauthor=S.+S.+Chernauthor=U.+K.+Tanauthor=C.+W.+Changauthor=T.+W.+Chenauthor=C.+H.+Linauthor=Y.+Y.+Changauthor=C.+C.+Wang&title=Structure%E2%80%93activity+and+crystallographic+analysis+of+benzophenone+derivatives%E2%80%94the+potential+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLin%26aufirst%3DY.%2BT.%26aulast%3DMahindroo%26aufirst%3DN.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DYang%26aufirst%3DY.%2BN.%26aulast%3DChern%26aufirst%3DS.%2BS.%26aulast%3DTan%26aufirst%3DU.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DT.%2BW.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DY.%2BY.%26aulast%3DWang%26aufirst%3DC.%2BC.%26atitle%3DStructure%25E2%2580%2593activity%2520and%2520crystallographic%2520analysis%2520of%2520benzophenone%2520derivatives%25E2%2580%2594the%2520potential%2520anticancer%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D101%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Belotti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drudis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsotti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitelli, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taraboletti, G.</span><span> </span><span class="NLM_article-title">The microtubule-affecting drug paclitaxel has antiangiogenic activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1843</span><span class="NLM_x">–</span> <span class="NLM_lpage">1849</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=9816139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1SitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=1843-1849&author=D.+Belottiauthor=V.+Verganiauthor=T.+Drudisauthor=P.+Borsottiauthor=M.+R.+Pitelliauthor=G.+Vialeauthor=R.+Giavazziauthor=G.+Taraboletti&title=The+microtubule-affecting+drug+paclitaxel+has+antiangiogenic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The microtubule-affecting drug paclitaxel has antiangiogenic activity</span></div><div class="casAuthors">Belotti, Dorina; Vergani, Veronica; Drudis, Teresa; Borsotti, Patrizia; Pitelli, Maria Rosa; Viale, Giuseppe; Giavazzi, Raffaella; Taraboletti, Giulia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1843-1849</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endothelial cell migration is a crit. event during angiogenesis, and inhibitors of cell motility can affect the angiogenic process.  Paclitaxel, a microtubule-stabilizing antineoplastic cytotoxic drug, inhibits motility and invasiveness of several cell types.  The aim of this study was to investigate the effect of paclitaxel on endothelial cell functions and on angiogenesis.  In vivo, paclitaxel (20-28 mg/kg i.v.) significantly inhibited the angiogenic response induced by tumor cell supernatant embedded in a pellet of reconstituted basement membrane (Matrigel) injected s.c. into C57BL/6N mice.  In vitro, paclitaxel inhibited endothelial cell proliferation, motility, invasiveness, and cord formation on Matrigel in a dose-dependent manner.  The antiangiogenic activity of paclitaxel was not linked to its cytotoxicity, since inhibition of endothelial cell chemotaxis and invasiveness occurred at drug concns. which did not affect endothelial cell proliferation.  Another cytotoxic drug, cisplatin, that inhibited endothelial cell proliferation in vitro, did not affect angiogenesis in vivo.  These data indicate that paclitaxel has a strong antiangiogenic activity, a property that might contribute to its antineoplastic activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEwI_-XSTB_7Vg90H21EOLACvtfcHk0lhBF2BJeRU_GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1SitLo%253D&md5=fa2918912bb43c219952c4c4003c73f5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBelotti%26aufirst%3DD.%26aulast%3DVergani%26aufirst%3DV.%26aulast%3DDrudis%26aufirst%3DT.%26aulast%3DBorsotti%26aufirst%3DP.%26aulast%3DPitelli%26aufirst%3DM.%2BR.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DTaraboletti%26aufirst%3DG.%26atitle%3DThe%2520microtubule-affecting%2520drug%2520paclitaxel%2520has%2520antiangiogenic%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1996%26volume%3D2%26spage%3D1843%26epage%3D1849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mekhail, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markman, M.</span><span> </span><span class="NLM_article-title">Paclitaxel in cancer therapy</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1517%2F14656566.3.6.755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12036415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1CqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=755-766&author=T.+M.+Mekhailauthor=M.+Markman&title=Paclitaxel+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel in cancer therapy</span></div><div class="casAuthors">Mekhail, Tarek M.; Markman, Maurie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-766</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  The last decade witnessed the introduction of exciting new chemotherapeutic agents.  Among these, paclitaxel emerged as one of the most powerful compds.  Paclitaxel promotes the polymn. of tubulin, thereby causing cell death by disrupting the normal microtubule dynamics required for cell division and vital interphase processes.  Mechanisms of acquired resistance to paclitaxel include alterations of tubulin structure and the amplification of membrane phosphoglycoproteins that function as drug-efflux pumps.  Toxicities assocd. with paclitaxel include hypersensitivity reaction, neurotoxicity and hematol. toxicities.  Toxicities may be both dose- and schedule-dependent.  Paclitaxel has activity against a broad band of tumor types, including breast, ovarian, lung, head and neck cancers.  Paclitaxel also has activity in other malignancies that are refractory to conventional chemotherapy, including previously-treated lymphoma and small cell lung cancers and esophageal, gastric endometrial, bladder and germ cell tumors.  Paclitaxel is also active against AIDS-assocd. Kaposi's sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbdrcIMqjxiLVg90H21EOLACvtfcHk0lhBF2BJeRU_GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1CqsrY%253D&md5=258be69b5cce3cc7c4654cd65229a3e4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14656566.3.6.755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.3.6.755%26sid%3Dliteratum%253Aachs%26aulast%3DMekhail%26aufirst%3DT.%2BM.%26aulast%3DMarkman%26aufirst%3DM.%26atitle%3DPaclitaxel%2520in%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2002%26volume%3D3%26spage%3D755%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, R. C.</span><span> </span><span class="NLM_article-title">The clinical-pharmacology and use of antimicrotubule agents in cancer chemotherapeutics</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1016%2F0163-7258%2891%2990086-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=1687171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK38XhvVOgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1991&pages=35-84&author=E.+K.+Rowinskyauthor=R.+C.+Donehower&title=The+clinical-pharmacology+and+use+of+antimicrotubule+agents+in+cancer+chemotherapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics</span></div><div class="casAuthors">Rowinsky, Eric K.; Donehower, Ross C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-84</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    </div><div class="casAbstract">A review with >500 refs.  Mechanisms of antineoplastic action and resistance and clin. pharmacol., therapeutic applications, and clin. toxicities of selected antimicrotubule agents (vincristine, vinblastine, vindesine, vinorelbine, and taxol) are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTPZ9qEQhDorVg90H21EOLACvtfcHk0lhBF2BJeRU_GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvVOgt7o%253D&md5=575a2df3b5700d2587ca1ab45e1a6645</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0163-7258%2891%2990086-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0163-7258%252891%252990086-2%26sid%3Dliteratum%253Aachs%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DDonehower%26aufirst%3DR.%2BC.%26atitle%3DThe%2520clinical-pharmacology%2520and%2520use%2520of%2520antimicrotubule%2520agents%2520in%2520cancer%2520chemotherapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D1991%26volume%3D52%26spage%3D35%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Nam, N. H.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 analogues as antimitotic antitumor agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1697</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2174%2F0929867033457151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12871118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1Wgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=1697-1722&author=N.+H.+Nam&title=Combretastatin+A-4+analogues+as+antimitotic+antitumor+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 analogues as antimitotic antitumor agents</span></div><div class="casAuthors">Nam, Nguyen-Hai</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1697-1722</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is a major target for anticancer drug discovery.  As a result, antimitotic agents constitute an important class of the current anticancer drugs.  Hundreds of tubulin inhibitors, naturally occurring, semisynthetic or synthetic, have been reported.  Among these, combretastatin A-4 (CA-4), isolated from a South African tree Combretum caffrum, is one of the most potent antimitotic agents.  CA-4 shows strong cytotoxicity against a variety of cancer cells, including multi-drug resistant cancer cell lines.  It has also been demonstrated to exert highly selective effects in proliferating endothelial cells.  CA-4 disodium phosphate (CA4DP), a water-sol. prodrug of CA-4, shows potent antivascular and antitumor effects in a wide variety of preclin. tumor models.  Consequently, a no. of CA-4 analogs has been synthesized and evaluated.  In this paper, the structure-activity relationships and pharmacol. properties of the CA-4 derivs. as a class of potent antimitotic anticancer agents are reviewed and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcRUgR4DDrfbVg90H21EOLACvtfcHk0lhBF2BJeRU_GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1Wgurk%253D&md5=7eeed63b294477bb55c7392ab3948d77</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F0929867033457151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867033457151%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DN.%2BH.%26atitle%3DCombretastatin%2520A-4%2520analogues%2520as%2520antimitotic%2520antitumor%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2003%26volume%3D10%26spage%3D1697%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Bhattacharyya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, M.</span><span> </span><span class="NLM_article-title">Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1002%2Fmed.20097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=17464966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=155-183&author=B.+Bhattacharyyaauthor=D.+Pandaauthor=S.+Guptaauthor=M.+Banerjee&title=Anti-mitotic+activity+of+colchicine+and+the+structural+basis+for+its+interaction+with+tubulin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin</span></div><div class="casAuthors">Bhattacharyya, Bhabatarak; Panda, Dulal; Gupta, Suvroma; Banerjee, Mithu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-183</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In this review, an attempt has been made to throw light on the mechanism of action of colchicine and its different analogs as anti-cancer agents.  Colchicine interacts with tubulin and perturbs the assembly dynamics of microtubules.  Though its use has been limited because of its toxicity, colchicine can still be used as a lead compd. for the generation of potent anti-cancer drugs.  Colchicine binds to tubulin in a poorly reversible manner with high activation energy.  The binding interaction is favored entropically.  In contrast, binding of its simple analogs AC or DAAC is enthalpically favored and commences with comparatively low activation energy.  Colchicine-tubulin interaction, which is normally pH dependent, has been found to be independent of pH in the presence of microtubule-assocd. proteins, salts or upon cleavage of carboxy termini of tubulin.  Biphasic kinetics of colchicines-tubulin interaction has been explained in light of the variation in the residues around the drug-binding site on β-tubulin.  Using the crystal structure of the tubulin-DAMAcolchicine complex, a detailed discussion on the pharmacophore concept that explains the variation of affinity for different colchicine site inhibitors (CSI) has been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9F4KA4GVMr7Vg90H21EOLACvtfcHk0liu4H-r3y5MqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVSjsA%253D%253D&md5=720f26c98a40dd91634dbe558d982e98</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fmed.20097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20097%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharyya%26aufirst%3DB.%26aulast%3DPanda%26aufirst%3DD.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DM.%26atitle%3DAnti-mitotic%2520activity%2520of%2520colchicine%2520and%2520the%2520structural%2520basis%2520for%2520its%2520interaction%2520with%2520tubulin%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D155%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, R. C.</span><span> </span><span class="NLM_article-title">Drug therapy—paclitaxel (Taxol)</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1056%2FNEJM199504133321507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=7885406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A280%3ADyaK2M7ptFKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1995&pages=1004-1014&author=E.+K.+Rowinskyauthor=R.+C.+Donehower&title=Drug+therapy%E2%80%94paclitaxel+%28Taxol%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel (taxol)</span></div><div class="casAuthors">Rowinsky E K; Donehower R C</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1004-14</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDsoUwRBKuB62q3xNe7a7QfW6udTcc2eb2bwTrrybh6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7ptFKisg%253D%253D&md5=918362934f39ee3362db9d2bed1c71cb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJM199504133321507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199504133321507%26sid%3Dliteratum%253Aachs%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DDonehower%26aufirst%3DR.%2BC.%26atitle%3DDrug%2520therapy%25E2%2580%2594paclitaxel%2520%2528Taxol%2529%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1995%26volume%3D332%26spage%3D1004%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kruczynski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, B. T.</span><span> </span><span class="NLM_article-title">Vinflunine, the latest vinca alkaloid in clinical development: a review of its preclinical anticancer properties</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1016%2FS1040-8428%2801%2900183-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=11682323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A280%3ADC%252BD3MrnsVGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=159-173&author=A.+Kruczynskiauthor=B.+T.+Hill&title=Vinflunine%2C+the+latest+vinca+alkaloid+in+clinical+development%3A+a+review+of+its+preclinical+anticancer+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties</span></div><div class="casAuthors">Kruczynski A; Hill B T</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-73</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">Vinflunine is a new Vinca alkaloid uniquely fluorinated, by the use of superacid chemistry, in a little exploited region of the catharanthine moiety.  In vitro investigations have confirmed the mitotic-arresting and tubulin-interacting properties of vinflunine shared by other Vinca alkaloids.  However, differences in terms of the inhibitory effects of vinflunine on microtubules dynamics and its tubulin binding affinities have been identified which appear to distinguish it from the other Vinca alkaloids.  Vinflunine induced smaller spirals with a shorter relaxation time, effects, which might be associated with reduced neurotoxicity.  Studies investigating the in vitro cytotoxicity of vinflunine in combination therapy have revealed a high level of synergy when vinflunine was combined with either cisplatin, mitomycin C, doxorubicin or 5-fluorouracil.  Furthermore, although vinflunine appears to participate in P-glycoprotein-mediated drug resistance mechanisms, it has proved only a weak substrate for this protein and a far less potent inducer of resistance than vinorelbine.  Vinflunine was identified in preclinical studies as having marked antitumour activity in vivo against a large panel of experimental tumour models, with tumour regressions being recorded in human renal and small cell lung cancer tumour xenografts.  Overall its level of activity was superior to that of vinorelbine in many of the experimental models used.  Interestingly, an in vivo study using a well vascularised adenocarcinoma of the colon has suggested that vinflunine mediates its antitumour activity at least in part via an antivascular mechanism, even at sub-cytotoxic doses.  Therefore, these data provide a favourable preclinical profile for vinflunine, supporting its promising candidacy for clinical development.  Phase I evaluations of vinflunine have been completed in Europe and phase II clinical trials are now ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2XApFJuUMRYkFb3mqPUYDfW6udTcc2eb2bwTrrybh6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MrnsVGlsQ%253D%253D&md5=65fa3755e13ca2227f3e12e00877874a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1040-8428%2801%2900183-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1040-8428%252801%252900183-4%26sid%3Dliteratum%253Aachs%26aulast%3DKruczynski%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DB.%2BT.%26atitle%3DVinflunine%252C%2520the%2520latest%2520vinca%2520alkaloid%2520in%2520clinical%2520development%253A%2520a%2520review%2520of%2520its%2520preclinical%2520anticancer%2520properties%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2001%26volume%3D40%26spage%3D159%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Altaha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, J.</span><span> </span><span class="NLM_article-title">Epothilones: a novel class of non-taxane microtubule-stabilizing agents</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1707</span><span class="NLM_x">–</span> <span class="NLM_lpage">1712</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2174%2F1381612023394043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12171542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD38XlslKhtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1707-1712&author=R.+Altahaauthor=T.+Fojoauthor=E.+Reedauthor=J.+Abraham&title=Epothilones%3A+a+novel+class+of+non-taxane+microtubule-stabilizing+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilones: a novel class of non-taxane microtubule-stabilizing agents</span></div><div class="casAuthors">Altaha, Ramin; Fojo, Tito; Reed, Eddie; Abraham, Jame</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1707-1712</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  The epothilones are a novel class of non-taxane microtubule-stabilizing agents obtained from the fermn. of the cellulose degrading myxobacteria, Sorangium cellulosum.  Preclin. studies have shown that the epothilones are more potent than the taxanes and active in some taxane-resistant models.  Similar to paclitaxel and other taxanes, the epothilones block cells in mitosis, resulting in cell death.  The chief components of the fermn. process are epothilones A and B, with epothilones C and D found in smaller amts.  Trace amts. of other epothilones have also been detected.  Pre-clin. studies have shown that epothilone B is the most active form, exhibiting significantly higher antitumor activity than paclitaxel and docetaxel.  Several phase I and phase II clin. trials are ongoing with epothilone B and BMS 247550, an epothilone B analog.  Preliminary reports indicate these agents are active against human cancers in heavily pre-treated patients.  The epothilones appear to be well tolerated, with a side effect profile that is similar to that reported with the taxanes.  This article will review some basic aspects of epothilone chem. and biol., and pre-clin. and preliminary clin. experience with epothilone B and its analog, BMS 247550.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtxmpHV7S5fbVg90H21EOLACvtfcHk0liu4H-r3y5MqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlslKhtro%253D&md5=8a817f51e738385550307f4a034253ab</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1381612023394043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612023394043%26sid%3Dliteratum%253Aachs%26aulast%3DAltaha%26aufirst%3DR.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DReed%26aufirst%3DE.%26aulast%3DAbraham%26aufirst%3DJ.%26atitle%3DEpothilones%253A%2520a%2520novel%2520class%2520of%2520non-taxane%2520microtubule-stabilizing%2520agents%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2002%26volume%3D8%26spage%3D1707%26epage%3D1712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannakakou, P.</span><span> </span><span class="NLM_article-title">Targeting microtubules for cancer chemotherapy</span> <span class="citation_source-journal">Curr. Med. Chem.: Anti-Cancer Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2174%2F1568011053352569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=15720262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-71&author=J.+Zhouauthor=P.+Giannakakou&title=Targeting+microtubules+for+cancer+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting microtubules for cancer chemotherapy</span></div><div class="casAuthors">Zhou, Jun; Giannakakou, Paraskevi</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chem. compds. that interfere with microtubules such as the vinca alkaloids and taxanes are important chemotherapeutic agents for the treatment of cancer.  As knowledge of microtubule-targeting drugs increases, the mechanism underlying the anticancer activity of these agents may mainly lie in their inhibitory effects on spindle microtubule dynamics, rather than in their effects on microtubule polymer mass.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell cycle progression at mitosis and eventually leading to apoptotic cell death.  The effectiveness of microtubule-targeting drugs for cancer therapy has been impaired by various side effects, notably neurol. and hematol. toxicities.  Drug resistance is another notorious factor that thwarts the effectiveness of these agents, as with many other cancer chemotherapeutics.  Several new microtubule-targeting agents have shown potent activity against the proliferation of various cancer cells, including cells that display resistance to the existing microtubule-targeting drugs.  Continued investigation of the mechanisms of action of microtubule-targeting drugs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance may provide more effective therapeutic options for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI0IucAUr4V7Vg90H21EOLACvtfcHk0lggSZ3GknvGgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D&md5=e5d34ca2c4d4adf0e6975989da8aaee8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1568011053352569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011053352569%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGiannakakou%26aufirst%3DP.%26atitle%3DTargeting%2520microtubules%2520for%2520cancer%2520chemotherapy%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Tron, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirali, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagliai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busacca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of combretastatin A4: present and future directions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3033</span><span class="NLM_x">–</span> <span class="NLM_lpage">3044</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0512903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFyjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3033-3044&author=G.+C.+Tronauthor=T.+Piraliauthor=G.+Sorbaauthor=F.+Pagliaiauthor=S.+Busaccaauthor=A.+A.+Genazzani&title=Medicinal+chemistry+of+combretastatin+A4%3A+present+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of combretastatin A4: Present and future directions</span></div><div class="casAuthors">Tron, Gian Cesare; Pirali, Tracey; Sorba, Giovanni; Pagliai, Francesca; Busacca, Sara; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3033-3044</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with refs.  A review on the medicinal chem. of combretastatin A4 (CA-4), a compd. with antitumor properties.  The mechanism of action of CA-4, including its ability to inhibit tubulin polymn., is discussed, along with selected analogs of CA-4 modified on the arom. rings A and B, substituted Ph rings, heterocycling rings, non-substituted arom. rings, modifications on the double bond, and analogs where the olefinic group is replaced by a ring.  Some issues related to the pharmacol. of CA-4 and future directions in research are considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGNHvpiUH4mbVg90H21EOLACvtfcHk0lggSZ3GknvGgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFyjuro%253D&md5=be023d8f1f059f952308bb06196459da</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm0512903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512903%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DPagliai%26aufirst%3DF.%26aulast%3DBusacca%26aufirst%3DS.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DMedicinal%2520chemistry%2520of%2520combretastatin%2520A4%253A%2520present%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3033%26epage%3D3044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walicke, P. A.</span><span> </span><span class="NLM_article-title">A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=189-197&author=D.+W.+Siemannauthor=D.+J.+Chaplinauthor=P.+A.+Walicke&title=A+review+and+update+of+the+current+status+of+the+vasculature-disabling+agent+combretastatin-A4+phosphate+%28CA4P%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DWalicke%26aufirst%3DP.%2BA.%26atitle%3DA%2520review%2520and%2520update%2520of%2520the%2520current%2520status%2520of%2520the%2520vasculature-disabling%2520agent%2520combretastatin-A4%2520phosphate%2520%2528CA4P%2529%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, S.</span><span> </span><span class="NLM_article-title">Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1334</span><span class="NLM_x">–</span> <span class="NLM_lpage">1344</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1038%2Fsj.bjc.6601261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=14520469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1Cmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2003&pages=1334-1344&author=K.+Horiauthor=S.+Saito&title=Microvascular+mechanisms+by+which+the+combretastatin+A-4+derivative+AC7700+%28AVE8062%29+induces+tumour+blood+flow+stasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis</span></div><div class="casAuthors">Hori, K.; Saito, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1334-1344</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors previously reported that a novel combretastatin A-4 deriv., AC7700, has remarkable antitumor effects because of an irreversible stasis of tumor blood flow (TBF) and subsequent loss of nutrient supply to tumor tissue.  Since early 2002, under the new designation AVE8062, AC7700 has undergone clin. trials in Europe and the US.  Questions remain, however, concerning how AC7700 blocks TBF and why the TBF stasis does not recover.  In this study, using a rat tumor LY80, a variant of Yoshida sarcoma, the authors examd. whether TBF cessation after AC7700 administration is due to a direct action of the agent on tumor blood vessels.  The authors constructed electrodes that can drop a small quantity of the drug soln. directly at the site of blood flow measurement and inserted them s.c. and into the tumor.  The authors compared the blood flow responses of normal vessels and tumor vessels after administration of 10-μl doses of various concns. (0.2, 1, 10, and 50 mg ml-1) of the AC7700 soln.  In addn., the authors assessed TBF stasis after i.v. and intra-arterial 10 mg kg-1 AC7700 administration in an LY80-induced kidney tumor.  To det. why the TBF stasis is irreversible, the authors obsd. AC7700-induced changes in host arterioles and the tumor vascular network of the Sato lung carcinoma using a vital microscopic rat transparent chamber.  Since an increase in tumor interstitial fluid pressure brings about a decrease in TBF, the authors also measured 10 mg kg-1 AC7700-induced changes in this pressure.  The sensitivity of the blood flow response after intratumoral application of AC7700 was markedly higher in normal vessels relative to tumor vessels.  Intra-arterial administration of AC7700 did not have stronger effects on TBF stasis than did i.v. administration.  Intravital microscopy showed that AC7700 induced a powerful and long-lasting constriction of host arterioles, so that complete stasis of blood flow occurred in downstream vessels, which supplied blood to tumors.  Owing to this stasis, the lumens of numerous tumor vessels narrowed or completely disappeared, and numerous erythrocytes stagnated in drainage vessels of the tumor vascular network.  Hemolysis of these erythrocytes occurred after 2-3 h, resulting in complete thrombosis.  There was no indication of reperfusion in vessels showing hemolysis.  This hemolysis is thought to be the main cause for the irreversibility of TBF stasis.  Since the tumor interstitial fluid pressure decreased after i.v. AC7700 administration, the possibility of stasis of TBF being caused by tumor vascular compression was excluded.  All these results strongly suggest that the main target of AC7700 is host arterioles and that the stasis of TBF induced by AC7700 is not triggered by a direct action of the drug on tumor vessels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplroi2amwQXbVg90H21EOLACvtfcHk0lgE4ntrYOSfEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1Cmu70%253D&md5=68c723d7334ac342d2c5c1b7c06b5294</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601261%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DS.%26atitle%3DMicrovascular%2520mechanisms%2520by%2520which%2520the%2520combretastatin%2520A-4%2520derivative%2520AC7700%2520%2528AVE8062%2529%2520induces%2520tumour%2520blood%2520flow%2520stasis%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D89%26spage%3D1334%26epage%3D1344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Shan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y.</span><span> </span><span class="NLM_article-title">Developments of combretastatin A-4 derivatives as anticancer agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2174%2F092986711794480221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=21143124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsl2lt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=523-538&author=Y.+Shanauthor=J.+Zhangauthor=Z.+Liuauthor=M.+Wangauthor=Y.+Dong&title=Developments+of+combretastatin+A-4+derivatives+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Developments of combretastatin A-4 derivatives as anticancer agents</span></div><div class="casAuthors">Shan, Y.; Zhang, J.; Liu, Z.; Wang, M.; Dong, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-538</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is one of several members of a small family of globular proteins.  It offers a potential target for anticancer drug design and development.  Combretastatin A-4 (CA-4) is a potent anticancer and antiangiogenesis natural substance isolated from Combretum caffrum.  Modifications on the Ca-4 structure have led to a great no. of novel CA-4 derivs. as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer.  In this review, the recent developments of novel CA-4 derivs. via the modifications on the A- and B-ring and the double bond as anticancer agents are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUzBhk-7FdB7Vg90H21EOLACvtfcHk0lgE4ntrYOSfEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsl2lt70%253D&md5=81b78f1ee900478f3771ba7e9b7ef1d9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F092986711794480221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794480221%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DY.%26atitle%3DDevelopments%2520of%2520combretastatin%2520A-4%2520derivatives%2520as%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D523%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Theeramunkong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massarotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aprile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caprioglio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaninetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teruggi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirali, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tron, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span> </span><span class="NLM_article-title">Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4977</span><span class="NLM_x">–</span> <span class="NLM_lpage">4986</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200555r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlaitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4977-4986&author=S.+Theeramunkongauthor=A.+Caldarelliauthor=A.+Massarottiauthor=S.+Aprileauthor=D.+Caprioglioauthor=R.+Zaninettiauthor=A.+Teruggiauthor=T.+Piraliauthor=G.+Grosaauthor=G.+C.+Tronauthor=A.+A.+Genazzani&title=Regioselective+Suzuki+coupling+of+dihaloheteroaromatic+compounds+as+a+rapid+strategy+to+synthesize+potent+rigid+combretastatin+analogues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective Suzuki Coupling of Dihaloheteroaromatic Compounds as a Rapid Strategy To Synthesize Potent Rigid Combretastatin Analogues</span></div><div class="casAuthors">Theeramunkong, Sewan; Caldarelli, Antonio; Massarotti, Alberto; Aprile, Silvio; Caprioglio, Diego; Zaninetti, Roberta; Teruggi, Alessia; Pirali, Tracey; Grosa, Giorgio; Tron, Gian Cesare; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4977-4986</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combretastatin A-4 (CA-4) is a potent tubulin depolymg. agent able to inhibit tumor growth and with antivascular effects.  Although it is in clin. trials, the search for novel analogs that may display better/different features is still ongoing.  In this manuscript we describe the synthesis of novel constrained analogs of CA-4 obtained in only two synthetic steps exploiting a regioselective Suzuki coupling of dihalogenated heteroarom. and alicyclic compds.  All the compds. synthesized have been evaluated for cytotoxicity and for their ability to inhibit tubulin assembly.  One of them, I, displayed low nanomolar cytotoxicity and proved to have a pharmacodynamic profile similar to that of CA-4 and a better pharmacokinetic profile, but most important of all, this synthetic strategy may pave the way for the easy and rapid generation of novel rigid analogs of combretastatins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCcsEeiXLwXLVg90H21EOLACvtfcHk0lgE4ntrYOSfEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlaitbs%253D&md5=235e7be73c6f7f974bd9e129381933cd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm200555r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200555r%26sid%3Dliteratum%253Aachs%26aulast%3DTheeramunkong%26aufirst%3DS.%26aulast%3DCaldarelli%26aufirst%3DA.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DCaprioglio%26aufirst%3DD.%26aulast%3DZaninetti%26aufirst%3DR.%26aulast%3DTeruggi%26aufirst%3DA.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DGrosa%26aufirst%3DG.%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DRegioselective%2520Suzuki%2520coupling%2520of%2520dihaloheteroaromatic%2520compounds%2520as%2520a%2520rapid%2520strategy%2520to%2520synthesize%2520potent%2520rigid%2520combretastatin%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4977%26epage%3D4986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz-Lopez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez Cara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrion, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4248</span><span class="NLM_x">–</span> <span class="NLM_lpage">4258</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100245q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4248-4258&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=O.+Cruz-Lopezauthor=C.+Lopez+Caraauthor=M.+D.+Carrionauthor=A.+Brancaleauthor=E.+Hamelauthor=L.+Chenauthor=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Synthesis+and+antitumor+activity+of+1%2C5-disubstituted+1%2C2%2C4-triazoles+as+cis-restricted+combretastatin+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm100245q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100245q%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DCruz-Lopez%26aufirst%3DO.%26aulast%3DLopez%2BCara%26aufirst%3DC.%26aulast%3DCarrion%26aufirst%3DM.%2BD.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520antitumor%2520activity%2520of%25201%252C5-disubstituted%25201%252C2%252C4-triazoles%2520as%2520cis-restricted%2520combretastatin%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4248%26epage%3D4258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Congiu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocco, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onnis, V.</span><span> </span><span class="NLM_article-title">Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">989</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=989-993&author=C.+Congiuauthor=M.+T.+Coccoauthor=V.+Onnis&title=Design%2C+synthesis%2C+and+in+vitro+antitumor+activity+of+new+1%2C4-diarylimidazole-2-ones+and+their+2-thione+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCongiu%26aufirst%3DC.%26aulast%3DCocco%26aufirst%3DM.%2BT.%26aulast%3DOnnis%26aufirst%3DV.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520in%2520vitro%2520antitumor%2520activity%2520of%2520new%25201%252C4-diarylimidazole-2-ones%2520and%2520their%25202-thione%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D989%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesberger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overmoyer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makkar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stambler, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCrae, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remick, S. C.</span><span> </span><span class="NLM_article-title">A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">3408</span><span class="NLM_x">–</span> <span class="NLM_lpage">3416</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=3408-3416&author=A.+Dowlatiauthor=K.+Robertsonauthor=M.+Cooneyauthor=W.+P.+Petrosauthor=M.+Stratfordauthor=J.+Jesbergerauthor=N.+Rafieauthor=B.+Overmoyerauthor=V.+Makkarauthor=B.+Stamblerauthor=A.+Taylorauthor=J.+Waasauthor=J.+S.+Lewinauthor=K.+R.+McCraeauthor=S.+C.+Remick&title=A+phase+I+pharmacokinetic+and+translational+study+of+the+novel+vascular+targeting+agent+combretastatin+A-4+phosphate+on+a+single-dose+intravenous+schedule+in+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DK.%26aulast%3DCooney%26aufirst%3DM.%26aulast%3DPetros%26aufirst%3DW.%2BP.%26aulast%3DStratford%26aufirst%3DM.%26aulast%3DJesberger%26aufirst%3DJ.%26aulast%3DRafie%26aufirst%3DN.%26aulast%3DOvermoyer%26aufirst%3DB.%26aulast%3DMakkar%26aufirst%3DV.%26aulast%3DStambler%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DWaas%26aufirst%3DJ.%26aulast%3DLewin%26aufirst%3DJ.%2BS.%26aulast%3DMcCrae%26aufirst%3DK.%2BR.%26aulast%3DRemick%26aufirst%3DS.%2BC.%26atitle%3DA%2520phase%2520I%2520pharmacokinetic%2520and%2520translational%2520study%2520of%2520the%2520novel%2520vascular%2520targeting%2520agent%2520combretastatin%2520A-4%2520phosphate%2520on%2520a%2520single-dose%2520intravenous%2520schedule%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D3408%26epage%3D3416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbraith, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sena, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gumbrell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. M.</span><span> </span><span class="NLM_article-title">Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2815</span><span class="NLM_x">–</span> <span class="NLM_lpage">2822</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1200%2FJCO.2003.05.185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12807934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=2815-2822&author=G.+J.+S.+Rustinauthor=S.+M.+Galbraithauthor=H.+Andersonauthor=M.+Stratfordauthor=L.+K.+Folkesauthor=L.+Senaauthor=L.+Gumbrellauthor=P.+M.+Price&title=Phase+I+clinical+trial+of+weekly+combretastatin+A4+phosphate%3A+clinical+and+pharmacokinetic+results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results</span></div><div class="casAuthors">Rustin, Gordon J. S.; Galbraith, Susan M.; Anderson, Helen; Stratford, Michael; Folkes, Lisa K.; Sena, Luiza; Gumbrell, Lindsey; Price, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2815-2822</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors.  The drug was delivered by a 10-min weekly infusion for 3 wk followed by a week gap, with intrapatient dose escalation.  Dose escalation was accomplished by doubling until grade 2 toxicity was seen.  The starting dose was 5 mg/m2.  Thirty-four patients received 167 infusions.  CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized to the glucuronide.  CA4 area under the curve (AUC) increased from 0.169 at 5 mg/m2 to 3.29 μmol/h/L at 114 mg/m2.  The mean CA4 AUC in eight patients at 68 mg/m2 was 2.33 μmol/h/L compared with 5.8 μmol/h/L at 25 mg/kg (the lowest ED) in the mouse.  The only toxicity that possibly was related to the drug dose up to 40 mg/m2 was tumor pain.  Dose-limiting toxicity was reversible ataxia at 114 mg/m2, vasovagal syncope and motor neuropathy at 88 mg/m2, and fatal ischemia in previously irradiated bowel at 52 mg/m2.  Other drug-related grade 2 or higher toxicities seen in more than one patient were pain, lymphopenia, fatigue, anemia, diarrhea, hypertension, hypotension, vomiting, visual disturbance, and dyspnea.  One patient at 68 mg/m2 had improvement in liver metastases of adrenocortical carcinoma.  CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg/m2; these are doses at which tumor blood flow redn. has been recorded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqITxI8x4o-zLVg90H21EOLACvtfcHk0ljisFDAqfVzEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKjsLk%253D&md5=1543943847e0f14e61addc1d38ce3100</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.05.185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.05.185%26sid%3Dliteratum%253Aachs%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26aulast%3DGalbraith%26aufirst%3DS.%2BM.%26aulast%3DAnderson%26aufirst%3DH.%26aulast%3DStratford%26aufirst%3DM.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DSena%26aufirst%3DL.%26aulast%3DGumbrell%26aufirst%3DL.%26aulast%3DPrice%26aufirst%3DP.%2BM.%26atitle%3DPhase%2520I%2520clinical%2520trial%2520of%2520weekly%2520combretastatin%2520A4%2520phosphate%253A%2520clinical%2520and%2520pharmacokinetic%2520results%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D2815%26epage%3D2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Stevenson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haller, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giantonio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span> </span><span class="NLM_article-title">Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4428</span><span class="NLM_x">–</span> <span class="NLM_lpage">4438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1200%2FJCO.2003.12.986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=14645433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVajsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4428-4438&author=J.+P.+Stevensonauthor=M.+Rosenauthor=W.+J.+Sunauthor=M.+Gallagherauthor=D.+G.+Hallerauthor=D.+Vaughnauthor=B.+Giantonioauthor=R.+Zimmerauthor=W.+P.+Petrosauthor=M.+Stratfordauthor=D.+Chaplinauthor=S.+L.+Youngauthor=M.+Schnallauthor=P.+J.+O%E2%80%99Dwyer&title=Phase+I+trial+of+the+antivascular+agent+combretastatin+A4+phosphate+on+a+5-day+schedule+to+patients+with+cancer%3A+magnetic+resonance+imaging+evidence+for+altered+tumor+blood+flow"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow</span></div><div class="casAuthors">Stevenson, James P.; Rosen, Mark; Sun, Weijing; Gallagher, Maryann; Haller, Daniel G.; Vaughn, David; Giantonio, Bruce; Zimmer, Ross; Petros, William P.; Stratford, Michael; Chaplin, David; Young, Scott L.; Schnall, Mitchell; O'Dwyer, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4428-4438</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Combretastatin A4 (CA4) phosphate (CA4P) inhibits microtubule polymn. and is toxic to proliferating endothelial cells in vitro.  It causes reversible vascular shutdown in established tumors in vivo, consistent with an antivascular mechanism of action.  The present study investigated escalating doses of CA4P administered i.v. to patients with advanced cancer.  Patients and Methods: Patients with solid malignancies and good performance status received CA4P as a 10-min infusion daily for 5 days repeated every 3 wk.  Pharmacokinetic sampling was performed during cycle 1.  Patients receiving ≥ 52 mg/m2/d had serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies to measure changes in tumor perfusion with CA4P treatment.  Results: Thirty-seven patients received 133 treatment cycles.  CA4P dose levels ranged from 6 mg/m2 to 75 mg/m2 daily.  Severe pain at sites of known tumor was dose limiting at 75 mg/m2.  Dose-limiting cardiopulmonary toxicity (syncope and dyspnea or hypoxia) was noted as well in two patients treated at 75 mg/m2.  Other toxicities included hypotension, ataxia, dyspnea, nausea or vomiting, headache, and transient sensory neuropathy.  Plasma CA4P and CA4 area under the concn.-time curve and maximal concn. values increased linearly with dose.  Tumor perfusion, as measured by the first-order rate const. of gadolinium plasma to tissue transfer during DCE-MRI studies, was found to decrease in eight of 10 patients.  Relationships were also demonstrated between perfusion changes and pharmacokinetic indexes.  A partial response was obsd. in a patient with metastatic soft tissue sarcoma, and 14 patients exhibited disease stability for a min. of two cycles.  Conclusion: Doses of CA4P on a daily times five schedule of 52 to 65 mg/m2 were reasonably well-tolerated.  The 52 mg/m2 dose is recommended for further study based on cumulative phase 1 experience with CA4P.  Antitumor efficacy was obsd., and the use of DCE-MRI provided a valuable noninvasive measure of the vascular effects of CA4P treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC3zNAd2c3FrVg90H21EOLACvtfcHk0ljisFDAqfVzEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVajsrk%253D&md5=c5498364f4125668879a02622fa52c29</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.12.986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.12.986%26sid%3Dliteratum%253Aachs%26aulast%3DStevenson%26aufirst%3DJ.%2BP.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DW.%2BJ.%26aulast%3DGallagher%26aufirst%3DM.%26aulast%3DHaller%26aufirst%3DD.%2BG.%26aulast%3DVaughn%26aufirst%3DD.%26aulast%3DGiantonio%26aufirst%3DB.%26aulast%3DZimmer%26aufirst%3DR.%26aulast%3DPetros%26aufirst%3DW.%2BP.%26aulast%3DStratford%26aufirst%3DM.%26aulast%3DChaplin%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DS.%2BL.%26aulast%3DSchnall%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520antivascular%2520agent%2520combretastatin%2520A4%2520phosphate%2520on%2520a%25205-day%2520schedule%2520to%2520patients%2520with%2520cancer%253A%2520magnetic%2520resonance%2520imaging%2520evidence%2520for%2520altered%2520tumor%2520blood%2520flow%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4428%26epage%3D4438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Beerepoot, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radema, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span> </span><span class="NLM_article-title">Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1491</span><span class="NLM_x">–</span> <span class="NLM_lpage">1498</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1200%2FJCO.2005.02.7458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=16574998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFyksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=1491-1498&author=L.+V.+Beerepootauthor=S.+A.+Rademaauthor=E.+O.+Witteveenauthor=T.+Thomasauthor=C.+Wheelerauthor=S.+Kempinauthor=E.+E.+Voest&title=Phase+I+clinical+evaluation+of+weekly+administration+of+the+novel+vascular-targeting+agent%2C+ZD6126%2C+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors</span></div><div class="casAuthors">Beerepoot, Laurens V.; Radema, Sandra A.; Witteveen, Els O.; Thomas, Tawnie; Wheeler, Catherine; Kempin, Sanford; Voest, Emile E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1491-1498</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: ZD6126 is a novel vascular-targeting agent that induces selective effects on the morphol. of endothelial cells by disrupting the tubulin cytoskeleton.  This leads to cell detachment and tumor vessel congestion, resulting in extensive central necrosis in a range of tumor xenograft models.  Results from a phase I dose-escalation study of ZD6126 are reported.  Patients and Methods: Thirty-two patients with advanced cancer received weekly ZD6126 infusion (5 to 28 mg/m2).  Assessments for safety and pharmacokinetics were performed.  Circulating endothelial cells (CECs) were quantified as a pharmacodynamic marker of vascular damage.  Results: Maximum concns. of the active species were obsd. 5 to 25 min from the start of infusion, and decayed in a biexponential manner with a half-life of 1 to 3 h.  Maximum serum concn. and area under the time-concn. curve increased with dose in a linear fashion across the dose range of 5 to 28 mg/m2.  One patient treated at 10 mg/m2 with a history of ischemic heart disease experienced acute myocardial infarction 2 wk after drug discontinuation.  Four others had asymptomatic creatine phosphokinase-muscle-brain elevation.  Maximum-tolerated dose (MTD) was reached at 20 mg/m2/wk.  Dose-limiting toxicities at 28 mg/m2 were hypoxia caused by pulmonary embolism and an asymptomatic decrease in left ventricular ejection fraction.  No objective antitumor responses were obsd.  CEC levels increased in the hours after infusion, indicating potential effect of the compd. on the vasculature.  Conclusion: ZD6126 administered as a weekly infusion was clin. well tolerated.  The MTD was reached at 20 mg/m2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN6AH51OrSh7Vg90H21EOLACvtfcHk0lj4y-C3Mj2MJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFyksbg%253D&md5=1e9c22f9719fc1717eb3ffb51f1ee066</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.02.7458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.02.7458%26sid%3Dliteratum%253Aachs%26aulast%3DBeerepoot%26aufirst%3DL.%2BV.%26aulast%3DRadema%26aufirst%3DS.%2BA.%26aulast%3DWitteveen%26aufirst%3DE.%2BO.%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DWheeler%26aufirst%3DC.%26aulast%3DKempin%26aufirst%3DS.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26atitle%3DPhase%2520I%2520clinical%2520evaluation%2520of%2520weekly%2520administration%2520of%2520the%2520novel%2520vascular-targeting%2520agent%252C%2520ZD6126%252C%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D1491%26epage%3D1498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barge, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DelProposto, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLuca, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evelhoch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, C.</span><span> </span><span class="NLM_article-title">Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=159-167&author=P.+M.+LoRussoauthor=S.+M.+Gadgeelauthor=A.+Wozniakauthor=A.+J.+Bargeauthor=H.+K.+Jonesauthor=Z.+S.+DelPropostoauthor=P.+A.+DeLucaauthor=J.+L.+Evelhochauthor=S.+A.+Boernerauthor=C.+Wheeler&title=Phase+I+clinical+evaluation+of+ZD6126%2C+a+novel+vascular-targeting+agent%2C+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DBarge%26aufirst%3DA.%2BJ.%26aulast%3DJones%26aufirst%3DH.%2BK.%26aulast%3DDelProposto%26aufirst%3DZ.%2BS.%26aulast%3DDeLuca%26aufirst%3DP.%2BA.%26aulast%3DEvelhoch%26aufirst%3DJ.%2BL.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DWheeler%26aufirst%3DC.%26atitle%3DPhase%2520I%2520clinical%2520evaluation%2520of%2520ZD6126%252C%2520a%2520novel%2520vascular-targeting%2520agent%252C%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D159%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Delmonte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sessa, C.</span><span> </span><span class="NLM_article-title">AVE8062: a new combretastatin derivative vascular disrupting agent</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1541</span><span class="NLM_x">–</span> <span class="NLM_lpage">1548</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1541-1548&author=A.+Delmonteauthor=C.+Sessa&title=AVE8062%3A+a+new+combretastatin+derivative+vascular+disrupting+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DSessa%26aufirst%3DC.%26atitle%3DAVE8062%253A%2520a%2520new%2520combretastatin%2520derivative%2520vascular%2520disrupting%2520agent%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1541%26epage%3D1548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Salmon, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemann, D. W.</span><span> </span><span class="NLM_article-title">Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4090</span><span class="NLM_x">–</span> <span class="NLM_lpage">4094</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1078-0432.CCR-06-0163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=16818709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVaksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4090-4094&author=H.+W.+Salmonauthor=D.+W.+Siemann&title=Effect+of+the+second-generation+vascular+disrupting+agent+OXi4503+on+tumor+vascularity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity</span></div><div class="casAuthors">Salmon, Howard W.; Siemann, Dietmar W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4090-4094</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: As first-generation small-mol. vascular disrupting agents (VDA) have begun to enter clin. trials, second-generation agents are under active development.  One such agent is the combretastatin A4 disodium phosphate (CA4P) analog OXi4503 (CA1P).  Exptl. Design: C3H/HeJ mice bearing KHT sarcomas were treated with CA4P and OXi4503 and the effect on tumor vasculature was detd. by evaluating the extent of vascular shutdown (Hoechst-33342 vessel staining) and tumor perfusion inhibition (dynamic contrast-enhanced magnetic resonance imaging).  Dynamic contrast-enhanced magnetic resonance imaging and tumor necrosis end points also were used to examine the pathophysiol. tumor effects following repeated exposures to these agents.  Results: Single doses of either agent (CA4P, 100 mg/kg; OXi4503, 25 mg/kg) resulted in an 80% to 90% redn. in tumor perfusion 4 h after treatment.  Whereas recovery in tumor perfusion was obsd. 48 h posttreatment, this recovery was significantly slower in mice treated with OXi4503.  Tumors re-treated with either VDA 72 h after the first drug exposure showed a similar redn. and recovery in tumor perfusion.  Histol. evidence showed the presence of a smaller viable rim after exposure to OXi4503 than that obsd. after CA4P treatment.  Furthermore, the extent of recovery of tumor necrosis 72 h after drug treatment was less for OXi4053.  Conclusions: The present studies show that the second-generation VDA OXi4503 possesses significant antivascular effects in solid tumors.  Importantly, the vasculature of tumors of mice that had received an initial dose this agent was as responsive to a subsequent treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgCf_4-SNSdrVg90H21EOLACvtfcHk0lj4y-C3Mj2MJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVaksrY%253D&md5=fe8670c2b50177c5e8510454fe1bb34c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0163%26sid%3Dliteratum%253Aachs%26aulast%3DSalmon%26aufirst%3DH.%2BW.%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26atitle%3DEffect%2520of%2520the%2520second-generation%2520vascular%2520disrupting%2520agent%2520OXi4503%2520on%2520tumor%2520vascularity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D4090%26epage%3D4094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Patterson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1078-0432.CCR-11-2414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=22235096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1415-1425&author=D.+M.+Pattersonauthor=M.+Zweifelauthor=M.+R.+Middletonauthor=P.+M.+Priceauthor=L.+K.+Folkesauthor=M.+R.+L.+Stratfordauthor=P.+Rossauthor=S.+Halfordauthor=J.+Petersauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=A.+R.+Padhaniauthor=G.+J.+S.+Rustin&title=Phase+I+clinical+and+pharmacokinetic+evaluation+of+the+vascular-disrupting+agent+OXi4503+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Patterson, Dan M.; Zweifel, Martin; Middleton, Mark R.; Price, Patricia M.; Folkes, Lisa K.; Stratford, Michael R. L.; Ross, Phil; Halford, Sarah; Peters, Jane; Balkissoon, Jai; Chaplin, Dai J.; Padhani, Anwar R.; Rustin, Gordon J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1415-1425</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Preclin. studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clin. evaluated vascular-disrupting agents.  Exptl. Design: Escalating doses of OXi4503 were given i.v. over 10 min on days 1, 8, and 15 every 28 days to patients with advanced solid tumors.  RESULTS: Doses were escalated in single-patient cohorts from 0.06 to 1.92 mg/m2, then expanded cohorts to 15.4 mg/m2 in 43 patients.  Common adverse drug reactions were hypertension, tumor pain, anemia, lymphopenia, and easily controllable nausea/vomiting and fatigue.  Five patients experienced different drug-related dose-limiting toxicities, atrial fibrillation, increased troponin, blurred vision, diplopia, and tumor lysis.  Prophylactic amlodipine failed to prevent adverse events.  Pharmacokinetics showed dose-dependent linear increases in peak plasma concns. and area under the curve value of OXi4503.  One partial response was seen in a heavily pretreated patient with ovarian cancer.  Dynamic contrast-enhanced MRI confirmed a dose effect and showed significant antivascular effects in 10 of 13 patients treated at doses of 11 mg/m2 or higher.  CONCLUSIONS: The max. tolerated dose was 8.5 mg/m2 but escalation to 14 mg/m2 was possible with only temporary reversible cerebrovascular toxicity by excluding hypertensive patients.  As a tumor response was seen at 14 mg/m2 and max. tumor perfusion redns. were seen at doses of 11 mg/m2 or higher, the recommended phase II dose is from 11 to 14 mg/m2.  Clin Cancer Res; 18(5); 1415-25.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgz59a0dQud7Vg90H21EOLACvtfcHk0lj4y-C3Mj2MJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wlurc%253D&md5=9414d480dc5eef26ec066054dc96b124</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2414%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BM.%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DPrice%26aufirst%3DP.%2BM.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DRoss%26aufirst%3DP.%26aulast%3DHalford%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DJ.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520I%2520clinical%2520and%2520pharmacokinetic%2520evaluation%2520of%2520the%2520vascular-disrupting%2520agent%2520OXi4503%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1415%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Lippert, J. W.</span><span> </span><span class="NLM_article-title">Vascular disrupting agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=605-615&author=J.+W.+Lippert&title=Vascular+disrupting+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLippert%26aufirst%3DJ.%2BW.%26atitle%3DVascular%2520disrupting%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D605%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Cai, S. X.</span><span> </span><span class="NLM_article-title">Small molecule vascular disrupting agents: potential new drugs for cancer treatment</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=79-101&author=S.+X.+Cai&title=Small+molecule+vascular+disrupting+agents%3A+potential+new+drugs+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DS.%2BX.%26atitle%3DSmall%2520molecule%2520vascular%2520disrupting%2520agents%253A%2520potential%2520new%2520drugs%2520for%2520cancer%2520treatment%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D79%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Griggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesketh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindle, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, E. D.</span><span> </span><span class="NLM_article-title">Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">835</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1054%2Fbjoc.2000.1653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=11259100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVGrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2001&pages=832-835&author=J.+Griggsauthor=R.+Heskethauthor=G.+A.+Smithauthor=K.+M.+Brindleauthor=J.+C.+Metcalfeauthor=G.+A.+Thomasauthor=E.+D.+Williams&title=Combretastatin-A4+disrupts+neovascular+development+in+non-neoplastic+tissue"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue</span></div><div class="casAuthors">Griggs, J.; Hesketh, R.; Smith, G. A.; Brindle, K. M.; Metcalfe, J. C.; Thomas, G. A.; Williams, E. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">832-835</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Combretastatin-A4 phosphate (cis-CA-4) is a tubulin-binding agent currently undergoing clin. trials as an anti-tumor drug.  We have investigated whether CA-4 functions as a tumor-specific anti-vascular agent using the hyperplastic thyroid as a novel in vivo model of neovascularization.  CA-4 elicited pathol. changes in normal tissue, manifested as the induction of multiple, discrete intravascular thrombi.  These vascular-damaging effects indicate that CA-4P does not function as a tumor-specific agent but targets neovasculature irresp. of the primary angiogenic stimulus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGyDxpgfxzrVg90H21EOLACvtfcHk0liM1MAfPtIP6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVGrt7g%253D&md5=ce21a9cfa07aea8e9c41f9ca7a917c4f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2000.1653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2000.1653%26sid%3Dliteratum%253Aachs%26aulast%3DGriggs%26aufirst%3DJ.%26aulast%3DHesketh%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DG.%2BA.%26aulast%3DBrindle%26aufirst%3DK.%2BM.%26aulast%3DMetcalfe%26aufirst%3DJ.%2BC.%26aulast%3DThomas%26aufirst%3DG.%2BA.%26aulast%3DWilliams%26aufirst%3DE.%2BD.%26atitle%3DCombretastatin-A4%2520disrupts%2520neovascular%2520development%2520in%2520non-neoplastic%2520tissue%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D84%26spage%3D832%26epage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hasani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighl, N.</span><span> </span><span class="NLM_article-title">Classification and toxicities of vascular disrupting agents</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.3816%2FCLC.2011.n.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=21273175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlektbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=18-25&author=A.+Hasaniauthor=N.+Leighl&title=Classification+and+toxicities+of+vascular+disrupting+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Classification and toxicities of vascular disrupting agents</span></div><div class="casAuthors">Hasani, Arman; Leighl, Natasha</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-25</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">CIG Media Group, LP</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are an exciting new group of targeted therapies under active clin. research in many solid tumors, in particular, lung cancer.  Small-mol. VDAs are the focus of current clin. research, and consist of the flavonoids and the tubulin-binding agents.  Toxicities of single-agent VDAs are characterized by acute, transient, and generally noncumulative side effects including headaches, nausea and vomiting, tumor pain, hypertension, and tachycardia.  Flavonoid agents can also cause infusion site pain, visual disturbances, electrocardiac abnormalities, and symptoms consistent with an acute release of serotonin.  Tubulin-binding agents can result in cardiac ischemia, abdominal pain, neuromotor abnormalities and cerebellar ataxia, and acute hemodynamic changes.  Clin. trials investigating VDAs in combination with traditional chemotherapy have also shown the potential for significant pharmacol. and adverse toxicity interactions.  Further research will need to focus on pharmacokinetic and pharmacodynamic parameters to optimize dosing schedules, det. effective combinations with chemotherapy, and minimize toxicities assocd. with VDAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFp5v18P6467Vg90H21EOLACvtfcHk0liM1MAfPtIP6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlektbo%253D&md5=22784c563952161686eb2b4f7294ee68</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3816%2FCLC.2011.n.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLC.2011.n.002%26sid%3Dliteratum%253Aachs%26aulast%3DHasani%26aufirst%3DA.%26aulast%3DLeighl%26aufirst%3DN.%26atitle%3DClassification%2520and%2520toxicities%2520of%2520vascular%2520disrupting%2520agents%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2011%26volume%3D12%26spage%3D18%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeves, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1093%2Fannonc%2Fmdq708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=21273348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2036-2041&author=M.+Zweifelauthor=G.+C.+Jaysonauthor=N.+S.+Reedauthor=R.+Osborneauthor=B.+Hassanauthor=J.+Ledermannauthor=G.+Shreevesauthor=L.+Poupardauthor=S.+P.+Luauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=G.+J.+S.+Rustin&title=Phase+II+trial+of+combretastatin+A4+phosphate%2C+carboplatin%2C+and+paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span></div><div class="casAuthors">Zweifel M; Jayson G C; Reed N S; Osborne R; Hassan B; Ledermann J; Shreeves G; Poupard L; Lu S-P; Balkissoon J; Chaplin D J; Rustin G J S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2036-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.  PATIENTS AND METHODS:  Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks.  RESULTS:  Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited.  Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia.  Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine.  The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%.  CONCLUSIONS:  The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P.  A planned randomised trial will test this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKPQKWSYY7Sqe0F5ixvZgXfW6udTcc2eYnWCm_932H-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D&md5=6b960ad4dcccdbbc67ffa9398e85d2be</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq708%26sid%3Dliteratum%253Aachs%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DReed%26aufirst%3DN.%2BS.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DHassan%26aufirst%3DB.%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DShreeves%26aufirst%3DG.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%2BP.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520II%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%252C%2520carboplatin%252C%2520and%2520paclitaxel%2520in%2520patients%2520with%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2036%26epage%3D2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Rustin, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeves, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span> </span><span class="NLM_article-title">A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1038%2Fsj.bjc.6605650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=20389300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1OnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=1355-1360&author=G.+J.+Rustinauthor=G.+Shreevesauthor=P.+D.+Nathanauthor=A.+Gayaauthor=T.+S.+Ganesanauthor=D.+Wangauthor=J.+Boxallauthor=L.+Poupardauthor=D.+J.+Chaplinauthor=M.+R.+L.+Stratfordauthor=J.+Balkissoonauthor=M.+Zweifel&title=A+phase+Ib+trial+of+CA4P+%28combretastatin+A-4+phosphate%29%2C+carboplatin%2C+and+paclitaxel+in+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer</span></div><div class="casAuthors">Rustin, G. J.; Shreeves, G.; Nathan, P. D.; Gaya, A.; Ganesan, T. S.; Wang, D.; Boxall, J.; Poupard, L.; Chaplin, D. J.; Stratford, M. R. L.; Balkissoon, J.; Zweifel, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1355-1360</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The vascular disrupting agent combretastatin A4 phosphate (CA4P) causes major regression of animal tumors when given as combination therapy.  Methods: Patients with advanced cancer refractory to std. therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin.  Results: Combretastatin A4 phosphate was escalated from 36 to 54 mg m-2 with the carboplatin area under the concn. curve (AUC) 4-5, from 27 to 54 mg m-2 with paclitaxel 135-175 mg m-2, and from 54 to 72 mg m-2 with carboplatin AUC 5 and paclitaxel 175 mg m-2.  Grade 3 or 4 neutropenia was seen in 17%, and thrombocytopenia only in 4% of 46 patients.  Grade 1-3 hypertension (26% of patients) and grade 1-3 tumor pain (65% of patients) were the most typical non-haematol. toxicities.  Dose-limiting toxicity of grade 3 hypertension or grade 3 ataxia was seen in two patients at 72 mg m-2.  Responses were seen in 10 of 46 (22%) patients with ovarian, esophageal, small-cell lung cancer, and melanoma.  Conclusion: The combination of CA4P with carboplatin and paclitaxel was well tolerated in the majority of patients with adequate premedication and had antitumor activity in patients who were heavily pretreated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxlNCzTLZmbVg90H21EOLACvtfcHk0ljRfnv-dorJGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1OnurY%253D&md5=00921730bb1bce41c4f3cac0c7501402</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605650%26sid%3Dliteratum%253Aachs%26aulast%3DRustin%26aufirst%3DG.%2BJ.%26aulast%3DShreeves%26aufirst%3DG.%26aulast%3DNathan%26aufirst%3DP.%2BD.%26aulast%3DGaya%26aufirst%3DA.%26aulast%3DGanesan%26aufirst%3DT.%2BS.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBoxall%26aufirst%3DJ.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DZweifel%26aufirst%3DM.%26atitle%3DA%2520phase%2520Ib%2520trial%2520of%2520CA4P%2520%2528combretastatin%2520A-4%2520phosphate%2529%252C%2520carboplatin%252C%2520and%2520paclitaxel%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26spage%3D1355%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Ciric, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sersa, G.</span><span> </span><span class="NLM_article-title">Radiotherapy in combination with vascular-targeted therapies</span> <span class="citation_source-journal">Radiol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.2478%2Fv10019-010-0025-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=22933894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1GgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=67-78&author=E.+Ciricauthor=G.+Sersa&title=Radiotherapy+in+combination+with+vascular-targeted+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy in combination with vascular-targeted therapies</span></div><div class="casAuthors">Ciric, Eva; Sersa, Gregor</div><div class="citationInfo"><span class="NLM_cas:title">Radiology and Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">67-78</span>CODEN:
                <span class="NLM_cas:coden">RONCEM</span>;
        ISSN:<span class="NLM_cas:issn">1318-2099</span>.
    
            (<span class="NLM_cas:orgname">Radiology and Oncology</span>)
        </div><div class="casAbstract">A review.  Background. Given the crit. role of tumor vasculature in tumor development, considerable efforts have been spent on developing therapeutic strategies targeting the tumor vascular network.  A variety of agents have been developed, with two general approaches being pursued.  Antiangiogenic agents (AAs) aim to interfere with the process of angiogenesis, preventing new tumor blood vessel formation.  Vascular-disrupting agents (VDAs) target existing tumor vessels causing tumor ischemia and necrosis.  Despite their great therapeutic potential, it has become clear that their greatest clin. utility may lie in combination with conventional anticancer therapies.  Radiotherapy is a widely used treatment modality for cancer with its distinct therapeutic challenges.  Thus, combining the two approaches seems reasonable.  Conclusions. Strong biol. rationale exist for combining vascular-targeted therapies with radiation.  AAs and VDAs were shown to alter the tumor microenvironment in such a way as to enhance responses to radiation.  The results of preclin. and early clin. studies have confirmed the therapeutic potential of this new treatment strategy in the clin. setting.  However, concerns about increased normal tissue toxicity, have been raised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRfiUGL_14qbVg90H21EOLACvtfcHk0ljRfnv-dorJGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1GgsLo%253D&md5=7f880fc4134cae459e1f8b108c1efbc2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2478%2Fv10019-010-0025-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2478%252Fv10019-010-0025-9%26sid%3Dliteratum%253Aachs%26aulast%3DCiric%26aufirst%3DE.%26aulast%3DSersa%26aufirst%3DG.%26atitle%3DRadiotherapy%2520in%2520combination%2520with%2520vascular-targeted%2520therapies%26jtitle%3DRadiol.%2520Oncol.%26date%3D2010%26volume%3D44%26spage%3D67%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaya, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dancey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Othman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellsted, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, P.-s.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedley, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Violet, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malaroda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green,, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buscombe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begent, R. H.</span><span> </span><span class="NLM_article-title">A phase I trial of radioimmunotherapy with (131)I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4484</span><span class="NLM_x">–</span> <span class="NLM_lpage">4492</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1078-0432.CCR-09-0035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=19549771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFajt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4484-4492&author=T.+Meyerauthor=A.+M.+Gayaauthor=G.+Danceyauthor=M.+R.+L.+Stratfordauthor=S.+Othmanauthor=S.+K.+Sharmaauthor=D.+Wellstedauthor=N.+J.+Taylorauthor=J.+J.+Stirlingauthor=L.+Poupardauthor=L.+K.+Folkesauthor=P.-s.+Chanauthor=R.+B.+Pedleyauthor=K.+A.+Chesterauthor=K.+Owenauthor=J.+A.+Violetauthor=A.+Malarodaauthor=A.+J.+Green%2Cauthor=J.+Buscombeauthor=A.+R.+Padhaniauthor=G.+J.+Rustinauthor=R.+H.+Begent&title=A+phase+I+trial+of+radioimmunotherapy+with+%28131%29I-A5B7+anti-CEA+antibody+in+combination+with+combretastatin-A4-phosphate+in+advanced+gastrointestinal+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas</span></div><div class="casAuthors">Meyer, Tim; Gaya, Andrew M.; Dancey, Gairin; Stratford, Michael R. L.; Othman, Shokri; Sharma, Surinder K.; Wellsted, David; Taylor, N. Jane; Stirling, J. James; Poupard, Linda; Folkes, Lisa K.; Chan, Pei-san; Pedley, R. Barbara; Chester, Kerry A.; Owen, Karen; Violet, John A.; Malaroda, Alessandra; Green, Alan J.; Buscombe, John; Padhani, Anwar R.; Rustin, Gordon J.; Begent, Richard H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4484-4492</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In preclin. models, radioimmunotherapy with 131I-A5B7 anti-carcinoembryonic antigen (CEA) antibody (131I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone.  We conducted a phase I trial detg. the dose-limiting toxicity (DLT), max. tolerated dose, efficacy, and mechanism of this combination in patients with gastrointestinal adenocarcinomas.  Exptl. Design: Patients had CEA of 10 to 1,000 μg/L, QTc ≤450 ms, no cardiac arrhythmia/ischemia, and adequate hematol./biochem.  Tumor was suitable for blood flow anal. by dynamic contrast enhanced-magnetic resonance imaging (MRI).  The starting dose was 1,800 MBq/m2 of 131I-A5B7 on day 1 and 45 mg/m2 CA4P given 48 and 72 h post-131I-A5B7, then weekly for up to seven weeks.  RESULTS: Twelve patients were treated, with mean age of 63 years (range, 32-77).  Two of six patients at the first dose level had DLTs (grade 4 neutropenia).  The dose was reduced to 1,600 MBq/m2, and CA4P escalated to 54 mg/m2.  Again, two of six patients had DLTs (neutropenia).  Of ten assessable patients, three had stable disease and seven had progressive disease.  Single-photon emission computed tomog. confirmed tumor antibody uptake in all 10 patients.  DCE-MRI confirmed falls in kinetic parameters (Ktrans/IAUGC60) in 9 of 12 patients.  The change of both pharmacokinetic parameters reached a level expected to produce efficacy in one patient who had a minor response on computed tomog. and a reduced serum tumor marker level.  CONCLUSIONS: This is believed to be the first trial reporting the combination of radioimmunotherapy and vascular disruptive agent; each component was shown to function, and myelosuppression was dose-limiting.  Optimal dose and timing of CA4P, and moderate improvements in the performance of radioimmunotherapy seem necessary for efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9depZ77fXn7Vg90H21EOLACvtfcHk0ljRfnv-dorJGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFajt7o%253D&md5=4b579ec5d7a3ec78afe3c41441409d5e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0035%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DGaya%26aufirst%3DA.%2BM.%26aulast%3DDancey%26aufirst%3DG.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DOthman%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DWellsted%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DN.%2BJ.%26aulast%3DStirling%26aufirst%3DJ.%2BJ.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DChan%26aufirst%3DP.-s.%26aulast%3DPedley%26aufirst%3DR.%2BB.%26aulast%3DChester%26aufirst%3DK.%2BA.%26aulast%3DOwen%26aufirst%3DK.%26aulast%3DViolet%26aufirst%3DJ.%2BA.%26aulast%3DMalaroda%26aufirst%3DA.%26aulast%3DGreen%252C%26aufirst%3DA.%2BJ.%26aulast%3DBuscombe%26aufirst%3DJ.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%26aulast%3DBegent%26aufirst%3DR.%2BH.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520radioimmunotherapy%2520with%2520%2528131%2529I-A5B7%2520anti-CEA%2520antibody%2520in%2520combination%2520with%2520combretastatin-A4-phosphate%2520in%2520advanced%2520gastrointestinal%2520carcinomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4484%26epage%3D4492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Atkinson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falconer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siller, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, J. H.</span><span> </span><span class="NLM_article-title">Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">6902</span><span class="NLM_x">–</span> <span class="NLM_lpage">6912</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F0008-5472.CAN-10-1440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=20663911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2rsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=6902-6912&author=J.+M.+Atkinsonauthor=R.+A.+Falconerauthor=D.+R.+Edwardsauthor=C.+J.+Penningtonauthor=C.+S.+Sillerauthor=S.+D.+Shnyderauthor=M.+C.+Bibbyauthor=L.+H.+Pattersonauthor=P.+M.+Loadmanauthor=J.+H.+Gill&title=Development+of+a+novel+tumor-targeted+vascular+disrupting+agent+activated+by+membrane-type+matrix+metalloproteinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases</span></div><div class="casAuthors">Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, Dylan R.; Pennington, Caroline J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6902-6912</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage.  Several VDAs have progressed into early clin. trials, but their therapeutic value seems to be compromised by systemic toxicity.  In this report, we describe the design and characterization of a novel VDA, ICT2588, that is nontoxic until activated specifically in the tumor by membrane-type 1 matrix metalloproteinase (MT1-MMP).  HT1080 cancer cells expressing MT1-MMP were selectively chemosensitive to ICT2588, whereas MCF7 cells that did not express MT1-MMP were nonresponsive.  Preferential hydrolysis of ICT2588 to its active metabolite (ICT2552) was obsd. in tumor homogenates of HT1080 relative to MCF7 homogenates, mouse plasma, and liver homogenate.  ICT2588 activation was inhibited by the MMP inhibitor ilomastat.  In HT1080 tumor-bearing mice, ICT2588 administration resulted in the formation of the active metabolite, diminution of tumor vasculature, and hemorrhagic necrosis of the tumor.  The antitumor activity of ICT2588 was superior to its active metabolite, exhibiting reduced toxicity, improved therapeutic index, enhanced pharmacodynamic effect, and greater efficacy.  Coadministration of ICT2588 with doxorubicin resulted in a significant antitumor response (22.6 d growth delay), which was superior to the administration of ICT2588 or doxorubicin as a single agent, including complete tumor regressions.  Our findings support the clin. development of ICT2588, which achieves selective VDA targeting based on MT-MMP activation in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYqbra5OjQWbVg90H21EOLACvtfcHk0lgFAZz7dG53JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2rsb7I&md5=e41bcd4a06c42051f1a406a58425b24e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1440%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DJ.%2BM.%26aulast%3DFalconer%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DD.%2BR.%26aulast%3DPennington%26aufirst%3DC.%2BJ.%26aulast%3DSiller%26aufirst%3DC.%2BS.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DBibby%26aufirst%3DM.%2BC.%26aulast%3DPatterson%26aufirst%3DL.%2BH.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DGill%26aufirst%3DJ.%2BH.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520tumor-targeted%2520vascular%2520disrupting%2520agent%2520activated%2520by%2520membrane-type%2520matrix%2520metalloproteinases%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D6902%26epage%3D6912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rischin, D.</span><span> </span><span class="NLM_article-title">Phase I, pharmacokinetic, and pharmacodynamic evaluation of BNC105P, a novel anticancer agent that is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=27&author=J.+Desaiauthor=S.+Wongauthor=G.+Chongauthor=D.+Bibbyauthor=A.+Leskeauthor=G.+Kremmidiotisauthor=M.+Rosenauthor=D.+Rischin&title=Phase+I%2C+pharmacokinetic%2C+and+pharmacodynamic+evaluation+of+BNC105P%2C+a+novel+anticancer+agent+that+is+both+a+vascular+disrupting+agent+%28VDA%29+and+an+inhibitor+of+cancer+cell+proliferation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DChong%26aufirst%3DG.%26aulast%3DBibby%26aufirst%3DD.%26aulast%3DLeske%26aufirst%3DA.%26aulast%3DKremmidiotis%26aufirst%3DG.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DRischin%26aufirst%3DD.%26atitle%3DPhase%2520I%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamic%2520evaluation%2520of%2520BNC105P%252C%2520a%2520novel%2520anticancer%2520agent%2520that%2520is%2520both%2520a%2520vascular%2520disrupting%2520agent%2520%2528VDA%2529%2520and%2520an%2520inhibitor%2520of%2520cancer%2520cell%2520proliferation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26spage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavranos, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, B.</span><span> </span><span class="NLM_article-title">BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">–</span> <span class="NLM_lpage">1573</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1535-7163.MCT-09-0815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=20515948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1562-1573&author=G.+Kremmidiotisauthor=A.+F.+Leskeauthor=T.+C.+Lavranosauthor=D.+Beaumontauthor=J.+Gasicauthor=A.+Hallauthor=M.+O%E2%80%99Callaghanauthor=C.+A.+Matthewsauthor=B.+Flynn&title=BNC105%3A+a+novel+tubulin+polymerization+inhibitor+that+selectively+disrupts+tumor+vasculature+and+displays+single-agent+antitumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy</span></div><div class="casAuthors">Kremmidiotis, Gabriel; Leske, Annabell F.; Lavranos, Tina C.; Beaumont, Donna; Gasic, Jelena; Hall, Allison; O'Callaghan, Michael; Matthews, Clayton A.; Flynn, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1562-1573</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis.  Tumor vascular disruption is a therapeutic strategy of great potential; however, VDAs currently under development display a narrow therapeutic margin, with cardiovascular toxicity posing a dose-limiting obstacle.  Discovery of new VDAs, which display a wider therapeutic margin, may allow attainment of improved clin. outcomes.  To identify such compds., we used an in vitro selectivity screening approach that exploits the fact that tumor endothelial cells are in a const. state of activation and angiogenesis and do not undergo senescence.  Our effort yielded the compd. BNC105.  This compd. acts as a tubulin polymn. inhibitor and displays 80-fold higher potency against endothelial cells that are actively proliferating or are engaged in the formation of in vitro capillaries compared with nonproliferating endothelial cells or endothelium found in stable capillaries.  This selectivity was not obsd. with CA4, a VDA currently under evaluation in phase III clin. trials.  BNC105 is more potent and offers a wider therapeutic window.  CA4 produces 90% vascular disruption at its no obsd. adverse event level (NOAEL), whereas BNC105 causes 95% vascular disruption at 1/8th of its NOAEL.  Tissue distribution anal. of BNC105 in tumor-bearing mice showed that while the drug is cleared from all tissues 24 h after administration, it is still present at high concns. within the solid tumor mass.  Furthermore, BNC105 treatment causes tumor regressions with complete tumor clearance in 20% of treated animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLcKlwS1G0NrVg90H21EOLACvtfcHk0lgFAZz7dG53JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsLk%253D&md5=94a9f916319585f07bd4b8467b1b5a89</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0815%26sid%3Dliteratum%253Aachs%26aulast%3DKremmidiotis%26aufirst%3DG.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DLavranos%26aufirst%3DT.%2BC.%26aulast%3DBeaumont%26aufirst%3DD.%26aulast%3DGasic%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DC.%2BA.%26aulast%3DFlynn%26aufirst%3DB.%26atitle%3DBNC105%253A%2520a%2520novel%2520tubulin%2520polymerization%2520inhibitor%2520that%2520selectively%2520disrupts%2520tumor%2520vasculature%2520and%2520displays%2520single-agent%2520antitumor%2520efficacy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1562%26epage%3D1573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Flynn, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavranos, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostewicz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morizzi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span> </span><span class="NLM_article-title">Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[<i>b</i>]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6014</span><span class="NLM_x">–</span> <span class="NLM_lpage">6027</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200454y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6014-6027&author=B.+L.+Flynnauthor=G.+S.+Gillauthor=D.+W.+Grobelnyauthor=J.+H.+Chaplinauthor=D.+Paulauthor=A.+F.+Leskeauthor=T.+C.+Lavranosauthor=D.+K.+Chalmersauthor=S.+A.+Charmanauthor=E.+Kostewiczauthor=D.+M.+Shacklefordauthor=J.+Morizziauthor=E.+Hamelauthor=M.+K.+Jungauthor=G.+Kremmidiotis&title=Discovery+of+7-hydroxy-6-methoxy-2-methyl-3-%283%2C4%2C5-trimethoxybenzoyl%29benzo%5Bb%5Dfuran+%28BNC105%29%2C+a+tubulin+polymerization+inhibitor+with+potent+antiproliferative+and+tumor+vascular+disrupting+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm200454y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200454y%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DB.%2BL.%26aulast%3DGill%26aufirst%3DG.%2BS.%26aulast%3DGrobelny%26aufirst%3DD.%2BW.%26aulast%3DChaplin%26aufirst%3DJ.%2BH.%26aulast%3DPaul%26aufirst%3DD.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DLavranos%26aufirst%3DT.%2BC.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DKostewicz%26aufirst%3DE.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DJung%26aufirst%3DM.%2BK.%26aulast%3DKremmidiotis%26aufirst%3DG.%26atitle%3DDiscovery%2520of%25207-hydroxy-6-methoxy-2-methyl-3-%25283%252C4%252C5-trimethoxybenzoyl%2529benzo%255Bb%255Dfuran%2520%2528BNC105%2529%252C%2520a%2520tubulin%2520polymerization%2520inhibitor%2520with%2520potent%2520antiproliferative%2520and%2520tumor%2520vascular%2520disrupting%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6014%26epage%3D6027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span> </span><span class="NLM_article-title">Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2</span> <span class="citation_source-journal">Can. J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">2390</span><span class="NLM_x">–</span> <span class="NLM_lpage">2396</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1987&pages=2390-2396&author=G.+R.+Pettitauthor=S.+B.+Singh&title=Isolation%2C+structure%2C+and+synthesis+of+combretastatin+A-2%2C+A-3%2C+and+B-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DIsolation%252C%2520structure%252C%2520and%2520synthesis%2520of%2520combretastatin%2520A-2%252C%2520A-3%252C%2520and%2520B-2%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D1987%26volume%3D65%26spage%3D2390%26epage%3D2396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Cushman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarathnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of analogs of (<i>Z</i>)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethane as potential cytotoxic and antimitotic agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2293</span><span class="NLM_x">–</span> <span class="NLM_lpage">2306</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00090a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2293-2306&author=M.+Cushmanauthor=D.+Nagarathnamauthor=D.+Gopalauthor=H.+M.+Heauthor=C.+M.+Linauthor=E.+Hamel&title=Synthesis+and+evaluation+of+analogs+of+%28Z%29-1-%284-methoxyphenyl%29-2-%283%2C4%2C5-trimethoxyphenyl%29ethane+as+potential+cytotoxic+and+antimitotic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm00090a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00090a021%26sid%3Dliteratum%253Aachs%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DGopal%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DH.%2BM.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520analogs%2520of%2520%2528Z%2529-1-%25284-methoxyphenyl%2529-2-%25283%252C4%252C5-trimethoxyphenyl%2529ethane%2520as%2520potential%2520cytotoxic%2520and%2520antimitotic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2293%26epage%3D2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Gaukroger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadfield, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, A. T.</span><span> </span><span class="NLM_article-title">Structural requirements for the interaction of combretastatins with tubulin: How important is the trimethoxy unit?</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">3033</span><span class="NLM_x">–</span> <span class="NLM_lpage">3037</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=3033-3037&author=K.+Gaukrogerauthor=J.+A.+Hadfieldauthor=N.+J.+Lawrenceauthor=S.+Nolanauthor=A.+T.+McGown&title=Structural+requirements+for+the+interaction+of+combretastatins+with+tubulin%3A+How+important+is+the+trimethoxy+unit%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaukroger%26aufirst%3DK.%26aulast%3DHadfield%26aufirst%3DJ.%2BA.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DNolan%26aufirst%3DS.%26aulast%3DMcGown%26aufirst%3DA.%2BT.%26atitle%3DStructural%2520requirements%2520for%2520the%2520interaction%2520of%2520combretastatins%2520with%2520tubulin%253A%2520How%2520important%2520is%2520the%2520trimethoxy%2520unit%253F%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2003%26volume%3D1%26spage%3D3033%26epage%3D3037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Jordan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadfield, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, A. T.</span><span> </span><span class="NLM_article-title">Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1002%2F%28SICI%291098-1128%28199807%2918%3A4%3C259%3A%3AAID-MED3%3E3.0.CO%3B2-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=9664292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVeisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=259-296&author=A.+Jordanauthor=J.+A.+Hadfieldauthor=N.+J.+Lawrenceauthor=A.+T.+McGown&title=Tubulin+as+a+target+for+anticancer+drugs%3A+agents+which+interact+with+the+mitotic+spindle"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle</span></div><div class="casAuthors">Jordan, Allan; Hadfield, John A.; Lawrence, Nicholas J.; Mcgown, Alan T.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-296</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 193 refs.  Tubulin is the biochem. target for several clin. used anticancer drugs, including paclitaxel and the vinca alkaloids vincristine and vinblastine.  This review describes both the natural and synthetic agents which are known to interact with tubulin.  Syntheses of the more complex agents are referenced and the potential clin. use of the compds. is discussed.  This review describes the biochem. of tubulin, microtubules, and the mitotic spindle.  The agents are discussed in relation to the type of binding site on the protein with which they interact.  These are the colchicine, vinca alkaloid, rhizoxin/maytansine, and tubulin sulfhydryl binding sites.  Also included are the agents which either bind at other sites or unknown sites on tubulin.  The literature is reviewed up to Oct. 1997.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXj350MJMOy7Vg90H21EOLACvtfcHk0lgCyaBM5bkD1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVeisLY%253D&md5=c11865c6792d7989270ba2d7e891e1ed</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28199807%2918%3A4%3C259%3A%3AAID-MED3%3E3.0.CO%3B2-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528199807%252918%253A4%253C259%253A%253AAID-MED3%253E3.0.CO%253B2-U%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DA.%26aulast%3DHadfield%26aufirst%3DJ.%2BA.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DMcGown%26aufirst%3DA.%2BT.%26atitle%3DTubulin%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%253A%2520agents%2520which%2520interact%2520with%2520the%2520mitotic%2520spindle%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1998%26volume%3D18%26spage%3D259%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Lawrence, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadfield, J. A.</span><span> </span><span class="NLM_article-title">Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4</span> <span class="citation_source-journal">J. Fluorine Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1016%2FS0022-1139%2803%2900117-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1yqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2003&pages=101-108&author=N.+J.+Lawrenceauthor=L.+A.+Hepworthauthor=D.+Rennisonauthor=A.+T.+McGownauthor=J.+A.+Hadfield&title=Synthesis+and+anticancer+activity+of+fluorinated+analogues+of+combretastatin+A-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4</span></div><div class="casAuthors">Lawrence, Nicholas J.; Hepworth, Lucy A.; Rennison, David; McGown, Alan T.; Hadfield, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorine Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-108</span>CODEN:
                <span class="NLM_cas:coden">JFLCAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-1139</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The synthesis of a series of fluorinated benzaldehydes and their use in the Wittig synthesis of fluoro-substituted stilbenes is described. 3,5-Difluoro-4-hydroxybenzaldehyde and 3-fluoro-4-methoxybenzaldehyde are prepd. by Duff formylation of 3,5-difluorophenol and 2-fluoroanisole, resp.  2-Methoxy-3,4-difluorobenzaldehyde was obtained by Friedel-Crafts formylation of 2,3-difluoroanisole with α,α-dichloromethyl Me ether.  The aldehydes were used to make a series of fluorinated analogs of the anticancer combretastatins A-1, A-2 and A-4.  The in vitro anticancer properties of the fluoro combretastatins are reported.  The most active fluoro analog 3-deoxy-3-fluoro-combretastatin A-4 (Z-2) retains the potent cell growth inhibitory properties of CA-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUjL6IaBeQ2LVg90H21EOLACvtfcHk0lgCyaBM5bkD1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1yqs7s%253D&md5=7276d416c796d7221358e488d55c0abb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0022-1139%2803%2900117-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-1139%252803%252900117-9%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DHepworth%26aufirst%3DL.%2BA.%26aulast%3DRennison%26aufirst%3DD.%26aulast%3DMcGown%26aufirst%3DA.%2BT.%26aulast%3DHadfield%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520and%2520anticancer%2520activity%2520of%2520fluorinated%2520analogues%2520of%2520combretastatin%2520A-4%26jtitle%3DJ.%2520Fluorine%2520Chem.%26date%3D2003%26volume%3D123%26spage%3D101%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettitt, R. K.</span><span> </span><span class="NLM_article-title">Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (<i>Z</i>)- and (<i>E</i>)-combretastatin A-4</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4087</span><span class="NLM_x">–</span> <span class="NLM_lpage">4099</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0205797" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4087-4099&author=G.+R.+Pettitauthor=M.+R.+Rhodesauthor=D.+L.+Heraldauthor=E.+Hamelauthor=J.+M.+Schmidtauthor=R.+K.+Pettitt&title=Antineoplastic+agents.+445.+Synthesis+and+evaluation+of+structural+modifications+of+%28Z%29-+and+%28E%29-combretastatin+A-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm0205797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0205797%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DRhodes%26aufirst%3DM.%2BR.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DPettitt%26aufirst%3DR.%2BK.%26atitle%3DAntineoplastic%2520agents.%2520445.%2520Synthesis%2520and%2520evaluation%2520of%2520structural%2520modifications%2520of%2520%2528Z%2529-%2520and%2520%2528E%2529-combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4087%26epage%3D4099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Hatanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohsumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, T.</span><span> </span><span class="NLM_article-title">Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3371</span><span class="NLM_x">–</span> <span class="NLM_lpage">3374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3371-3374&author=T.+Hatanakaauthor=K.+Fujitaauthor=K.+Ohsumiauthor=R.+Nakagawaauthor=Y.+Fukudaauthor=Y.+Niheiauthor=Y.+Sugaauthor=Y.+Akiyamaauthor=T.+Tsuji&title=Novel+B-ring+modified+combretastatin+analogues%3A+syntheses+and+antineoplastic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DOhsumi%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DNihei%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DT.%26atitle%3DNovel%2520B-ring%2520modified%2520combretastatin%2520analogues%253A%2520syntheses%2520and%2520antineoplastic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3371%26epage%3D3374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Maya, A. B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, B. d.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelaez Lamamie de Clairac, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caballero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barasoain, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medarde, M.</span><span> </span><span class="NLM_article-title">Design, synthesis and cytotoxic activities of naphthyl analogues of combretastatin A-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2549</span><span class="NLM_x">–</span> <span class="NLM_lpage">2551</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2549-2551&author=A.+B.+S.+Mayaauthor=B.+d.+Reyauthor=R.+Pelaez+Lamamie+de+Clairacauthor=E.+Caballeroauthor=I.+Barasoainauthor=J.+M.+Andreuauthor=M.+Medarde&title=Design%2C+synthesis+and+cytotoxic+activities+of+naphthyl+analogues+of+combretastatin+A-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaya%26aufirst%3DA.%2BB.%2BS.%26aulast%3DRey%26aufirst%3DB.%2Bd.%26aulast%3DPelaez%2BLamamie%2Bde%2BClairac%26aufirst%3DR.%26aulast%3DCaballero%26aufirst%3DE.%26aulast%3DBarasoain%26aufirst%3DI.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DMedarde%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520cytotoxic%2520activities%2520of%2520naphthyl%2520analogues%2520of%2520combretastatin%2520A-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2549%26epage%3D2551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Pérez-Melero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maya, A. B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Rey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peláez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caballero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medarde, M.</span><span> </span><span class="NLM_article-title">A new family of quinoline and quinoxaline analogues of combretastatins</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3771</span><span class="NLM_x">–</span> <span class="NLM_lpage">3774</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=3771-3774&author=C.+P%C3%A9rez-Meleroauthor=A.+B.+S.+Mayaauthor=B.+del+Reyauthor=R.+Pel%C3%A1ezauthor=E.+Caballeroauthor=M.+Medarde&title=A+new+family+of+quinoline+and+quinoxaline+analogues+of+combretastatins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Melero%26aufirst%3DC.%26aulast%3DMaya%26aufirst%3DA.%2BB.%2BS.%26aulast%3Ddel%2BRey%26aufirst%3DB.%26aulast%3DPel%25C3%25A1ez%26aufirst%3DR.%26aulast%3DCaballero%26aufirst%3DE.%26aulast%3DMedarde%26aufirst%3DM.%26atitle%3DA%2520new%2520family%2520of%2520quinoline%2520and%2520quinoxaline%2520analogues%2520of%2520combretastatins%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D3771%26epage%3D3774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Medarde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maya, A. B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Melero, C.</span><span> </span><span class="NLM_article-title">Naphthalene combretastatin analogues: Synthesis, cytotoxicity and antitubulin activity</span> <span class="citation_source-journal">J. Enzyme Inhib. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1080%2F14756360412331280473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=15662956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=521-540&author=M.+Medardeauthor=A.+B.+S.+Mayaauthor=C.+Perez-Melero&title=Naphthalene+combretastatin+analogues%3A+Synthesis%2C+cytotoxicity+and+antitubulin+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthalene combretastatin analogs: Synthesis, cytotoxicity and antitubulin activity</span></div><div class="casAuthors">Medarde, Manuel; Maya, Ana B. S.; Perez-Melero, Concepcion</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">521-540</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Synthesis and evaluation of new combretastatin analogs with varied modifications on the bridge and the arom. rings, have shown that the 2-naphthyl moiety is a good surrogate for the 3-hydroxy-4-methoxyphenyl (B-ring) of combretastatin A-4.  Other bicyclic systems, such as 6(7)-quinolyl and 5-indolyl, can replace the B-ring, but they produce less potent analogs in the cytotoxicity and tubulin polymn. inhibition assays.  Other modifications are detrimental for the potency of the studied analogs.  The combretastatin 2-naphthyl deriv., 2-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]naphthalene, and the related 6-quinolyl combretastatin analog are the most potent among the derivs. of this type.  Previous and new results in this family of combretastatin analogs are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL-veEQ785ZrVg90H21EOLACvtfcHk0ljdFGka3jJyYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqsg%253D%253D&md5=7f457aee0291399ca5b85289cd0f2339</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1080%2F14756360412331280473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756360412331280473%26sid%3Dliteratum%253Aachs%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DMaya%26aufirst%3DA.%2BB.%2BS.%26aulast%3DPerez-Melero%26aufirst%3DC.%26atitle%3DNaphthalene%2520combretastatin%2520analogues%253A%2520Synthesis%252C%2520cytotoxicity%2520and%2520antitubulin%2520activity%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2004%26volume%3D19%26spage%3D521%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span> </span><span class="NLM_article-title">Concise synthesis and structure–activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4247</span><span class="NLM_x">–</span> <span class="NLM_lpage">4257</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049802l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4247-4257&author=J.+P.+Liouauthor=Y.+L.+Changauthor=F.+M.+Kuoauthor=C.+W.+Changauthor=H.+Y.+Tsengauthor=C.+C.+Wangauthor=Y.+N.+Yangauthor=J.+Y.+Changauthor=S.+J.+Leeauthor=H.+P.+Hsieh&title=Concise+synthesis+and+structure%E2%80%93activity+relationships+of+combretastatin+A-4+analogues%2C+1-aroylindoles+and+3-aroylindoles%2C+as+novel+classes+of+potent+antitubulin+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm049802l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049802l%26sid%3Dliteratum%253Aachs%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DKuo%26aufirst%3DF.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DTseng%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DY.%2BN.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DConcise%2520synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520combretastatin%2520A-4%2520analogues%252C%25201-aroylindoles%2520and%25203-aroylindoles%252C%2520as%2520novel%2520classes%2520of%2520potent%2520antitubulin%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4247%26epage%3D4257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Sriram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grohmann, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strecker, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wootton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franken, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trawick, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinney, K. G.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">8161</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=8161-8171&author=M.+Sriramauthor=J.+J.+Hallauthor=N.+C.+Grohmannauthor=T.+E.+Streckerauthor=T.+Woottonauthor=A.+Frankenauthor=M.+L.+Trawickauthor=K.+G.+Pinney&title=Design%2C+synthesis+and+biological+evaluation+of+dihydronaphthalene+and+benzosuberene+analogs+of+the+combretastatins+as+inhibitors+of+tubulin+polymerization+in+cancer+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSriram%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DJ.%2BJ.%26aulast%3DGrohmann%26aufirst%3DN.%2BC.%26aulast%3DStrecker%26aufirst%3DT.%2BE.%26aulast%3DWootton%26aufirst%3DT.%26aulast%3DFranken%26aufirst%3DA.%26aulast%3DTrawick%26aufirst%3DM.%2BL.%26aulast%3DPinney%26aufirst%3DK.%2BG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520dihydronaphthalene%2520and%2520benzosuberene%2520analogs%2520of%2520the%2520combretastatins%2520as%2520inhibitors%2520of%2520tubulin%2520polymerization%2520in%2520cancer%2520chemotherapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D8161%26epage%3D8171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Andreani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granaiola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locatelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morigi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rambaldi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varoli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, M. W.</span><span> </span><span class="NLM_article-title">Antitumor activity of substituted <i>E</i>-3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6922</span><span class="NLM_x">–</span> <span class="NLM_lpage">6924</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0607808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6922-6924&author=A.+Andreaniauthor=S.+Burnelliauthor=M.+Granaiolaauthor=A.+Leoniauthor=A.+Locatelliauthor=R.+Morigiauthor=M.+Rambaldiauthor=L.+Varoliauthor=M.+W.+Kunkel&title=Antitumor+activity+of+substituted+E-3-%283%2C4%2C5-trimethoxybenzylidene%29-1%2C3-dihydroindol-2-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm0607808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0607808%26sid%3Dliteratum%253Aachs%26aulast%3DAndreani%26aufirst%3DA.%26aulast%3DBurnelli%26aufirst%3DS.%26aulast%3DGranaiola%26aufirst%3DM.%26aulast%3DLeoni%26aufirst%3DA.%26aulast%3DLocatelli%26aufirst%3DA.%26aulast%3DMorigi%26aufirst%3DR.%26aulast%3DRambaldi%26aufirst%3DM.%26aulast%3DVaroli%26aufirst%3DL.%26aulast%3DKunkel%26aufirst%3DM.%2BW.%26atitle%3DAntitumor%2520activity%2520of%2520substituted%2520E-3-%25283%252C4%252C5-trimethoxybenzylidene%2529-1%252C3-dihydroindol-2-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6922%26epage%3D6924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Li, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Z. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackett, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werbovetz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnsamuel, J.</span><span> </span><span class="NLM_article-title">Conformationally restricted analogs of combretastatin A-4 derived from SU5416</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5382</span><span class="NLM_x">–</span> <span class="NLM_lpage">5385</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=5382-5385&author=P.+K.+Liauthor=Z.+L.+Xiaoauthor=Z.+G.+Huauthor=B.+Panditauthor=Y.+J.+Sunauthor=D.+L.+Sackettauthor=K.+Werbovetzauthor=A.+Lewisauthor=J.+Johnsamuel&title=Conformationally+restricted+analogs+of+combretastatin+A-4+derived+from+SU5416"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%2BK.%26aulast%3DXiao%26aufirst%3DZ.%2BL.%26aulast%3DHu%26aufirst%3DZ.%2BG.%26aulast%3DPandit%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DY.%2BJ.%26aulast%3DSackett%26aufirst%3DD.%2BL.%26aulast%3DWerbovetz%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DA.%26aulast%3DJohnsamuel%26aufirst%3DJ.%26atitle%3DConformationally%2520restricted%2520analogs%2520of%2520combretastatin%2520A-4%2520derived%2520from%2520SU5416%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D5382%26epage%3D5385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span> </span><span class="NLM_article-title">Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">1228</span><span class="NLM_x">–</span> <span class="NLM_lpage">1238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1111%2Fj.1476-5381.2009.00112.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=19302593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2009&pages=1228-1238&author=X.+Renauthor=M.+Daiauthor=L.-P.+Linauthor=P.-K.+Liauthor=J.+Ding&title=Anti-angiogenic+and+vascular+disrupting+effects+of+C9%2C+a+new+microtubule-depolymerizing+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent</span></div><div class="casAuthors">Ren, Xuan; Dai, Mei; Lin, Li-Ping; Li, Pui-Kai; Ding, Jian</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1228-1238</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: The crit. role of blood supply in the growth of solid tumors makes blood vessels an ideal target for anti-tumor drug discovery.  The anti-angiogenic and vascular disrupting activities of C9, a newly synthesized microtubule-depolymg. agent, were investigated with several in vitro and in vivo models.  Possible mechanisms involved in its activity were also assessed.  Exptl. approach: Microtubule-depolymg. actions were assessed by surface plasmon resonance binding, competitive inhibition and cytoskeleton immunofluorescence.  Anti-angiogenic and vascular disrupting activities were tested on proliferation, migration, tube formation with human umbilical vein endothelial cells, and in rat aortic ring, chick chorioallantoic membrane and Matrigel plug assays.  Western blots and Rho activation assays were employed to examine the role of Raf-MEK-ERK (mitogen-activated ERK kinase, extracellular signal-regulated kinase) and Rho/Rho kinase signaling.  Key results: C9 inhibited proliferation, migration and tube formation of endothelial cells and inhibited angiogenesis in aortic ring and chick chorioallantoic membrane assays.  C9 induced disassembly of microtubules in endothelial cells and down-regulated Raf-MEK-ERK signaling activated by pro-angiogenic factors.  In addn., C9 disrupted capillary-like networks and newly formed vessels in vitro and rapidly decreased perfusion of neovasculature in vivo.  Endothelial cell contraction and membrane blebbing induced by C9 in neovasculature was dependent on the Rho/Rho kinase pathway.  Conclusions and implications: Anti-angiogenic and vascular disruption by C9 was assocd. with changes in morphol. and function of endothelial cells, involving the Raf-MEK-ERK and Rho/Rho kinase signaling pathways.  These findings strongly suggest that C9 is a new microtubule-binding agent that could effectively target tumor vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojex2iPcTR5LVg90H21EOLACvtfcHk0lgcgYziGoCPHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWmtbc%253D&md5=12d6a380c08e9244adef040586f2d0a9</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00112.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00112.x%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DL.-P.%26aulast%3DLi%26aufirst%3DP.-K.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DAnti-angiogenic%2520and%2520vascular%2520disrupting%2520effects%2520of%2520C9%252C%2520a%2520new%2520microtubule-depolymerizing%2520agent%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D156%26spage%3D1228%26epage%3D1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Rischin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span> </span><span class="NLM_article-title">Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1158%2F1078-0432.CCR-11-0937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=21690571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5152-5160&author=D.+Rischinauthor=D.+C.+Bibbyauthor=G.+Chongauthor=G.+Kremmidiotisauthor=A.+F.+Leskeauthor=C.+A.+Matthewsauthor=S.+S.+Wongauthor=M.+A.+Rosenauthor=J.+Desai&title=Clinical%2C+pharmacodynamic%2C+and+pharmacokinetic+evaluation+of+BNC105P%3A+a+phase+I+trial+of+a+novel+vascular+disrupting+agent+and+inhibitor+of+cancer+cell+proliferation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation</span></div><div class="casAuthors">Rischin, Danny; Bibby, David C.; Chong, Geoff; Kremmidiotis, Gabriel; Leske, Annabell F.; Matthews, Clayton A.; Wong, Shirley S.; Rosen, Mark A.; Desai, Jayesh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5152-5160</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and pharmacodynamic (PD) effects of BNC105P, an inhibitor of tubulin polymn. that has vascular disrupting and antiproliferative effects.  Exptl. Design: BNC105P was administered as a 10-min infusion on days 1 and 8 of a 21-day cycle in a first-in-human phase I study.  A dynamic accelerated dose titrn. method was used for dose escalation.  Plasma concns. of BNC105P (phosphate prodrug) and BNC105 (active agent) were detd.  PD assessments were carried out using dynamic contrast enhanced (DCE)-MRI and anal. of a blood-borne biomarker.  RESULTS: Twenty-one subjects with advanced solid tumors were enrolled on 6 dose levels (range: 2.1-18.9 mg/m2).  The recommended dose level was 16 mg/m2 and was well tolerated.  BNC105P (prodrug) rapidly converted to BNC105 with a half-life of 0.13 h.  Plasma concns. of BNC105 generally increased in proportion to dose with a half-life of 0.57 h.  Pharmacodymanically active plasma levels were obtained with a dose dependant redn. in the levels of polymd. tubulin (on-target action) being obsd. in PBMCs.  DCE-MRI also indicated blood flow changes in the tumor lesions of a no. of subjects.  CONCLUSIONS: BNC105P has a favorable toxicity profile at the recommended dose of 16 mg/m2 and is assocd. with PD changes consistent with its known mechanism of action.  Phase II studies in renal cancer and mesothelioma have commenced.  Clin Cancer Res; 17(15); 5152-60.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofFtL953e-x7Vg90H21EOLACvtfcHk0lgcgYziGoCPHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbk%253D&md5=277c9745f593ee87871faa0915b93dc0</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0937%26sid%3Dliteratum%253Aachs%26aulast%3DRischin%26aufirst%3DD.%26aulast%3DBibby%26aufirst%3DD.%2BC.%26aulast%3DChong%26aufirst%3DG.%26aulast%3DKremmidiotis%26aufirst%3DG.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DMatthews%26aufirst%3DC.%2BA.%26aulast%3DWong%26aufirst%3DS.%2BS.%26aulast%3DRosen%26aufirst%3DM.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26atitle%3DClinical%252C%2520pharmacodynamic%252C%2520and%2520pharmacokinetic%2520evaluation%2520of%2520BNC105P%253A%2520a%2520phase%2520I%2520trial%2520of%2520a%2520novel%2520vascular%2520disrupting%2520agent%2520and%2520inhibitor%2520of%2520cancer%2520cell%2520proliferation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5152%26epage%3D5160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Li, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span> </span><span class="NLM_article-title">Imidazolone-amide bridges and their effects on tubulin polymerization in cis-locked vinylogous combretastatin-A4 analogues: synthesis and biological evaluation</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3579</span><span class="NLM_x">–</span> <span class="NLM_lpage">3584</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=3579-3584&author=Y.+W.+Liauthor=J.+Liuauthor=N.+Liuauthor=D.+Shiauthor=X.+T.+Zhouauthor=J.+G.+Lvauthor=J.+Zhuauthor=C.+H.+Zhengauthor=Y.+J.+Zhou&title=Imidazolone-amide+bridges+and+their+effects+on+tubulin+polymerization+in+cis-locked+vinylogous+combretastatin-A4+analogues%3A+synthesis+and+biological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%2BT.%26aulast%3DLv%26aufirst%3DJ.%2BG.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DC.%2BH.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26atitle%3DImidazolone-amide%2520bridges%2520and%2520their%2520effects%2520on%2520tubulin%2520polymerization%2520in%2520cis-locked%2520vinylogous%2520combretastatin-A4%2520analogues%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D3579%26epage%3D3584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Li, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Study on the binding modes of the colchicine-site inhibitors and construction of their structural model</span> <span class="citation_source-journal">Acta Chim. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1735</span><span class="NLM_x">–</span> <span class="NLM_lpage">1739</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2008&pages=1735-1739&author=Y.+W.+Liauthor=Y.+J.+Zhouauthor=J.+Zhuauthor=C.+H.+Zhengauthor=J.+Chenauthor=C.+Q.+Shengauthor=J.+G.+Luauthor=H.+Tangauthor=Y.+N.+Liauthor=J.+Zhang&title=Study+on+the+binding+modes+of+the+colchicine-site+inhibitors+and+construction+of+their+structural+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSheng%26aufirst%3DC.%2BQ.%26aulast%3DLu%26aufirst%3DJ.%2BG.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DStudy%2520on%2520the%2520binding%2520modes%2520of%2520the%2520colchicine-site%2520inhibitors%2520and%2520construction%2520of%2520their%2520structural%2520model%26jtitle%3DActa%2520Chim.%2520Sin.%26date%3D2008%26volume%3D66%26spage%3D1735%26epage%3D1739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Nguyen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermone, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaharevitz, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wipf, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gussio, R.</span><span> </span><span class="NLM_article-title">A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6107</span><span class="NLM_x">–</span> <span class="NLM_lpage">6116</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050502t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1WitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6107-6116&author=T.+L.+Nguyenauthor=C.+McGrathauthor=A.+R.+Hermoneauthor=J.+C.+Burnettauthor=D.+W.+Zaharevitzauthor=B.+W.+Dayauthor=P.+Wipfauthor=E.+Hamelauthor=R.+Gussio&title=A+common+pharmacophore+for+a+diverse+set+of+colchicine+site+inhibitors+using+a+structure-based+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach</span></div><div class="casAuthors">Nguyen, Tam Luong; McGrath, Connor; Hermone, Ann R.; Burnett, James C.; Zaharevitz, Daniel W.; Day, Billy W.; Wipf, Peter; Hamel, Ernest; Gussio, Rick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6107-6116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modulating the structure and function of tubulin and microtubules is an important route to anticancer therapeutics, and therefore, small mols. that bind to tubulin and cause mitotic arrest are of immense interest.  A large no. of synthetic and natural compds. with diverse structures have been shown to bind at the colchicine site, one of the major binding sites on tubulin, and inhibit tubulin assembly.  Using the recently detd. x-ray structure of the tubulin:colchicinoid complex as the template, we employed docking studies to det. the binding modes of a set of structurally diverse colchicine site inhibitors.  These binding models were subsequently used to construct a comprehensive, structure-based pharmacophore that in combination with mol. dynamics simulations confirms and extends our understanding of binding interactions at the colchicine site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp40uoXQZMHULVg90H21EOLACvtfcHk0lgI_4h3yyKJnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1WitL8%253D&md5=443f25ca9212b379813d91ccdf820c5a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm050502t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050502t%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BL.%26aulast%3DMcGrath%26aufirst%3DC.%26aulast%3DHermone%26aufirst%3DA.%2BR.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26aulast%3DZaharevitz%26aufirst%3DD.%2BW.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DGussio%26aufirst%3DR.%26atitle%3DA%2520common%2520pharmacophore%2520for%2520a%2520diverse%2520set%2520of%2520colchicine%2520site%2520inhibitors%2520using%2520a%2520structure-based%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6107%26epage%3D6116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Yao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span> </span><span class="NLM_article-title">Synthesis and antifungal activities of novel 2-aminotetralin derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">5293</span><span class="NLM_x">–</span> <span class="NLM_lpage">5300</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0701167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5293-5300&author=B.+Yaoauthor=H.+T.+Jiauthor=Y.+B.+Caoauthor=Y.+J.+Zhouauthor=J.+Zhuauthor=J.+G.+Luauthor=Y.+W.+Liauthor=J.+Chenauthor=C.+H.+Zhengauthor=Y.+Y.+Jiangauthor=R.+M.+Liangauthor=H.+Tang&title=Synthesis+and+antifungal+activities+of+novel+2-aminotetralin+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm0701167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0701167%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DH.%2BT.%26aulast%3DCao%26aufirst%3DY.%2BB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%2BG.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DC.%2BH.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DLiang%26aufirst%3DR.%2BM.%26aulast%3DTang%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520antifungal%2520activities%2520of%2520novel%25202-aminotetralin%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5293%26epage%3D5300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">App, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2588</span><span class="NLM_x">–</span> <span class="NLM_lpage">2603</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980123i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2588-2603&author=L.+Sunauthor=N.+Tranauthor=F.+Tangauthor=H.+Appauthor=P.+Hirthauthor=G.+McMahonauthor=C.+Tang&title=Synthesis+and+biological+evaluations+of+3-substituted+indolin-2-ones%3A+a+novel+class+of+tyrosine+kinase+inhibitors+that+exhibit+selectivity+toward+particular+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases</span></div><div class="casAuthors">Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2588-2603</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs).  These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells.  By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells.  Structure-activity anal. for these compds. and their relative potency and selectivity to inhibit particular RTKs has detd. that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones contg. bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compd. contg. an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs.  Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs.  The structure-activity anal. supports the use of subsets of these compds. as specific chem. leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoPixq8Am5rVg90H21EOLACvtfcHk0lgI_4h3yyKJnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D&md5=536302b717170a630008dac14832204c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm980123i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980123i%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DApp%26aufirst%3DH.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%25203-substituted%2520indolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520tyrosine%2520kinase%2520inhibitors%2520that%2520exhibit%2520selectivity%2520toward%2520particular%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2588%26epage%3D2603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Petit, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karajannis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shido, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span> </span><span class="NLM_article-title">The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1951</span><span class="NLM_x">–</span> <span class="NLM_lpage">1961</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=1951-1961&author=I.+Petitauthor=M.+A.+Karajannisauthor=L.+Vincentauthor=L.+Youngauthor=J.+Butlerauthor=A.+T.+Hooperauthor=K.+Shidoauthor=H.+Stellerauthor=D.+J.+Chaplinauthor=E.+Feldmanauthor=S.+Rafii&title=The+microtubule-targeting+agent+CA4P+regresses+leukemic+xenografts+by+disrupting+interaction+with+vascular+cells+and+mitochondrial-dependent+cell+death"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetit%26aufirst%3DI.%26aulast%3DKarajannis%26aufirst%3DM.%2BA.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DL.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DHooper%26aufirst%3DA.%2BT.%26aulast%3DShido%26aufirst%3DK.%26aulast%3DSteller%26aufirst%3DH.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DFeldman%26aufirst%3DE.%26aulast%3DRafii%26aufirst%3DS.%26atitle%3DThe%2520microtubule-targeting%2520agent%2520CA4P%2520regresses%2520leukemic%2520xenografts%2520by%2520disrupting%2520interaction%2520with%2520vascular%2520cells%2520and%2520mitochondrial-dependent%2520cell%2520death%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D1951%26epage%3D1961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Cushman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarathnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborti, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">2579</span><span class="NLM_x">–</span> <span class="NLM_lpage">2588</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00112a036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADyaK3MXkvFWksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=2579-2588&author=M.+Cushmanauthor=D.+Nagarathnamauthor=D.+Gopalauthor=A.+K.+Chakrabortiauthor=C.+M.+Linauthor=E.+Hamel&title=Synthesis+and+evaluation+of+stilbene+and+dihydrostilbene+derivatives+as+potential+anticancer+agents+that+inhibit+tubulin+polymerization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization</span></div><div class="casAuthors">Cushman, Mark; Nagarathnam, Dhanapalan; Gopal, D.; Chakraborti, Asit K.; Lin, Chii M.; Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2579-88</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">cis- And trans-dihydrostilbenes and some N-arylbenzylamines were synthesized and evaluated for their cytotoxicity in five cancer cell cultures A-549 lung carcinoma, NCF-7 breast carcinoma, HT-δ colon adenocarcinoma, SKMEL-5 melanoma and MLM melanoma.  Several cis-stilbenes, structurally similar to combretastatins, were highly cytotoxic in all five cell lines, and active as inhibitors of tubulin polymn.  The most active compds. also inhibited the binding of colchicine to tubulin.  The most potent of the new compds., both as a tubulin polymn. inhibitor and as a cytotoxic agent, was (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene (I) which was almost as potent as combrestatins A-4, the most active of the combrestatins, as a tubulin polymn. inhibitor.  I was a approx. 140 times more cytotoxic against HT-29:adenocarcinoma cells and about 10 times more cytotoxic against MCF-η breast carcinoma cells than combrestatin A-4, but it was about 20 times less cytotoxic against A-549 lung carcinoma cells, 30 times less cytotoxic against SKMEL-5 melanoma cells, and 7 times less cytotoxic against NLM melanoma cells than combrestatin A-4.  The relative potencies for the cis, dihydro, and trans compds., resp., as inhibitors of tubulin polymn. are in agreement with the relative potencies previously obsd. for combretastatin A-Δ, dihydrocombrestatin A-4, and trans-combrestatin A-4.  The relative potencies were also reflected as a result of the cytotoxicity assays.  Structure-activity relationships of this group of compds. are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUMaB6teYTTrVg90H21EOLACvtfcHk0lgI_4h3yyKJnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkvFWksLc%253D&md5=fe12d2c046d97aa417a1b7ece35d3414</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm00112a036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00112a036%26sid%3Dliteratum%253Aachs%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DGopal%26aufirst%3DD.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520stilbene%2520and%2520dihydrostilbene%2520derivatives%2520as%2520potential%2520anticancer%2520agents%2520that%2520inhibit%2520tubulin%2520polymerization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D2579%26epage%3D2588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, W. J.</span><span> </span><span class="NLM_article-title">Highly potent triazole-based tubulin polymerization inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061142s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=749-754&author=Q.+Zhangauthor=Y.+Y.+Pengauthor=X.+I.+Wangauthor=S.+M.+Keenanauthor=S.+Aroraauthor=W.+J.+Welsh&title=Highly+potent+triazole-based+tubulin+polymerization+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm061142s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061142s%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DY.%2BY.%26aulast%3DWang%26aufirst%3DX.%2BI.%26aulast%3DKeenan%26aufirst%3DS.%2BM.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26atitle%3DHighly%2520potent%2520triazole-based%2520tubulin%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D749%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span> <span class="citation_source-journal">Cell Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm300596s&amp;key=10.1385%2FCBB%3A38%3A1%3A1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm300596s&amp;key=12663938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm300596s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=1-21&author=E.+Hamel&title=Evaluation+of+antimitotic+agents+by+quantitative+comparisons+of+their+effects+on+the+polymerization+of+purified+tubulin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span></div><div class="casAuthors">Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Most antimitotic compds. have highly specific interactions with tubulin, the major protein component of microtubules.  It is, therefore, often desirable to characterize interactions of these agents with tubulin.  In particular, quant. comparisons between new and old ("std.") agents, between different classes of agent, and between structural analogs (e.g., for a structure-activity relationship study) are important.  Because antimitotic drugs have a variety of effects on tubulin and bind at multiple distinct sites on the protein, the tubulin assembly reaction is probably the only universally applicable reaction that can be analyzed.  In my lab., we use the assembly of purified tubulin induced by higher concns. of monosodium glutamate as our basic assay system.  This report presents a detailed description of our current routine assay, including the effects of a variety of reaction components on the reaction.  In addn., the variety of effects that reaction components can have on the quant. results obtained with drugs, using the colchicine site drug combretastatin A-4 as a model compd., is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLvDICXLUiYbVg90H21EOLACvtfcHk0lgNhz2zvLK0yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D&md5=c37c365cc707e237f43feffca64d706b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1385%2FCBB%3A38%3A1%3A1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FCBB%253A38%253A1%253A1%26sid%3Dliteratum%253Aachs%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DEvaluation%2520of%2520antimitotic%2520agents%2520by%2520quantitative%2520comparisons%2520of%2520their%2520effects%2520on%2520the%2520polymerization%2520of%2520purified%2520tubulin%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2003%26volume%3D38%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Bailly, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bal, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finet, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hildebrand, M.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wattez, N.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5437</span><span class="NLM_x">–</span> <span class="NLM_lpage">5444</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030903d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5437-5444&author=C.+Baillyauthor=C.+Balauthor=P.+Barbierauthor=S.+Combesauthor=J.-P.+Finetauthor=M.-P.+Hildebrandauthor=V.+Peyrotauthor=N.+Wattez&title=Synthesis+and+biological+evaluation+of+4-arylcoumarin+analogues+of+combretastatins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm030903d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030903d%26sid%3Dliteratum%253Aachs%26aulast%3DBailly%26aufirst%3DC.%26aulast%3DBal%26aufirst%3DC.%26aulast%3DBarbier%26aufirst%3DP.%26aulast%3DCombes%26aufirst%3DS.%26aulast%3DFinet%26aufirst%3DJ.-P.%26aulast%3DHildebrand%26aufirst%3DM.-P.%26aulast%3DPeyrot%26aufirst%3DV.%26aulast%3DWattez%26aufirst%3DN.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25204-arylcoumarin%2520analogues%2520of%2520combretastatins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5437%26epage%3D5444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Babu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strobel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockway, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickols, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjoholm, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegfried, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiakos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span> </span><span class="NLM_article-title">Acetyl analogs of combretastatin A-4: synthesis and biological studies</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2359</span><span class="NLM_x">–</span> <span class="NLM_lpage">2367</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=2359-2367&author=B.+Babuauthor=M.+Leeauthor=L.+Leeauthor=R.+Strobelauthor=O.+Brockwayauthor=A.+Nickolsauthor=R.+Sjoholmauthor=S.+Tzouauthor=S.+Chavdaauthor=D.+Destaauthor=G.+Fraleyauthor=A.+Siegfriedauthor=W.+Penningtonauthor=R.+M.+Hartleyauthor=C.+Westbrookauthor=S.+L.+Mooberryauthor=K.+Kiakosauthor=J.+A.+Hartleyauthor=M.+Lee&title=Acetyl+analogs+of+combretastatin+A-4%3A+synthesis+and+biological+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBabu%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DStrobel%26aufirst%3DR.%26aulast%3DBrockway%26aufirst%3DO.%26aulast%3DNickols%26aufirst%3DA.%26aulast%3DSjoholm%26aufirst%3DR.%26aulast%3DTzou%26aufirst%3DS.%26aulast%3DChavda%26aufirst%3DS.%26aulast%3DDesta%26aufirst%3DD.%26aulast%3DFraley%26aufirst%3DG.%26aulast%3DSiegfried%26aufirst%3DA.%26aulast%3DPennington%26aufirst%3DW.%26aulast%3DHartley%26aufirst%3DR.%2BM.%26aulast%3DWestbrook%26aufirst%3DC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DKiakos%26aufirst%3DK.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DM.%26atitle%3DAcetyl%2520analogs%2520of%2520combretastatin%2520A-4%253A%2520synthesis%2520and%2520biological%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D2359%26epage%3D2367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0','PDB','1SA0'); return false;">PDB: 1SA0</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300596s&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm300596s%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-12%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300596s" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799e6c94e78d942","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
